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Abstract 
The polymorphic yeast Candida albicans is an important opportunistic human 
pathogen and the most common causative agent of fungal invasive infections. Host 
physical barriers and immune system integrity are crucial factors in controlling the 
establishment of Candida infections. However, the high adaptability of C. albicans to 
different host niches is also a determinant factor. The host-fungus interplay is dynamic 
and the balance between fungal elimination and tissue damage depends on both the 
host response and how the pathogen reacts to immune effector molecules and cells.  
The murine model of hematogenously disseminated C. albicans infection is widely 
used to ascertain strain virulence and host-fungus interactions. However, distinct C. 
albicans strains may present distinct virulence phenotypes and elicit quantitatively and 
qualitatively different immune responses. Hence, results obtained with one strain 
cannot be taken as representative of the whole species. Moreover, most studies 
focused on C. albicans internalization and killing by phagocytes, rather than on the 
overall immune response. Here, a comparative analysis of the early immune response, 
host survival and kidney fungal burden was done in mice infected intravenously with 
three C. albicans strains with different attributed virulence, SC5314, ATCC 90028 and 
ATCC 32354. Strain SC5314 was the most virulent and elicited a more marked 
inflammatory response, with higher neutrophil recruitment. In contrast, ATCC 32354 
presented the lowest virulence and stimulated less markedly the innate immune 
response than the other strains. These results provide additional evidence on the 
association between C. albicans virulence and the early immune response, which may 
be useful in delineating vaccination or immunotherapeutic strategies against 
disseminated candidiasis.      
Secretion of C. albicans hydrolytic enzymes during infection is a virulence attribute that 
aids adhesion to and invasion of host tissues, and immune evasion. Among these 
enzymes, secreted aspartyl proteases (Sap) encoded by a 10-member gene family 
(SAP1 to SAP10) have been particularly studied. Several members of the Sap family 
were claimed to play a significant role in the progression of candidiasis established by 
the hematogenous or intraperitoneal routes. This assumption was based on the 
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observed attenuated virulence of sap-null mutant strains. However, the exclusive 
contribution of SAP genes to their attenuated phenotype was not unequivocally 
confirmed, as the Ura status of several mutant strains could also have contributed to 
the attenuation. In this study, the importance of SAP1 to SAP6 in murine models of 
hematogenously disseminated candidiasis and C. albicans peritonitis was reassessed 
by using sap-null mutant strains not affected in their URA3 gene expression. In 
systemic candidiasis established by intravenous infection, SAT1-flipping constructed 
Δsap123 and Δsap456 mutants did not present a significant reduction in virulence 
contrasting the attenuated virulence found in equivalent Ura-blaster mutants. Using 
the newly assessed mutant strains, the median survival time of BALB/c mice infected 
with the Δsap123 strain was similar to that of wild-type (WT) SC5314-infected mice, 
while those infected with mutant strains lacking SAP5 showed slightly extended 
survival times. Nevertheless, WT and Δsap456 strains were equally able to invade mice 
kidneys. Likewise, SAP4 to SAP6 deficiency had no noticeable impact on the immune 
response elicited in the spleen and kidneys of C. albicans-infected mice. These results 
suggest that Sap1 to Sap6 do not play a significant role in C. albicans virulence in the 
murine model of hematogenously disseminated candidiasis. Contrastingly, in the 
murine model of C. albicans peritonitis, ∆sap456-infected mice presented lower kidney 
fungal burden than WT- or ∆sap123-infected mice.  WT-infected mice presented 
higher proportions of T regulatory cells (Foxp3+) in the spleen and mesenteric lymph 
nodes than non-infected or sap-null mutant-infected counterparts. In addition, 
CD4+CD25+ T cells of WT-infected mice were the most effective in suppressing the 
proliferative response of CD4+CD25- T cells whereas those of ∆sap456-infected mice 
were the least suppressive. Furthermore, CD4+ T cells of WT-infected mice were the 
ones producing the highest levels of IL-10. Interestingly, ∆sap456-infected mice 
presented less Foxp3+ cells in kidney lesions than the other fungal challenged mice. 
Altogether, these results implicate Sap4 to Sap6 in the host immune response to C. 
albicans peritonitis, providing additional evidence for the role of these enzymes in this 
infection model.  
To circumvent host immune defenses, C. albicans developed multiple evasion 
mechanisms. Among these, production of Saps has been particularly highlighted due to 
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their ability to degrade and/or inactivate diverse host immune effector molecules. The 
mammalian pattern recognition receptor galectin-3 (Gal-3) was shown to specifically 
bind β-1,2 mannosides on C. albicans cell wall. This interaction directly induces fungal 
cell death and also promotes pro-inflammatory cytokine TNF-α production by host 
cells. In this study, we assessed whether this lectin could be degraded by native Sap2 
or recombinant Sap1 to Sap3 isoenzymes. All C. albicans Saps tested degraded and 
inactivated the host receptor Gal-3. This may constitute a fungal strategy to control 
and evade host immune mechanisms dependent on Gal-3. Degradation of this protein 
might thus generate a protective microenvironment of reduced Gal-3 activity, which 
may facilitate C. albicans survival in the host. 
Previous reports have shown that mice immunized with Sap2 were protected against 
mucosal or peritoneal C. albicans infection. Here, we extended these studies and 
evaluated the suitability of C. albicans recombinant Sap2 (rSap2) as protective 
immunogen for vaccination against hematogenously disseminated candidiasis. Four 
different immunogenic preparations were tested, respectively using Alum, Imiquimod, 
Freund’s or CpG plus Alum as adjuvants. Moreover, as the hypha-associated isoenzyme 
Sap5 is preferentially expressed during systemic candidiasis, it was also evaluated as 
target antigen for Candida vaccination, together with Alum or Imiquimod. All these 
approaches failed in protecting the immunized mice from fungal infection. This 
suggests that the C. albicans enzymes Sap2 and Sap5, despite their potential role in 
virulence, do not appear to be suitable target proteins in immunopreventive strategies 
against hematogenously disseminated candidiasis.   
In summary, results presented in this thesis provide additional evidence for the 
differential involvement of Saps in distinct C. albicans infection models. Moreover, 
these results, by showing that host immune response to C. albicans is affected by lack 
of SAP expression, are in support of a previously hypothesized immunomodulatory role 
for Saps. Finally, the lack of host immune protection against hematogenously 
disseminated candidiasis by means of Sap immunization reinforces the limited role of 
these proteins in this type of infection.  
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Resumo 
A levedura polimórfica Candida albicans é um importante patógeno oportunista em 
humanos, sendo o mais frequente agente causador de infeções fúngicas invasivas. A 
integridade das barreiras físicas do hospedeiro, bem como do seu sistema imunitário, 
são fatores cruciais no controlo de infeções por leveduras do género Candida. Todavia, 
a grande adaptabilidade de C. albicans a diferentes nichos do hospedeiro é também 
um fator determinante. As interações fungo-hospedeiro são dinâmicas e o equilíbrio 
entre a eliminação do fungo e o dano tecidular depende tanto da resposta do 
hospedeiro, como da forma como o patógeno reage às células e moléculas imunitárias. 
O modelo de candidíase sistémica originada pela via endovenosa em murganhos é 
amplamente utilizado para avaliar a virulência das estirpes e as interações entre fungo 
e hospedeiro. No entanto, estirpes diferentes de C. albicans podem apresentar 
fenótipos de virulência distintos e desencadear respostas imunitárias, quer qualitativa, 
quer quantitativamente, diferentes. Deste modo, os resultados obtidos com uma 
estirpe não poderão ser considerados representativos da espécie. Além disso, a 
maioria dos estudos incidiram na internalização e morte de C. albicans por células 
fagocíticas, em detrimento da resposta imunitária global. Nesta tese foi feita uma 
análise comparativa da resposta imunitária precoce, da carga fúngica renal e da 
sobrevivência de murganhos infetados pela via endovenosa com três estirpes de C. 
albicans, com reconhecidas diferenças de virulência, SC5314, ATCC 90028 e ATCC 
32354. A estirpe SC5314 foi a mais virulenta e desencadeou uma resposta inflamatória 
mais exuberante, com um maior recrutamento de neutrófilos. Pelo contrário, a estirpe 
ATCC 32354 foi a menos virulenta e estimulou menos a resposta imunitária do que as 
outras estirpes. Estes resultados reforçam a associação entre a virulência de C. 
albicans e a resposta imunitária precoce, o que poderá ser útil no planeamento de 
estratégias de vacinação ou imunoterapêuticas contra a candidíase disseminada.  
A secreção de enzimas hidrolíticas por C. albicans durante a infeção é considerada um 
fator de virulência que auxilia a adesão e invasão de tecidos do hospedeiro e a evasão 
à resposta imunitária. Entre estas enzimas, as proteases aspárticas secretadas (Sap), 
codificadas pela família de genes SAP1 a SAP10 foram estudadas mais 
aprofundadamente. Foi atribuído um papel importante a vários membros desta família 
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na progressão da candidíase estabelecida pelas vias endovenosa e intra-peritoneal. 
Para tal contribuíram a virulência atenuada observada em mutantes deficientes nestas 
proteases. Contudo, o contributo exclusivo dos genes SAP para o fenótipo observado 
não foi inequivocamente demonstrado, uma vez que a inserção ectópica do gene 
URA3 em vários mutantes poderá ter contribuído para a diminuição da virulência. 
Neste estudo reavaliou-se a importância dos genes SAP1 a SAP6 na infeção 
disseminada por via endovenosa e na peritonite causada por C. albicans, usando 
mutantes deficientes nestes genes sem expressão de URA3 afetada. Na candidíase 
sistémica estabelecida pela via endovenosa, os mutantes Δsap123 e Δsap456, 
construídos pelo método “SAT1-flipping” não apresentaram uma redução significativa 
na virulência, contrariamente ao observado nos mutantes correspondentes, 
construídos pelo método “Ura-blaster”. Utilizando os mutantes novos, o tempo médio 
de sobrevida de murganhos BALB/c infetados com o mutante Δsap123 foi muito 
semelhante ao observado em murganhos infetados com a estirpe selvagem SC5314, 
enquanto os murganhos infetados com mutantes deficientes na expressão do gene 
SAP5 tiveram tempos de sobrevida ligeiramente mais alargados. No entanto, tanto a 
estirpe selvagem, como o mutante Δsap456, foram igualmente capazes de invadir os 
rins de murganhos infetados. Da mesma forma, a deficiência na expressão de SAP4 a 
SAP6 não afetou significativamente a resposta imunitária desencadeada, quer no baço, 
quer nos rins, de murganhos infetados com a levedura. Estes resultados sugerem que 
as Sap1 a Sap6 não desempenham um papel essencial na virulência de C. albicans no 
modelo de candidíase sistémica estabelecido pela via endovenosa. Pelo contrário, no 
modelo de peritonite causado por C. albicans, os murganhos infetados com a estirpe 
Δsap456 apresentaram carga fúngica renal menor do que a dos murganhos infetados 
com as estirpes selvagem ou Δsap123. Os murganhos infetados com a estirpe 
selvagem apresentaram frequências de células T reguladoras (Foxp3+) superiores às 
observadas nos murganhos infetados com as estirpes mutantes, tanto no baço como 
nos gânglios linfáticos mesentéricos. Além disso, as células T CD4+CD25+ de murganhos 
infetados com a estirpe selvagem suprimiram de modo mais marcado a proliferação de 
células T CD4+CD25- do que as células correspondentes de murganhos infetados com 
as estirpes mutantes, enquanto as células de murganhos infetados com a estirpe 
Δsap456 apresentaram o fenótipo menos supressor. Adicionalmente, as células T CD4+ 
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de murganhos infetados com a estirpe selvagem foram as que produziram níveis mais 
elevados de IL-10. É particularmente interessante a observação de uma menor 
presença de células Foxp3+ nas lesões renais de murganhos infetados com o mutante 
Δsap456 em comparação com o observado nos murganhos infetados com as outras 
estirpes. O conjunto dos resultados obtidos implica o envolvimento das enzimas Sap4 a 
Sap6 na resposta imunitária à peritonite causada por C. albicans, acrescentando 
informação adicional sobre o papel destas proteases neste modelo de infeção.  
C. albicans desenvolveu diversos mecanismos para ultrapassar a defesa imunitária do 
hospedeiro. Entre eles, destaca-se a produção de Saps pela capacidade destas enzimas 
em degradar e/ou inativar diversas moléculas da resposta imunitária do hospedeiro. O 
recetor de padrões microbianos galectina-3 (Gal-3) liga especificamente 
oligomanosídeos β-1,2 presentes na parede celular de C. albicans. Esta interação induz 
a morte da levedura e promove a produção da citoquina pro-inflamatória TNF-α pelas 
células do hospedeiro. Neste estudo foi avaliada a degradação da Gal-3 pelas Sap2 
nativa e Sap1, Sap2 e Sap3 recombinantes. Todas as Saps testadas foram capazes de 
degradar e inativar a Gal-3.  Esta poderá constituir uma estratégia para controlar e 
evadir os mecanismos imunitários dependentes de Gal-3. A degradação deste recetor 
poderá originar um microambiente de atividade Gal-3 reduzida, o que poderá facilitar 
a sobrevivência do patogéneo no hospedeiro. 
Estudos prévios mostraram que murganhos imunizados com Sap2 ficaram protegidos 
contra a candidíase mucocutânea e contra a peritonite causada por C. albicans. Aqui, 
alargamos estes estudos e avaliamos a adequação do uso das Sap2 recombinante 
(rSap2) como imunogénio para vacinação contra a candidíase sistémica estabelecida 
por via endovenosa. Foram testadas quatro formulações imunogénicas diferentes, 
utilizando como adjuvantes Alum, Imiquimod, Freund e uma mistura de CpG e Alum. 
Adicionalmente, como a isoenzyma Sap5 é expressa preferencialmente durante a 
candidíase sistémica, foi igualmente avaliado o seu uso como antigénio alvo para 
vacinação contra a doença, utilizando Alum ou Imiquimod como adjuvantes. Nenhuma 
das preparações testadas resultou na proteção dos murganhos imunizados contra a 
infeção fúngica. Estes resultados sugerem que as enzimas Sap2 e Sap5, apesar do seu 
potencial papel na virulência de C. albicans, poderão não ser proteínas-alvo adequadas 
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para utilização em estratégias imuno-preventivas contra a candidíase sistémica 
estabelecida pela via endovenosa.  
Em resumo, os resultados apresentados nesta tese fornecem informações adicionais 
sobre o envolvimento diferencial das Saps em modelos de infeção distintos. Além 
disso, estes resultados, ao mostrarem que a resposta imunitária do hospedeiro é 
afetada pela falta de expressão de genes SAP, suportam um papel imuno-modulador 
das Saps que havia sido previamente sugerido. Finalmente, a falta de proteção 
imunitária do hospedeiro contra a candidíase sistémica estabelecida pela via 
endovenosa reforça o papel limitado destas proteases neste tipo de infeção.   
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1. General introduction 
The genus Candida is composed of a very heterogenous group of more than 150 yeast 
species (1), yet only a few are recognized human pathogens. The species most 
commonly encountered in medical practices are C. albicans, C. glabrata, C. tropicalis, 
C. parapsilosis and C. krusei (2, 3). Besides the yeast form, the majority of the members 
of the genus can also display a filamentous type of growth, as pseudohyphae. In 
addition, C. albicans and C. dubliniensis also form true hyphae, in addition to 
pseudohyphae (2). 
Even though the prevalence of infections caused by non-albicans Candida species is 
rising, the majority of candidiasis cases, regardless of clinical setting and geographical 
location, are still caused by C. albicans (4). 
C. albicans commonly colonizes the human gastrointestinal, respiratory and 
reproductive tracts, and the skin (5), generating no obvious pathology. However, under 
certain conditions, C. albicans is capable of causing a wide spectrum of infections, from 
superficial thrush to life-threatening systemic candidiasis, making it the most prevalent 
fungal pathogen in humans (6, 7).  
Transition from colonization to mucosal invasion and/or systemic dissemination 
depends upon host and fungal factors (8). Infection of a host starts with the adherence 
of fungi to the epithelial surface layers and further dissemination to different host sites 
(9). The immune status of the host is important for the transition from commensal to 
pathogen (10). However, the adaptation of C. albicans to new niches within the host is 
also critical for this transition (2). Fungi respond to change in a specific environment by 
inducing transcriptional and translational changes that promote survival and fitness 
under the new environmental conditions (11-13). 
2. Candida infections 
Clinical disease can be divided into two broad categories, mucocutaneous and systemic 
infection, each with its own risk factors.  
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2.1. Mucocutaneous candidiasis 
Infections of the skin and mucous membranes due to Candida spp. are growing in 
incidence and can occur either in immunocompromised or in immunocompetent 
patients (14-16). 
 
Oropharyngeal candidiasis  
Oropharyngeal candidiasis (OPC) is very common in HIV-positive individuals, affecting 
nearly 90% of subjects at some stage during the course of HIV disease progression (17-
20). C. albicans is always the most prevalent species in this type of infection, followed 
by C. glabrata, C. dubliniensis and C. tropicalis (17). 
In non-HIV-infected individuals, the epidemiological data of OPC are not as intensively 
studied as in HIV-infected individuals. Predisposing factors in these patients include 
concomitant treatments with corticosteroids, antibiotics or immunosuppressive and 
anticancer drugs (21), diabetes, elderly and infancy (22). The most important 
predisposing factor for OPC other than T-cell immunodeficiency is the wearing of 
removable dentures (23). 
 
Candida esophagitis  
Candida esophagitis occurs in patients with chronic diseases, most of whom have been 
previously treated with antibiotics or steroids, but the disease most frequently occurs 
in those with advanced HIV infection and affects 10% of patients with AIDS (24, 25). 
Some of these patients have concomitant OPC (26). 
 
Vulvovaginal candidiasis  
Vulvovaginal candidiasis (VVC) is a mucosal infection caused by several Candida spp. 
with C. albicans as the most common yeast obtained from vaginal fungal cultures (27-
30). Approximately 70% to 75% of women experience at least one episode of VVC in 
their lifetime, and 20% suffer from recurrence (28, 31), usually caused by the same 
single strain through sequential infections (32, 33). Subjects at higher risks for VVC are 
pregnant HIV-infected women and, to a lesser extent, HIV-negative pregnant women 
(34). HIV-infected women have higher frequencies of Candida spp. colonization than 
HIV-negative women (34-36), yet the influence of CD4+ T cell numbers in the 
 5 
 
occurrence of VVC is not consensual. Other risk factors are diabetes, and antibacterial 
vaginal or systemic therapy (5). 
 
Chronic mucocutaneous candidiasis  
Chronic mucocutaneous candidiasis (CMC) is a set of syndromes in which patients have 
chronic and/or recurrent infections of the skin, nails, and mucous membranes due to 
Candida spp. (5), without a known underlying cause (37). 
 
2.2. Disseminated candidiasis 
Candida species have emerged as an important cause of bloodstream and deep tissue 
infections. Bloodstream infections caused by these organisms are also designated as 
candidemia, which often lead to Candida spread to internal organs, a condition known 
as disseminated or systemic candidiasis. Most cases occur in hospitalized patients and 
up to half are associated with intensive care units (38-41). 
 
Nosocomial Candida infections 
The incidence of nosocomial fungal infections (defined as invasive fungal infections 
acquired in a health care-associated setting) has dramatically increased. As the 
population of immunosuppressed individuals has increased (secondarily to the 
increased prevalence of cancer, chemotherapy, organ transplantation, and 
autoimmune diseases), so has the incidence of Candida invasive infections (42, 43).  
 
Frequency  
Candida species are by far the most common fungi causing invasive disease in humans 
(44-46).  
Data from the most recent studies in the US indicate that Candida spp. are now the 
third most frequent nosocomial bloodstream isolates (47-51). However, in Europe, 
Candida species are considered to be between the fifth and tenth most common 
causative pathogen of bloodstream infections (41). The true incidence of disseminated 
candidiasis may nevertheless be markedly underrepresented in studies focusing on 
blood cultures, because of the difficult diagnostic in these samples (52, 53) and thus, 
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studies which reflect clinical diagnoses of disseminated candidiasis, rather than relying 
upon blood cultures, have indicated a predicted value of 24 cases per 100,000 
population in the US (54). Hence an estimated number of 60-70,000 cases of 
disseminated candidiasis occur per year in the US alone, with a health care cost 
associated of $2-4 billion/year (54, 55).  
Through the late 1980s, the predominant species causing invasive Candida infections 
was C. albicans. Indeed, C. albicans is by far the most virulent species of Candida in 
animal models (56-61). However, since the 1990s there has been a steady increase in 
the relative frequencies of non-albicans species of Candida causing disseminated 
candidiasis. This epidemiological trend has profound consequences for selection of 
empiric antifungal therapy. C. albicans has been responsible for approximately 50% of 
invasive Candida infections, with C. glabrata generally as the second most common 
cause of infection in the US and much of Europe, causing 15-25% of cases (44, 47, 50, 
62-70). In contrast, in Latin America, Portugal and Spain, C. parapsilosis is the second 
most common cause of invasive candidiasis (71-74). C. tropicalis was acknowledged as 
causative of 10-20% of cases in most studies. The frequency of other species remains 
low, except in major cancer centres where widespread azole prophylaxis is used. In 
such centres, C. krusei may cause 10% of cases of invasive Candida infections (71, 75-
78).  
 
Origin 
The origin of the infecting strain in the establishment of systemic infections is still 
controversial. Although the GI tract of most people is colonized by Candida, it is not 
clear whether the strains that colonize healthy hosts are responsible for causing 
subsequent invasive disease when those hosts acquire the appropriate risk factors, or 
if infections are caused by acquisition of more virulent strains from environmental 
sources in the nosocomial setting. Available data suggest that in most cases, the 
source of an infecting C. albicans strain is indeed endogenous flora (79-83), but that in 
certain circumstances exogenous transmission may occur in the nosocomial setting 
(84, 85). 
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Risk factors 
The majority of patients who develop disseminated candidiasis are not 
immunosuppressed in the classical sense (such as neutropenic, corticosteroid-treated, 
infected with HIV, etc.) (39, 41, 62, 63, 67, 70, 86, 87). Rather, the predominant risk 
factors for disseminated candidiasis are common iatrogenic and/or nosocomial 
conditions. In particular, 65-90% of patients with disseminated candidiasis harboured a 
central venous catheter (39, 62, 88-90). This and other medical devices are easily 
colonized by candidal cells from mucosal surfaces and provide the opportunity for 
these cells to form biofilms, which are more resistant to drugs and capable of greater 
tissue invasion, enabling fungal spread from one tissue site to another (91). 
Hospitalization in the intensive care unit (ICU) provides the opportunity for 
transmission of Candida among patients and has been shown to be an additional 
independent risk factor. Another important independent risk factor for development 
of disseminated candidiasis is colonization by Candida spp. (82, 92-96). Patients with 
higher colonization burdens and more sites colonized have a proportional higher risk 
of developing hematogenously disseminated disease (97, 98) (and treatments that 
lower colonization burden simultaneously decrease the risk of candidemia (99).  Broad-
spectrum antibiotic therapy may alter the growth of normal bacterial flora, resulting in 
increased Candida colonization burden (100-102) and, consequently, increasing the 
risk of disseminated candidiasis (103-105). Additionally, disruption of normal skin 
barriers, for example by burn injury or percutaneous catheter placement (104, 106-
111), and disruption of gut mucosal barriers by abdominal surgery, instrumentation, 
induction of mucositis (63, 111, 112) or parenteral nutrition (113), are major risk 
factors for invasive Candida infections. Direct translocation of Candida across the GI 
tract of animals and humans has been well documented (8, 113, 114), and GI surgery is 
a well-described clinical risk factor for development of disseminated candidiasis (115-
118). More recently, cardiac surgery has also been described as a major risk for 
disseminated candidiasis (119-121). Neutropenia or abnormalities in neutrophil 
function dramatically increases the risk of developing disseminated candidiasis and the 
expected mortality rate (67, 70, 92, 122-126). Concordant with their well-characterized 
suppression of phagocyte function, glucocorticoids also increase the risk of 
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disseminated candidiasis (123, 127-129). Similarly, diabetes markedly increases the 
incidence of both mucocutaneous and disseminated candidiasis (130, 131).  
Candidemia in cancer patients is also thought to develop from initial GI colonization 
with subsequent translocation into the bloodstream after administration of 
chemotherapy. In a murine model of GI candidiasis, systemic chemotherapy with 
cyclophosphamide, which causes simultaneously neutropenia and GI mucosal damage, 
led to disseminated fungal infection and 100% mortality ensued in mice previously 
colonized with C. albicans (114). In this study, neutropenia alone or combined with 
macrophage depletion did not result in Candida translocation and mice death. 
Likewise, GI mucosal damage alone was not sufficient for the development of 
candidemia. Instead, both neutropenia and GI mucosal damage were crucial for C. 
albicans dissemination from the GI tract. 
Patients with late stage HIV disease have an extremely high incidence of developing 
mucocutaneous candidiasis (130, 132). However, HIV infection is not an independent 
risk factor for disseminated candidiasis. The occurrence of disseminated candidiasis in 
patients infected with HIV is attributable to the increased incidence of the usual risk 
factors for candidemia, including indwelling catheters, broad-spectrum antibiotics, 
hospitalization in an ICU, parenteral nutrition, and neutropenia (106, 110). Patients 
infected with HIV who do not have additional risk factors for disseminated candidiasis 
are not at increased risk of developing the disease. 
 
Therapeutic strategies 
Not only are invasive Candida infections extremely difficult to diagnose, they are also 
difficult to treat. Even with first-line antifungal therapy, disseminated candidiasis has 
an attributable mortality of up to 40% (87, 133, 134) , or even over 50% attributable 
mortality in patients that undergone myeloablative chemotherapy (93, 105, 123) . 
Unfortunately, newer therapies, such as voriconazole, lipid-based amphotericin 
formulations, and echinocandins, have not considerably improved survival of patients 
with candidemia, compared to the classical amphotericin B deoxycholate (135-137). 
Data from several studies supported that delayed initiation of therapy for candidemia 
is associated with significantly higher mortality (138-140). 
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Because of the difficulties in confirming the diagnosis with laboratory studies, empiric 
therapy administration must often be based on a clinical diagnosis of disseminated 
candidiasis. A clinical diagnosis of disseminated candidiasis is typically made in a  
patient with signs, symptoms, and laboratory features consistent with infection, who 
does not respond to broad-spectrum antibacterials, and who has risk factors for 
disseminated candidiasis. In such patients, early empiric therapy is appropriately 
administered. If a clinical response is seen, a clinical diagnosis of disseminated 
candidiasis can be made retrospectively. Consensus guidelines on the empiric 
treatment of disseminated candidiasis are available (141, 142). In the guidelines of the 
European Society of Clinical Microbiology and Infectious Diseases (ESCMID), it is clear 
that all three echinocandins (anidulafungin, caspofungin and micafungin) are likely 
equivalently efficacious for the treatment of disseminated candidiasis in ICU patients. 
The use of fluconazole has only marginal support and voriconazole and liposomal 
amphotericin B have moderate support. Combination therapy is not recommended, 
either for these patients or for hemato-oncological patients. For the last group of 
patients, caspofungin and micafungin are the most appropriate antifungal drugs for 
treatment of invasive candidiasis and candidemia in neutropenic patients or 
hematopoietic stem cell transplant recipients. For empirical treatment in neutropenic 
patients, the use of caspofungin and liposomal amphotericin B have a strong 
recommendation, while there is moderate support for voriconazole and micafungin 
(142). 
From these guidelines it is also clear that catheter removal is not mandatory if 
echinocandin is being used (142, 143). 
 
3. Candida virulence factors 
Candida pathogenicity is a complex and highly regulated multifactorial process(144). 
The expression of several C. albicans genes or proteins associated with infection has 
been extensively studied. The role of a determined putative virulence factor can be 
assessed by comparing the biological response of the fungus with and without the 
factor. The most convincing evidence for a factor to be considered as a virulence 
determinant is the simultaneous loss of the factor and of virulence, and the regaining 
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of virulence when the factor is restored (144). Virulence factors must help the 
pathogen to grow at elevated temperatures, facilitate adherence, penetration and 
dissemination, or assist in resistance against or evasion from innate immune defenses.  
It has become clear that a complex combination of properties rather than a single 
putative virulence factor are usually required for a fungus to successfully adapt to the 
different host niches met during the infectious process (144, 145) .  
 
3.1. Morphogenesis 
One of the most unique characteristics of C. albicans is its ability to reversibly change 
between the unicellular yeast and filamentous (hyphae and pseudohyphae) growth 
modes (146). Polymorphism of C. albicans is known to be one of the most important 
virulence factors of the fungus (145, 147, 148) and has been associated with tissue 
destruction and invasion (149-153), although both C. albicans yeast and hyphal cells 
are found in infected host tissues (147). In fact, the nature of association between 
fungal morphogenesis and host invasion is a highly debated aspect of fungal virulence 
(154, 155). 
The switch from yeast to hyphal growth is controlled both by the environment and by 
numerous other stimuli. The standard trigger of hyphal growth is nutrient poor media 
and a rise in temperature, together with N-acetyl-glucosamine (GlcNAc) or serum 
(146). External pH is another signal regulating morphogenesis (156). In the host, C. 
albicans switches to the hyphal form to adhere to and penetrate through tissues, and 
this fungal plasticity has been demonstrated in several studies to be strongly required 
for C. albicans pathogenesis (157-159). 
The yeast-hypha transition process is regulated by different interconnected signal 
transduction pathways (160). Efg1 (161, 162), and Cph1 (161) have been identified as 
key transcriptional regulators for the cAMP-protein kinase (PKA) and the mitogen-
activated protein kinase (MAPK) pathways, respectively. The role of these factors in 
morphogenesis and their relevance for Candida infections was demonstrated by using 
strains which lacked either functional Efg1, Cph1 or both factors (147, 161-170) . 
Disruption of CPH1 caused attenuated C. albicans hyphal formation on solid media, 
while mutants lacking EFG1 failed to produce hyphal cells under most conditions 
investigated. Moreover, mutants lacking EFG1 had significantly attenuated virulence in 
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murine models of hematogenously disseminated infection (164, 171) , in a murine 
model of Candida peritonitis (172), in the interaction with macrophages (164), in the 
ability to colonize successfully on polyurethane central venous catheters (165), and 
also in the ability to invade or damage endothelial (166), epidermal (163, 173, 174) or 
intestinal cells (163).  
The transcription factor Rim101 regulates pH-dependent transition and mutant strains 
lacking RIM101 also have a defective virulence phenotype (175). The TEA/ATTS 
transcription factor Tec1 is essential for serum-induced filamentation (176) and the 
Δtuc1 mutant was found to be locked in the filamentous form, with negative 
consequences in its ability to cause disease. Furthermore, there are a number of other 
transcription factors (Czf1, Flo8, Hap5 Efh1, Ace2 Mcm1, Ash1 and Cph2) involved in 
filamentation under specific growth conditions (146). The attenuated virulence, or 
even avirulence, of the mutant strains lacking any of these genes seemed to be caused 
not only by the interference in the filamentation process, but also by a reduction or 
loss of expression of virulence-associated genes under their regulation (164, 177, 178) . 
 
3.2. Phenotypic switching 
Phenotypic switching in C. albicans affects several phenotypic and metabolic 
parameters, including recognized virulence traits. Colonies of C. albicans show 
reversible morphological variation that occurs spontaneously in stress, resulting in 
changes in cell surface, colony appearance, metabolic, biochemical and molecular 
attributes, with impact on fungal virulence (15, 179). Interestingly, strains isolated 
from vaginitis or systemically infected patients showed higher frequencies of 
switching, indicating a strong role for the switching phenomenon in establishing 
disease (180). Although many phenotype switching phenotypes have been described in 
C. albicans, the white-opaque system in strain WO-1 is the most studied (181, 182). 
The ability to switch to the opaque form (mating-competent form) depends on 
whether the mating type locus (MTL) is homozygous. Most C. albicans cells are unable 
to switch since they are heterozygous for the MTL (MTLa/MTLα) and express the 
heterodimeric α1/α2 repressor (182). Although transition occurs at very low levels, 
white-opaque switching can be induced by environmental signals. One of the most 
relevant is the induction of switching to the opaque phase by anaerobic conditions, 
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such as those encountered by passage of white cells through the mammalian intestine 
(183).  
Like the yeast-hyphae transition, white-opaque phase transition also influences fungal 
virulence (180, 184). Macrophages seem to preferentially phagocytose white cells 
(185) and that has also been recently observed with neutrophils. Neutrophils 
phagocytosed more efficiently white cells that were beginning filamentation, 
indicating that suppression of filamentation observed in opaque cells avoided 
neutrophil recognition and may represent a strategy for immune evasion (186).  In 
contrast, dendritic cells phagocytosed white and opaque phase cells equally (186). 
However, white cells are known to be more resistant to candidacidal activity of PMN 
(187). Indeed, the viability of opaque cells is reduced when compared to white cells 
under many growth conditions (188, 189). However, even though opaque cells are 
generally considered as less virulent than white cells in several murine models (184, 
190), they were found to be better able than white cells to infect skin (180).  
 
3.3. Adhesins 
Adherence of C. albicans cells to host tissues is a complex multifactorial phenomenon 
employing several types of adhesins expressed on morphogenetically changing cell 
surfaces.  
The C. albicans agglutinin-like sequence (ALS) gene family is composed of at least eight 
genes encoding cell-surface GPI-anchored proteins that have long been associated 
with adhesion of C. albicans cells to host tissues and even to abiotic surfaces (191, 
192). High allelic variability has been shown in ALS genes, often within the same C. 
albicans strain, leading to strikingly different adherence profiles (191, 193). Of the ALS 
family members, the ALS1 and ALS3 genes encode adhesins with the broadest array of 
substrate affinity (193). The structural and functional diversity within the Als family 
most certainly provides C. albicans with an array of cell wall proteins capable of 
recognizing and interacting with a wide range of host constituents during infection 
(193). The expression of some ALS genes has also been involved in biofilm formation 
(194, 195) and in other growth-related functions (191). ALS gene family members were 
differentially expressed in response to specific stimuli in vitro and have been 
associated with hyphal morphogenesis (196-198). The expression of Als proteins was 
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detected by immunohistochemistry in C. albicans cells infecting the kidneys, spleen, 
heart, liver and lungs of mice (196). ALS genes might be differentially regulated in a 
niche-specific fashion. ALS6 and ALS7 were expressed at relatively low levels, and ALS4 
appeared to be downregulated in vaginal samples. Interestingly, ALS expression 
patterns determined by RT-PCR in clinical samples were similar to those observed in 
the corresponding animal models of oral, vaginal and systemic candidiasis, and in 
reconstituted human epithelial models (199-201). Als3, and to a lesser extent Als1 and 
Als5, were found to be important for the epithelial and endothelial invasion process 
(193). Als3 also binds cadherins and induces fungal endocytosis by host cells (202). 
Moreover, Als3 binds ferritin and allows C. albicans to use iron in oral cavities (203).  
HWP1 (hyphal wall protein) encodes a cell-surface adhesin expressed during hyphal 
development (204, 205) that promotes strong interactions between C. albicans and 
host cells (206). Production of Hwp1 has been confirmed in the mouse model of 
systemic infection by immunohistochemistry (204). Studies with a hwp1-deficient C. 
albicans mutant have reported its reduced adherence and mortality in murine models 
(206, 207), and HWP1 expression has been analysed in samples from human oral and 
vaginal infections (208, 209). Nevertheless, Hwp1 appears to be important not only for 
invasion but also for benign interactions of C. albicans with the host (208, 209). 
 
3.4. Biofilm formation 
Biofilms are surface-associated microbial communities with significant environmental 
and medical impact. C. albicans is able to form biofilms on catheters, endotracheal 
tubes, pacemakers and other prosthetic devices and has been involved in the 
establishment of device-associated nosocomial infections (91, 210). Moreover, 
biofilms have reduced susceptibility to several components of the host immune 
response and to antifungal drug therapy (211). C. albicans biofilms are heterogenous 
three-dimensional structures containing hyphae form cells, with altered phenotype, 
growth rate, and gene expression compared to planktonic cells, enclosed in an 
extracellular polymer matrix consisting of polysaccharides and proteins (212). 
Heterogeneity of these biofilms depends on the substrate composition, environmental 
conditions, and strains involved. Biofilm formation was found to be linked to 
dimorphism and phenotypic switching, well-known virulence traits for candidal cells 
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(210, 211, 213) and a variety of genes, such as the ALS gene family and HWP1 are 
upregulated during biofilm formation (197, 199, 211, 214) , in particular, ALS1 and 
ALS3 expression was reported as necessary for biofilm formation (194, 215).  
ALS1, ALS3, and HWP1 are regulated by the transcription factor Bcr1 (biofilm and cell 
wall regulator), which is under the control of transcription factor Tec1 (214-217) . 
Nobile et al (194) suggested that Hwp1 and Als proteins might function as 
complementary adhesions in biofilm formation. The hypha-associated EFG1 gene is 
also required for normal biofilm growth, and hypha-deficient mutants had defective 
biofilms that also adhered poorly to the substrate (165, 218). Besides, biofilms are 
under tight regulation of gene expression that is controlled through quorum sensing 
molecules (219). 
 
3.5. Hydrolytic enzymes 
Three types of secreted enzymes have been described extensively: phospholipases, 
lipases and secreted aspartyl proteases. 
 
3.5.1. Phospholipases B  
Phospholipases B (PLB) are enzymes that hydrolyze ester linkages of 
glycophospholipids and also possess lysophospholipase transacylase activity. Plb 
activity was the major phospholipase activity found in C. albicans culture supernatants 
(220). They play a central role in cellular processes such as signal transduction and 
inflammation through their effect on the metabolism of phospholipids and 
lysophospholipids. C. albicans extracellular Plb are encoded by five putative genes. 
PLB1 (221), PLB2 (222) and PBL5 (223) have already been cloned and described. PLB 
expression has been detected in mucosal, gastrointestinal and systemic infection 
models. Differential expression of PLB1 and PLB2 was demonstrated, by using RT-PCR, 
in samples from human oral and vaginal infections (224, 225). Several studies 
investigated the role of Plb in C. albicans virulence. A clinical isolate producing high 
amounts of phospholipases was invasive in a murine model of disseminated 
candidiasis whereas a low-producing strain was not (226). In this infection model, 
phospholipase activity highly correlated with the severity of kidney burden (227) and 
phospholipase-activity was the only putative virulence factor tested that predicted 
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mortality (226). Leidich et al (228) and Mukherjee et al (229) showed that mutant 
strains lacking PLB1, which have 1% of the extracellular Plb activity of the wild-type 
strain, had significantly attenuated virulence in a model of disseminated infection in 
mice.  In a similar model of infection, a mutant strain deficient in PLB5 caused reduced 
liver and kidney fungal burdens (223). Noteworthy, the ability of Δplb1 null mutant to 
penetrate host cells was dramatically reduced (190, 230). However, adherence of the 
yeast cells to human endothelial or epithelial cells was not affected in a Δplb1 null 
mutant strain, suggesting that Plb most likely contribute to the pathogenicity of C. 
albicans by damaging host cell membranes and aiding the fungus to invade host 
tissues (231, 232). To this hypothesis certainly contribute the findings that Plb 
secretion is mainly concentrated at the growing tips of mature and developing hyphae 
(229, 233).  
 
3.5.2. Lipases  
At least ten members constitute C. albicans Lipase (LIP) gene family, and there is 
plenty evidence that this gene family is differentially expressed in vivo (234). 
Expression of LIP5, LIP6, LIP8, and LIP9, but not the other members was detected in a 
mouse model of C. albicans peritonitis (234). LIP1, LIP3 and LIP9 were found in infected 
gastric tissues, but undetectable in oral mucosa (235). Another study indicated that 
LIP4 preferentially plays a role in superficial infections (236). 
It is likely that these enzymes, like phospholipases, are involved in virulence of C. 
albicans, but their roles and functions during infection remain to be elucidated  (234, 
237).  
 
3.5.3. Secreted aspartyl proteases  
Microbial extracellular proteases are mostly secreted for the producing 
microorganisms to obtain readily available nutrients from complex materials or to 
compete with other environmental microbes (238). However, pathogenic 
microorganisms may also secrete proteases to accomplish other functions during the 
infective process, such as hydrolysing proteins of host cell membranes to facilitate 
adhesion and tissue invasion or damaging cells and molecules of the host defence 
system to evade or resist the host immune response (239-245). Classically, proteases 
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are ordered in four classes: serine, cysteine, metallo and aspartyl proteases. Aspartyl 
proteases are ubiquitous in nature and are involved in numerous biochemical 
processes (246). All secreted C. albicans proteases belong to the same class of enzymes 
– the aspartyl proteases. C. albicans secreted aspartyl proteases (saps) are essential for 
cell growth when proteins are the sole nitrogen source (247). Sap production is also 
involved in C. albicans pathogenicity and has been associated with several C. albicans 
virulence attributes, including hyphal formation, adhesion and phenotypic switching 
(241). 
So far, 10 SAP genes have been identified with open reading frames ranging from 1173 
to 1764 base pairs in length, and located on five different chromosomes.  
 
Processing, activation, and regulation of C. albicans secreted aspartyl proteases  
All 10 SAP genes of C. albicans encode preproprotein forms, which are processed along 
the secretory pathway. The prepropeptide, which includes a signal peptide and a 
propeptide, is approximately 60-200 amino acids longer than the mature enzyme and 
is essential for correct folding and secretion of the protein. The pathway of protease 
synthesis starts in the nucleus, from where the newly synthesized mRNA is transferred 
to the cytoplasm and translated into the preproenzyme on the rough endoplasmic 
reticulum (rER) where the N-terminal signal peptide is removed by the signal peptidase 
complex (248). The ‘pro’ region probably acts as an intramolecular chaperone that is 
required for proper folding in the rER, since Sap1 lacking its propeptide is retained in 
the rER (249). The ‘pro’ region is released and degraded by an exogenous protease 
leaving the folded enzyme in the active state (250). Later in the Trans Golgi Network 
(TGN), the propeptide is removed by a protease after conserved Lysine-Arginine 
sequences (251-253). The mature enzymes contain sequence motifs typical for all 
aspartyl proteases, including two highly conserved regions with reactive aspartyl 
residues of the active site and a third conserved region at the C-terminus of the 
protein (254, 255). Moreover, four cysteine residues, conserved in all aspartyl 
proteases, may form two disulphide bridges and are probably responsible for the 
maintenance of the three-dimensional structure (256). Once activated, mature Saps, 
with molecular weights between 35 and 50 kDa, are packaged into secretory vesicles 
and transported to the plasma membrane. There, Saps are either released into the 
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extracellular space (Sap1–8) or remain attached to the cell membrane or cell wall via a 
GPI anchor (Sap9 and Sap10, also called yapsin-like proteases) (254, 257). 
Since the SAP gene family encode preproenzymes, the regulation of protease 
expression can be controlled either at mRNA or protein levels. Comparisons of Sap 
protein and mRNA levels at identical time points (258) and kinetic studies of protease 
secretion by pulse chase (259) suggested that protease synthesis and secretion were 
tightly coupled, strongly implying that regulation of Sap activity occurred 
predominantly at the mRNA level. Most Sap proteins contain putative N-glycosylation 
sites, and treatment with endoglycosidase EndoH has revealed that Sap4, 6, 7, 8, 9 and 
10 were N-glycosylated (260), confirming previous observations of Albrecht et al (261) 
that the yapsin-like Saps were highly glycosylated.  
 
Purification, activity and biochemical properties of the C. albicans secreted proteases 
C. albicans proteolytic activity was first described by Staib (262) based on cell growth 
in media containing BSA as the sole source of protein, later attributed to an 
extracellular protease (263). Numerous studies of the biochemical properties of Sap 
isoenzymes have been performed afterwards, by using purified culture supernatants 
(264-266)or recombinant proteins obtained by recombinant expression in Pichia 
pastoris (260, 267) or Escherichia coli (268). Sap2 is the most abundantly secreted 
protein in vitro when C. albicans is grown in protease inducing media (247, 258). Thus, 
data from studies using culture supernatants largely correspond to Sap2 proteolytic 
activity. Structural studies of the C. albicans protease family have also concentrated on 
Sap2 (269, 270). The structure of Sap2 corresponds to the classical aspartyl protease 
pepsin.  
Studies on the biochemical properties of recombinant Saps revealed similarities and 
differences in their structures and active sites, pH optima and substrate specificities.  
The majority of the Sap isozymes (Sap1-6) showed highest proteolytic activity at acidic 
pH 3.0-6.0 (260, 264, 266-268, 271) , which is typical for aspartyl proteases. Sap1 to 
Sap3 have highest activity at lower pH values and Sap4 to Sap6 have highest activity at 
higher pH values, (260, 267, 268). Sap8 has the lowest optimum pH (2.5) (260). In 
contrast, Sap7 showed optimal activity at neutral pH, which is an unusual pH for 
 18 
 
aspartyl protease activity (260). In addition to different pH optima, cleavage site 
specificity of Candida Sap proteins has been suggested (265, 272).  
Sap versatility may contribute to the success of C. albicans as an opportunistic 
pathogen by providing C. albicans with a biological advantage and enhancing the 
pathogenic ability of the fungus in vivo (241). The production of several Sap 
isoenzymes with distinct pH optima may promote C. albicans colonization and 
infection of different tissues and host niches. A family of proteases with different 
substrate specificities would allow C. albicans to make use of an array of host proteins 
at several host sites to provide nitrogen for the yeast. However, C. albicans produce 
Saps with highly similar substrate specificities and similar optimum pH ranges 
simultaneously, which makes it possible that they have similar target proteins and 
overlapped functions. Nevertheless, it is still not clear whether the digestion of 
substrates by Saps in vivo is similar to that shown in vitro.  Although the specific host 
targets of Saps in vivo are not accurately known, some conclusions can be inferred 
from the combination of Sap in vitro proteolytic properties and results from several 
models of infection in which protease inhibitors or sap-deficient mutant strains were 
used.  
The great majority of studies focusing Sap substrate specificity were done in protease-
inducing growth medium, known to favour SAP2 expression (247, 258). Thus, the 
potential targets of the Sap family in vivo determined therein have been mainly based 
on Sap2 activity in vitro. One of the most remarkable properties of Sap2 is the diversity 
of proteins it can cleave. Sap2 is able to degrade many human proteins, like the ones 
that protect mucosal surfaces and cell-surface proteins, such as keratin, collagen, 
vimentin, fibronectin, laminin and mucins (273-278). The secretory immunoglobulin A 
(IgA) is also degraded (272, 279), what is worth mentioning since it is considerably 
more resistant to proteolysis than are monomeric or serum immunoglobulins. Wu and 
Samaranayake (280) suggested that Candida Sap proteins could degrade salivary 
proteins in the oral cavity because a reduction of total salivary protein concentration 
correlated with the degree of Sap expression, and Meiller et al (281) proved that 
histatin-5 was degraded by aspartyl proteases. C. albicans proteases may also evade 
host defenses by directly degrading molecules such as salivary lactoferrin, 
lactoperoxidase, cathepsin D (an intracellular lysosomal enzyme of leukocytes), and 
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complement (274, 282-284). In addition, Sap2 can degrade β2-macroglobulin, a natural 
protease inhibitor in human plasma (285), and cystatin A, a cysteine protease inhibitor 
found in human epidermal tissues and fluids (286). Sap can cleave pro-interleukin-1β 
into the proinflammatory cytokine interleukin-1β (287) and can also activate Hageman 
factor, a serine protease of the kallikrein-kinin system, which may cause increased 
vascular permeability in vivo (288). Similarly, Sap2 may also act on the blood clotting 
system by activating coagulation cofactor X (289), clotting factor XII, or prothrombin, 
which may result in the generation of thrombin and consequently blood clotting (290). 
These substrates have been mainly tested with Sap2, but it is likely that other Saps also 
target part of them, which may result in overlapping functional roles in vivo between 
members of this gene family. Despite Sap2 ability to degrade such a huge set of 
proteins, these can nevertheless be at environments in which pH does not favour SAP2 
expression and Sap2 proteolytic activity. Indeed, Sap2 is almost inactive at neutral pH, 
the pH found in the milieu of most of these proteins.  
Sap9 and Sap10 are regulatory proteases that may play a role in the cell surface 
integrity and shedding of cell-surface proteins (261). Target proteins may be proteins 
of the cell membrane, of the cell wall, or secreted proteins, including other Saps. 
However, Sap2 processing is independent of Sap9 and Sap10, since total proteolytic 
activity of Δsap9 and Δsap10 mutants was not reduced when comparing with the wild-
type strain (261). Processing of Sap9 and Sap10 target proteins is not essential for 
normal growth though it is necessary for normal separation of cells after budding 
(261).  
 
Differential expression and transcriptional regulation of SAP genes  
The existence of 10 SAP genes suggested that different proteases might target distinct 
host cells and tissues during C. albicans infections and might play key roles in the 
pathogenesis of C. albicans infections. In that sense, the different SAP genes would be 
differentially regulated and expressed under a variety of laboratory growth conditions, 
during the experimental C. albicans infections, and also in vivo.  
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In vitro SAP expression and regulation 
The initial SAP expression studies were performed in vitro to comprehend the 
regulation of SAP gene expression induced by changes in growth environment, 
morphological transition from yeast to hypha and phenotypic switching (241, 256, 
291). Under the protease-inducing conditions generally used, the major protease gene 
expressed in the yeast form of C. albicans was SAP2, which is regulated by exogenous 
protein or peptides. The accumulation of proteolytic products of Sap2 and peptides of 
eight or more amino acid residues, resulting from proteolysis of high-molecular weight 
proteins, led to the induction of SAP2 gene expression via a positive-feedback 
mechanism (247, 292). The widely used SC5314 strain possesses two SAP2 alleles, 
which are differentially regulated, either in vitro or in vivo. Under appropriate 
conditions, the SAP2-2 allele may serve as a signal sensor and amplifier to enhance its 
own expression, as well as to induce the SAP2-1 allele to achieve maximal proteolytic 
activity (293). Two other SAP genes, SAP1 and SAP3, are known to be differentially 
expressed in vitro when C. albicans undergoes phenotypic switching (264, 294). Both 
isoenzymes are expressed in the opaque but not in the white form of strain WO-1 
(264, 294).  
Curiously, SAP4–6 were almost exclusively expressed during hyphal formation at 
neutral pH, even in defined protein-free media, albeit most aspartyl proteases are 
usually only active under acidic conditions (247, 258). The SAP4–6 subfamily was 
usually assessed as a group during these early studies, and thus conclusions are to be 
applied to the subfamily as a whole. SAP8 expression is more strongly induced at 25ºC, 
suggesting that its expression is temperature regulated in vitro and, possibly in vivo 
(254). More recently, SAP9 and to a lesser extent SAP10 were found to be expressed in 
YPD preculture growth, and appeared to be independent of environmental conditions 
and morphology (271). It should also be noted that under all the laboratory growth 
conditions tested in these experiments SAP7 expression was never detected. After 
treatment with subinhibitory concentrations of antifungal agents, increased levels of 
mRNA transcripts were reported for several SAP genes. SAP2 and SAP9 expression was 
induced upon exposure to fluconazole and caspofungin in protease-inducing medium 
(295), while in non-inducing conditions, only SAP5 expression was found increased 
when treated with caspofungin. Barelle et al (296) also reported increased expression 
 21 
 
of SAP4, SAP5 and SAP6 after exposure to subinhibitory concentrations of azole 
antifungal agents in hyphal-inducing growth conditions.  
Protein expression studies have confirmed that the secretion of Sap5 in C. albicans was 
induced during hyphae formation, followed by secretion of Sap4 and Sap6 under acidic 
conditions, which occurred in vitro in parallel to the degradation of BSA (297).  
 
In vivo SAP expression and regulation  
The in vitro studies confirmed the differential expression of SAP gene family, indicating 
that it was a highly regulated process, and suggested that different members of the 
SAP family might also be differentially expressed in vivo, and might play distinct roles 
during different types or stages of infection and during antifungal treatment. This has 
been confirmed, in both mucosal and systemic C. albicans infections, by several studies 
using technologies such as reverse transcription polymerase chain reaction (RT-PCR) 
and in vivo expression technology (IVET) to assess SAP expression in human samples or 
in in vitro and in vivo experimental models. Using C. albicans-infected oral and vaginal 
reconstituted human epithelium (RHE), Naglik et al (173) reported that within 24h of 
infection, SAP9 was highly and constitutively expressed while SAP10 was also 
constitutively expressed though at lower levels. SAP5 was the only SAP gene that was 
clearly up-regulated during the infection period.  The unique up-regulation of SAP5 
during vaginal RHE infection was also reported by Lermann and Morschhaeuser (174). 
These results contrast the previous reported expression of SAP1–3 subfamily in the 
initial stages of epithelial colonization (298, 299).  
Expression of SAP gene family has been also assessed upon interaction with cells of the 
innate immune system. C. albicans SAP4–SAP6 expression was demonstrated during 
interaction with murine macrophages (267) and in cells incubated with human plasma, 
but not in cells which were incubated with whole blood or phagocytosed by 
polymorphonuclear neutrophils (300).  
To determine whether the in vitro models were representative of the in vivo situation, 
SAP expression was analysed in numerous animal infection models and in human 
samples. In a murine model of oropharyngeal candidiasis, SAP9 transcripts were 
detected continuously throughout the course of infection being SAP5 and SAP9 the 
most highly expressed (301). Staib et al (302) have also reported strong activation of 
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SAP5 and SAP6 during invasion of oesophageal mucosa by C. albicans hyphae. In 
contrast, in a mouse model of gastrointestinal infection, SAP4 and SAP6 were 
constitutively expressed, with SAP2, SAP3 and SAP5 mRNA only occasionally being 
detected (303). SAP gene expression was compared during gastric candidiasis in 
immunocompetent and immunodeficient mice by RT-PCR (304). Gene expression 
patterns were similar in both, suggesting that the immune status of the host has only a 
minor or no influence on the expression of SAP genes.  
The SAP expression profile of C. albicans was analysed in the course of murine vaginal 
infection using an in vivo expression technology (IVET) and green fluorescent protein-
expressing C. albicans reporter strains (302). Of the six SAP genes that were analysed 
(SAP1–SAP6) only SAP4 and SAP5 were detectable during infection. This contrasts the 
results of De Bernardis et al (305), in a rat vaginitis model, which reported the 
preferential expression of SAP2 though SAP1 and SAP3 expression was also found in 
this model. Discrepancies between these results may be explained by the fact that 
physiological mouse vaginal pH ranges between 6.2 and 6.5 (306), a pH interval which 
favours hyphal growth and thus expression of the hyphal-associated genes SAP4–6, 
while at the acidic rat pH (4.5) the expression of SAP1 to SAP3 might be preferential 
(307). 
Naglik et al. analysed SAP expression in subjects with oral and vaginal C. albicans 
infection or asymptomatic carriage (308, 309). In these studies, SAP1, SAP3, SAP4, 
SAP7 and SAP8 mRNA transcripts were predominantly expressed in infected patients 
as opposed to asymptomatic Candida carriers. However, more recently, the same 
group has analysed other groups of patients with oral and vaginal candidiasis and 
could not confirm such an association between SAP expression and infection/carriage. 
SAP9 and SAP5 were the most highly expressed genes in both types of infection and 
SAP2, SAP5, SAP9 and SAP10 were the most commonly expressed genes. These 
authors have also confirmed previous findings (308, 309) that SAP1, SAP3, and SAP8 
expression were more commonly found in vaginal rather than in oral disease.  
The differential expression of SAP genes was also observed during systemic infections. 
SAP5 was the first SAP gene induced after intraperitoneal (i.p.) infection or 
haematogenous dissemination (302). SAP5 expression at this stage of the infection did 
not correlate with the presence of germ tubes or hyphae, and SAP6 gene activation 
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was detected only when C. albicans hyphae were observed in the infected tissue. 
These authors also reported SAP2 induction in the late stages of infection (302). Similar 
conclusions can be taken from a similar model of i.p. infection in which expression of 
SAP2, SAP4–6 and SAP9 was reported for cells invading parenchymal organs (172).  
SAP genes are also regulated by biofilm formation, and higher levels of SAP5, SAP6 and 
SAP9 mRNA transcripts were detected in biofilm rather than during planktonic growth 
(310).  
The expression of SAP1–SAP6 was confirmed at the protein level by using 
immunoelectron microscopy and two different antibodies directed against Sap1–3 and 
Sap4–6 (172, 311) and the results largely agree with the studies reported above. Sap1 
to Sap3 antigens were found on yeast and hyphal cells, while Sap4 to Sap6 antigens 
were predominantly found on hyphal cells in close contact with host cells, in particular, 
eosinophilic leukocytes (172). Sap4 to Sap6 were also detected on hyphal cells that 
have been phagocytosed by murine macrophages (267). 
In conclusion, all these studies indicated that SAP gene expression and regulation, and 
consequently protein production, highly depend on the type and stage of C. albicans 
infection and on the pH conditions and substrate availability in the local environment.  
 
Global transcriptional regulators and SAP expression 
Key transcriptional regulators are known to manage C. albicans morphogenesis and 
the expression of several hyphal associated genes (2). The two transcriptional 
activators Cph1 and Efg1, which are controlled via the MAP kinase or cAMP pathways, 
respectively, regulate not only hypha formation (148), but also the expression of 
hyphal-associated genes, such as SAP4–6. Mutants lacking CPH1 clearly had reduced 
expression levels of SAP4-6, even though filamentous growth in infected tissue was not 
visibly impaired (177). Although efg1 and cph1/efg1 mutants did not produce germ 
tubes during infection, expression of the hyphal associated genes SAP4-6 was reduced 
but not completely abolished, demonstrating that in contrast to in vitro conditions, 
SAP4-6 activation during infection does not strictly depend on growth of C. albicans in 
the hyphal form (172, 177, 312). Nevertheless, these data suggest that the two signal 
transduction pathways are important for SAP4-6 expression in vivo (177).  
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Another transcription factor, Tec1, a member of the TEA/ATTS family of transcription 
factors, is predominantly expressed in the hyphal form of C. albicans. The promoters of 
the hyphal-associated SAP4–6 subfamily contain repetitive TEA/ATTS consensus 
sequence motifs, and expression of SAP4–6 was clearly affected in a tec1 null mutant 
(176). An additional transcriptional factor, Nrg1, represses a subset of genes regulated 
by the general repressor Tup1. Inactivation of Nrg1 results in filamentous and invasive 
growth and derepresses hypha-specific genes, such as SAP5 (313). At last, the 
transcription factor Mig1, like Nrg1, targets the Tup1 repressor to specific subsets of 
genes, including SAP9. However, Tup1 can act Mig1- and Nrg1-independently and 
repress the expression of SAP6 and SAP7 (314). In conclusion, it seems that 
synchronized regulation of germ-tube formation and protease production is essential 
for optimal invasive growth, because mutants lacking either the ability to produce 
hyphal cells or the secretion of hyphal associated proteases Sap4–6 have defects in 
parenchymal organ invasion (172).  
 
Sap production and C. albicans virulence 
The role of Saps as C. albicans virulence factors has been intensively investigated 
during the last decades. Proteolytic activity has been found in vitro in most isolates of 
pathogenic Candida species, including C. dubliniensis (315), C. tropicalis (255, 316, 317) 
and C. parapsilosis (318, 319). Sap activity is regarded as a virulence factor for C. 
albicans (256) and C. tropicalis (320), and its role as a virulence factor for C. 
parapsilosis has been recently highlighted (321). The proteolytic activity of other non-
pathogenic Candida species is generally lower, suggesting that virulence is correlated 
with the level of Sap production (322). 
Secreted aspartyl proteases also seem to be important for the establishment of 
mucosal C. dubliniensis infections. Like C. albicans, C. dubliniensis possesses several 
SAP genes (315, 323), but interestingly, C. dubliniensis does not have the orthologue of 
SAP5 and SAP6, genes involved in systemic C. albicans infections, which may account 
for the almost absent involvement of this species in systemic infections (323, 324).  
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C. albicans virulence modulation by aspartyl protease inhibitors  
The contribution of aspartyl proteases to C. albicans infectious process was first 
confirmed by using the classical aspartyl inhibitor pepstatin A. Colina et al. (273) 
showed that digestion of mucin could be inhibited by pepstatin, indicating that 
Candida Sap proteins may degrade mucosal barrier proteins. This may allow C. albicans 
to gain access to the oral and GI mucosa and may consequently indicate a role for 
Candida proteases in dissemination from these colonized sites. The addition of 
pepstatin inhibited the in vitro digestion of soluble and immobilized extracellular 
matrix proteins produced by a human endothelial cell line (277), what suggests that 
Candida Sap proteins contribute to cell damage and invasion of the subendothelial 
extracellular matrix, which in turn could facilitate dissemination via the circulatory 
system. Likewise, adherence of C. albicans to human mucosa (325), human buccal 
epithelial cells (Watts et al 1998), epidermal corneocytes (326), and epidermal 
keratinocytes (327) has been shown to be inhibited by pepstatin A, indicating that 
proteolytic activity of aspartyl proteases is necessary for the adhesion properties of C. 
albicans. In RHE models or epidermis of oral (173, 311), cutaneous (328) and vaginal 
candidiasis (173, 329), pepstatin reduced the tissue damage caused by Saps. But even 
in the presence of pepstatin, epithelial tissue damage was observed in late stages of 
RHE infections (173). This suggested that certain members of the Sap family might not 
be inhibited effectively by pepstatin or other hydrolytic enzymes of C. albicans, such as 
phospholipases and lipases that might also contribute to the development of mucosal 
lesions. On the contrary, Lermann and Morschhaeuser (174) stated that no inhibition 
in RHE damage could be observed upon pepstatin usage, indicating that dependence 
on Sap activity during the C. albicans pathogenesis process is highly variable. Besides, 
the authors also gave the possibility that pepstatin A did not fully inhibit Sap activity 
under the conditions used in the RHE infection experiments (174). In another in vitro  
model of oral epithelium, tissue invasion by C. albicans was reduced in the presence of 
pepstatin. The tissue invasion mechanism proposed was the degradation of E-cadherin 
by Saps, in particular by Sap5, since overexpression of SAP5 rescued the attenuated 
invasive phenotype of a Δrim101 null mutant, in which SAP4 to SAP6 expression is 
diminished (330).   
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Protective effects of pepstatin were also demonstrated in a rat vaginitis model, where 
administration of pepstatin after infection greatly accelerated the clearance of C. 
albicans from the rat vagina (331, 332). In a study of murine peritonitis, the addition of 
pepstatin significantly reduced liver and pancreas damage, as determined by 
decreased levels of alanine aminotransferase (ALT) and α-amylase enzyme activities, 
respectively (333). These findings indicated that pepstatin could attenuate C. albicans 
virulence in a systemic murine intraperitoneal model, probably by inhibiting tissue 
damage and invasion by Sap4 to Sap6, since a sap4-6 null mutant strain caused 
decreased tissue damage that could be no further reduced by the addition of pepstatin 
(333).  
While the evidence supporting a protective role for pepstatin in mucosal animal 
models is convincing, its potential use in acute systemic candidiasis remains 
unpersuasive. No real protective effect was observed after intravenous challenge with 
C. albicans by using pepstatin in vivo (334-337). Fallon et al. (334) showed that 
pretreatment of neutropenic mice with pepstatin A afforded strong dose-dependent 
protection against a subsequent lethal intranasal dose of C. albicans. Inhibition of Sap 
proteins by pepstatin prevented the initial penetration of C. albicans through mucosal 
surfaces, but not the dissemination of C. albicans once the cells had already reached 
the blood vessels, since no protection by pepstatin A was observed in mice challenged 
intravenously, and protection was markedly attenuated in mice given pepstatin A after 
intranasal challenge.   
Thus, one conclusion may be that pepstatin can prevent disseminated infections by 
inhibiting Candida penetration through the mucosal route, but cannot inhibit systemic 
infections when the Candida is administered via the intravenous route. However, 
pepstatin is not selective and is slightly toxic in animals, probably due to its inhibitory 
action on host aspartyl proteases, including cathepsin D and renin (335). Moreover, 
pepstatin accumulates in the liver and not the kidneys, which is a major target organ of 
C. albicans in systemic infections, and is thus likely to be rapidly cleared from the blood 
in vivo. Therefore, while pepstatin is a potent inhibitor of the C. albicans aspartyl 
proteases in vitro, its suitability as an antifungal agent in vivo is not convincing. 
The interest in discovering new compounds that inhibit Sap activity has grown 
considerably as a result of the evolving HIV epidemic. In the last two decades, the 
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treatment of HIV-positive patients with highly active antiretroviral therapy (HAART), 
which includes a cocktail of HIV reverse transcriptase and HIV protease inhibitors, has 
proved successful in delaying the onset of AIDS. Administration of HAART resulted in a 
significant improvement in the immune status of the HIV-positive individual reflected 
by an increase in the CD4+ T cell population. These patients also had a dramatically 
reduced incidence of oropharyngeal candidiasis (338-341). Given that Candida 
proteases and the HIV protease are members of the same aspartyl protease family, 
these findings indicated that HIV protease inhibitors could also inhibit Candida aspartyl 
proteases in vivo and consequently prevent or reduce Candida infections (342-344). In 
fact, several HIV protease inhibitors were able to inhibit Sap activity (343, 345-348), 
and to reduce the adherence of C. albicans to epithelial cells, further giving evidence 
that protease activity is involved in the attachment of Candida cells to host surfaces 
(303, 342, 344), what could explain the reduction of Candida infections in HIV patients 
treated with HAART. Regardless the strong inhibition of Sap expression in the oral 
cavity, these HIV protease inhibitors had a limited effect on C. albicans viability, thus 
having a limited potential as therapeutic agents in the treatment of C. albicans 
infections (349).  
HIV protease inhibitors did not influence the phagocytosis by polymorphonuclear 
neutrophils (348). Sap inhibition with pepstatin did not affect C. albicans cell viability in 
a Candida-neutrophils interaction study, confirming the view that Saps are not 
associated with survival in neutrophils (300).  
 
Role of Saps in C. albicans virulence using sap-deficient mutant strains 
Genetic manipulation of C. albicans has always been complicated by the diploid nature 
of the fungus and the fact that it has an unproven naturally functional sexual stage. As 
a result, for a long time it was very difficult to create mutant strains for the analysis of 
virulence properties. Before the development of modern molecular biology tools, 
many of the early studies investigated the role of proteases in C. albicans virulence 
using less proteolytic or nonproteolytic C. albicans mutants that were induced by 
chemical or UV mutagenesis. Macdonald and Odds (350) and Ross et al. (351) showed 
that proteolysis-deficient mutant strains of C. albicans were less pathogenic in mice 
than was the parental strain. This attenuated virulence for one of the mutants was 
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confirmed for the rat vaginitis model by De Bernardis et al. (352). Also, Kwon-Chung et 
al. (353) demonstrated similar reduced virulence with another proteolysis deficient 
mutant and showed that a spontaneous revertant, that regained half of its original 
proteolytic activity, was almost as virulent as the parental strain. However, all these 
studies have used protease-deficient mutants obtained by chemical or UV mutagenesis 
and, most certainly, these mutants also contained nonspecific mutations at other gene 
loci that may have affected the growth and/or virulence of C. albicans. Thus, the 
results had to be interpreted with extreme caution. 
Targeted gene disruption and the use of expression vectors have enabled the 
construction of null mutants lacking specific SAP genes or strains overexpressing 
determined SAP genes (174, 261, 354-356) . These sap null mutants have highlighted 
the relevance of distinct Saps in different models of Candida infection. Actually, the 
most definitive data regarding the contribution of the SAP family to Candida 
pathogenicity have been obtained, most probably, from the behaviour of the various 
selectively SAP-disrupted strains.  
 
Sap production and mucosal infections  
The role played by C. albicans proteases in mucosal infections has been frequently 
assessed by the ability of mutant strains deficient in one or multiple SAP genes to 
cause tissue damage in RHE models of oral and vaginal candidiasis. The results from 
the first studies have indicated that Sap1, Sap2, and Sap3 enzymes were important in 
both the oral (311, 357) and vaginal (299) models, since mutant strains lacking these 
genes caused less tissue damage than did the parental strain. These results were in 
accordance with previous observations that Sap1 and Sap3 were associated with 
mucosal tissue damage (298). However, more recently, two different groups, using 
independently constructed sap null mutant strains, have shown that even mutants 
lacking all of the SAP1–SAP3 or the SAP4–SAP6 genes displayed the same capacity to 
invade and damage both oral and vaginal RHE as their wild-type parental strain (173, 
174). They have stated that hypha formation was the predominant cause of tissue 
damage in these models, but Albrecht et al (261)proved that Sap9 and Sap10 were 
essential for maximal pathogenicity during interaction with oral epithelial tissue, since 
mutant strains deficient in SAP9 and/or SAP10 genes had altered adhesion properties 
 29 
 
to oral epithelial cells and induced considerably smaller tissue damage, which was 
restored by reintroducing the genes(261).  
Schaller et al. reported that SAP1–3, but not SAP4–6, contributed to C. albicans 
infections on cutaneous epidermis (328). De Bernardis et al. (358) also showed that 
sap1, sap2, and sap3 mutants, but not the sap4 to sap6 mutant, were less virulent in a 
rat vaginitis model, comparatively to wild-type strain SC5314, in particular the sap2 
mutant. Reintroduction of the SAP2 gene recovered the ability of the sap2 mutant to 
efficiently infect vaginal tissues, showing that Sap2 may play a pathogenic role in rat 
vaginitis. In contrast, although SAP7 is induced after murine vaginal infection, a sap7 
mutant strain was not affected in its virulence in this infection model, highlighting that  
SAP7 expression does not correlate with C. albicans virulence in vaginal infection in 
mice (356).  
In another model of mucosal candidiasis, the murine model of gastrointestinal  
infection, no demonstrable differences between sap1- to sap6-deficient strains and 
the parental strain could be observed in the ability to invade the stomach or to 
disseminate to the brain or in the number of fungi persisting in the faeces (359). It is 
possible that, contrarily to oral or vaginal infections, the infectious process of C. 
albicans gastrointestinal infection does not depend on Sap activity. Similar conclusions 
were taken from the results obtained in the infection model using chick chorioallantoic 
membrane, which has been described as an alternative to evaluate C. albicans 
virulence. In this model, virulence of SAP-disrupted mutants was not attenuated (360).  
It has become clear that the importance of Saps in general, and of individual Sap 
isoenzymes, for the virulence of C. albicans varies strongly, depending on the infection 
model, with even minor differences in the experimental setup having a significant 
impact on the dependence on protease activity for successful invasion and 
establishment in various host niches.  
 
Sap production and systemic infections  
The use of SAP-deficient strains has also implicated the Sap family in systemic C. 
albicans infections. During invasion of host cell tissue and during escape of host cells 
that have internalized the fungus, hypha-associated factors such as secreted 
hydrolases may be crucial. SAP4–6 were shown to be almost exclusively expressed 
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during hyphal formation at near neutral pH values in vitro (247, 258) and may thus be 
important for the invasive properties of C. albicans hyphal cells. 
 The first real evidence that Sap4–6 may target different tissue compartments and 
substrates in vivo came from animal experiments performed using SAP-disrupted 
mutants, which indicated that the Sap4–6 family contributed to systemic infections 
(355). In guinea pig and murine models of disseminated candidiasis, upon intravenous 
infection with the sap1, sap2, sap3, and sap4 to sap6 mutants, all animals had 
increased survival rates compared with those infected by the parental strain (354, 
355). The sap4 to sap6 mutant displayed the greatest attenuation not only in terms of 
lethality but also in terms of fungal burden in host organs, such as the kidneys and 
liver. However, the authors concluded that although Sap4 to Sap6 appeared to 
contribute more to systemic infections in both animal models than did Sap1 to Sap3, 
none of the C. albicans proteases was a single dominant factor during disseminated 
infections. In murine models of acute systemic candidiasis, sap7 mutant strain had 
partial attenuated virulence (356), and sap9 and sap10 mutant strains exhibited 
virulence phenotypes similar to the parental strain (261). 
In a model of murine peritonitis, the invasive properties of sap1, sap2, or sap3 mutants 
were indistinguishable from those of wild-type cells, but the sap4 to sap6 triple mutant 
showed strongly reduced invasiveness (172) and induced a significantly reduced 
activity of ALT and α-amylase (markers of liver and pancreas damage, respectively) in 
comparison to the parental strain, despite still producing hyphal cells (333). When the 
tissue damage of liver and pancreas caused by single sap4, sap5, and sap6 and double 
sap4 and sap6, sap5 and sap6, and sap4 and sap5 double mutants was compared to 
the damage caused by wild-type cells, all mutants which lacked functional SAP6 
showed significantly reduced tissue damage (172).  
These data indicated that the Sap4 to Sap6 subfamily contribute to tissue damage and 
invasion in systemic infections, probably by aiding penetration of tissue and survival of 
the fungus in phagocytes.  
Differential control and coordination of SAP expression appears to be essential for 
pathogenesis as overexpression of C. albicans Sap2 even reduced virulence. 
Furthermore, heterologous expression of SAP2 did not enhance virulence in the non-
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pathogenic yeast Saccharomyces cerevisiae (361), indicating that SAP expression per se 
does not necessarily correlate with virulence.  
It is clear that the use of sap-deficient strains has significantly advanced our 
understanding of the possible roles and functions of the proteases during Candida 
infections. However, almost the totality of these studies were based on the use of Ura-
blaster sap null mutants, which have not been complemented and thus, the nature of 
these mutants remain to be confirmed. The great majority of these mutant strains 
were generated from auxotrophic laboratory strain CAI4 with the most common 
method used for disrupting genes in C. albicans, the Ura blaster technique (362). The 
use of the URA3 marker for mutant construction in C. albicans can lead to a 
misinterpretation of the results in mutant virulence studies (363-365) . Although this 
can now be overcome by the integration of URA3 at the ENO1 (366) or RPS10 (364) 
locus, the mutant strains used in earlier studies did not share a site of URA3 
integration. Therefore, it is conceivable that the Ura status could have influenced the 
results, and thus, the attenuated nature of these mutants during acute systemic 
candidiasis remains to be confirmed unequivocally (367). More recently, an alternative 
method for constructing null mutants from the prototrophic wild-type strain SC5314, 
the SAT1-flipping strategy, has been published (368), and a new set of single, double 
and triple sap null mutants has been constructed by using this strategy (174), avoiding 
the recognized effect of Ura influence.  
Still, results obtained with disrupted strains should be interpreted with some caution, 
since the disruption of one SAP gene may be compensated for by the up-regulation or 
down-regulation of other SAP genes, or even other unrelated virulence-associated 
genes, which may account for some of the reported observations. These forced 
adaptations that C. albicans may need to undergo as a result of SAP gene disruption 
may introduce undesirable changes that could lead to misinterpretation of the 
obtained results. An example is the loss of heterozigosity for the chromosome R and 
loss of SAP2-2 allele in the Ura-blaster triple mutant Δsap4-6, which has resulted in an 
impaired ability of this mutant strain to utilize proteins as the sole nitrogen source, and 
that may have resulted in other misidentified phenotypic characteristics (369). In 
addition, only a single C. albicans strain has usually been used for all SAP disruption 
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studies and thus it is not known whether this strain is representative of all other C. 
albicans strains that cause clinical infections.  
In summary, the majority of the in vitro, animal model and in vivo studies support the 
view that distinct proteases of the Sap isoenzyme family have distinct functions during 
the different types and stages of infection (172, 311, 333, 355, 358, 359) yet, some of 
the roles and functions of Sap enzymes during C. albicans infections may need 
confirmation.  
 
Sap production and evasion of host immune responses  
C. albicans possesses several mechanisms of evasion of the host immune response and 
Saps have also been implicated in some of those processes.  In macrophage killing 
assays, a sap4-6 triple mutant was killed more efficiently after phagocytosis by murine 
macrophages than was the parent strain (267). As a result of macrophage ingestion, C. 
albicans may germinate inside the phagolysosome and secrete Sap4 to Sap6, which are 
optimally active at the same pH (4.7 to 4.8) as that found in the phagolysosome (267). 
The production of functional Sap4 to Sap6 proteases within the phagolysosome may 
result in the digestion of enzymes associated with Candida killing and might render C. 
albicans more resistant to macrophage attack. The macrophage proteins targeted by 
Sap4 to Sap6 are not yet known, but Sap4 to Sap6 may act either directly on 
phagolysosomal enzymes involved in microbial killing (cathepsin D and/or antifungal 
peptides) or on key enzymes of macrophage metabolism that are essential for optimal 
microbial killing (239). Interestingly, Sap4–6 do not appear to be involved in evasion of 
phagocytosis by human blood polymorphic nuclear (PMN) neutrophils, because 
disruption of the whole subfamily has no effect on C. albicans survival or escape and 
none of the individual members were found to be up-regulated after phagocytosis 
(300, 370). These findings strongly indicated that Sap4 to Sap6 might facilitate C. 
albicans evasion from host innate defences by resisting macrophage attack, but not 
neutrophil control. Interestingly, Sap9 has a major impact on recognition of C. albicans 
by PMN cells (371). Yet, the expression of SAP9 does not constitute an evasion 
mechanism, since killing of sap9 null mutants by PMNs was reduced in comparison to 
wild-type C. albicans and the induced PMN chemotaxis towards Δsap9 filaments, and 
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consequent effective PMN activation, was also reduced (371). In contrast, SAP9 
deletion had no impact on C. albicans phagocytosis and killing by macrophages (271). 
The production of secreted proteases has also been shown to interfere and inactivate 
host innate immune effector components, such as complement proteins and 
antimicrobial peptides. Saps in the culture supernatant of C. albicans cells and also 
recombinant Sap1, Sap2 and Sap3 degrade host complement components C3b, C4b 
and C5 besides inhibiting terminal complement complex formation. A triple knock out 
C. albicans strain Δsap1–3 and also the non-pathogenic yeast S. cerevisiae lack such 
degrading activities. In brief, the secretion of complement degrading proteases 
mediates complement escape and generates a protective microenvironment of 
reduced host complement activity (282).  
Additionally, Saps may impair antimicrobial peptide function. Sap9 was responsible for 
degradation and deactivation of histatin-5, a host antimicrobial peptide involved in the 
protection of the oral mucosa against C. albicans, resulting in loss of its anti-candidal 
potency (281). 
At last, Saps may contribute to evasion of the host humoral immune response by 
degrading immunoglobulins (372), including IgA, which is known to neutralize many 
toxins and enzymes (373) and to inhibit C. albicans attachment to buccal epithelial cells 
(374).  
These findings strongly indicate a functional role for Saps in the evasion and possible 
manipulation of mucosal and systemic immune responses. 
 
Sap production and host immune response 
Since Saps play a role in C. albicans virulence, it is thus expected that the host would 
respond to Sap production by counteracting Saps to prevent local infection and 
damage. In fact, high titres of anti-Sap antibodies have been observed in sera of 
candidiasis patients, indicating the presence of Sap antigens during human systemic 
infections (322, 325). Besides, Sap antigens have been detected in biopsies of oral 
epithelial lesions collected from HIV-infected patients (311) and in almost all autopsied 
organs of immunocompromised patients who had died of systemic C. albicans 
infections (375). In all cases, antigens were found within the cell wall of yeast and 
hyphal cells. By using immunofluorescence with an anti-Sap antibody, amorphous 
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deposits of protease antigen formed a ring surrounding C. albicans micro-abscesses in 
the kidney, which may correspond to pH-mediated denaturation of secreted proteases 
(375). The observation that most Sap antigens were present within the Candida cell 
wall was later confirmed (172, 298, 311, 328, 359, 376). The location of Sap antigen 
during infections, assessed by using specific antibodies against the different Sap 
proteins, showed that Sap1–3 antigens were present in both yeast and hyphal cells, 
while Sap4–6 antigens were mainly found in hyphal cells (172, 267). Expression of 
different isoforms of Saps was also demonstrated by using immunoelectron 
microscopy in samples from patients suffering from oral and cutaneous candidiasis, 
showing abundant Sap1-3 antigen levels and few Sap4-6 antigen levels (311, 377).  
While Sap antibodies were useful in demonstrating the expression and localization of 
the enzymes, the protective effect of Sap antibodies produced by infected hosts is 
more uncertain. Saps are known to be immunogenic and induce potentially protective 
host defences in mucosal and systemic animal models (331, 378-381). However, 
Ghadjari et al (382) attempted to protect mice from lethal C. albicans intravenous 
infection after passive antibody transfer with no success. The antibodies used were 
human recombinant antibodies against two Sap2 B-cell epitopes from a patient who 
had recovered from disseminated candidiasis. It is not yet known whether a strong 
immunological response against individual or multiple members of the Sap family can 
neutralize, inhibit or prevent extracellular protease activity resulting in effective 
protection against C. albicans infections in vivo.  
Finally, although an immunomodulatory role has already been suggested for some of 
these proteases (267, 329, 381, 383), the specific interactions between Candida 
aspartyl proteases and the host immune response remain to be investigated.  
 
3.6. C. albicans pathogenicity beyond virulence factors 
The majority of the studies focusing putative virulence factors support the view that 
secreted hydrolases (SAPs, PLBs and LIPs) contribute to nutrient acquisition and 
promote fungal penetration of host barriers (224), whereas the Als proteins and Hwp1 
promote adhesion to host tissue (196, 366, 384). 
However, the new genome-wide expression profiling studies examine the global 
transcriptional response of C. albicans to the host using ex vivo and in vivo infection 
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models. These studies have revealed that most infection-related changes in C. albicans 
gene expression reflect environmental adaptation and that the initial contacts with the 
host, and also disease progression, are highly associated with metabolic and stress 
adaptation. C. albicans nitrogen metabolism change following exposure to host 
immune defenses or growth in biofilms (300, 310, 385, 386) . Also, amino acid 
biosynthetic genes are induced following neutrophil attack, but not during tissue 
invasion (387). This is consistent with the observation that the inactivation of the 
amino acid starvation response or specific amino acid biosynthetic pathways does not 
attenuate the virulence of C. albicans (364, 388). Therefore, tissues appear to be 
amino acid replete and thus, SAP expression is probably induced in these infection 
models for other purposes other than nitrogen availability (144). Other genes that are 
up-regulated during the development of C. albicans tissue invasion are genes involved 
in iron and phosphate assimilation (387). Also the expression of pH sensing functions 
changes during exposure to human blood and during tissue invasion (300, 370, 387). 
These transcript profiling data are in agreement with previous mutant studies 
indicating that iron assimilation and pH sensing are required for the overall virulence 
of C. albicans (307, 389). Data from these global transcriptional studies further 
supported that stress adaptation is essential for the virulence of C. albicans. These 
global transcript profiling studies support previous observations that several stress 
genes, involved in the detoxification of reactive oxygen and nitrogen species, are 
induced when C. albicans cells are exposed to macrophages, neutrophils, blood or 
epithelial cells, or during oral infections (300, 370, 385, 386, 390) . Genes involved in 
protective functions, such as heat shock proteins, have also been found to be up-
regulated in infected kidneys and liver (387, 391). Stress adaptation is known to be 
essential for overall virulence, since inactivation of catalase, superoxide dismutase, or 
a flavohemoglobin involved in NO detoxification (300, 392-394) attenuates C. albicans 
virulence. Similar results are obtained by disrupting the stress-activated protein kinase, 
Hog1 (395), which is required for oxidative stress resistance (395, 396).  
Therefore, C. albicans appears to activate adaptive stress responses in a niche-specific 
fashion during disease establishment and progression. Genomic studies show that 
diverse changes in C. albicans gene expression occur during infection and that, 
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although virulence factors are important, environmental adaptation appears to be the 
main key to pathogenicity.  
 
4. C. albicans cell wall 
The yeast cell wall is a crucial extracellular organelle that maintains the viability of 
fungal cells by protecting the cell from lysis during environmental stress and 
morphogenesis (257). It corresponds to the primary way in which the organism 
interacts with its host and contributes to pathogenesis by mediating interactions with 
host-cells and eliciting host immune responses (397). Fungal cell walls combine skeletal 
and matrix components. The skeletal component of the C. albicans cell wall is based on 
a core structure of β-(1,3)-glucan covalently linked to β-(1,6)-glucan and chitin (poly-β-
(1,4)-N‑acetylglucosamine (GlcNAc), which are located towards the inside of the cell 
wall. The outer layer is enriched with cell wall proteins that are attached to this 
skeleton. Despite being buried beneath the mannoprotein outer layer, β-glucans and 
chitin can nevertheless become exposed at cell surface in the bud scars (398). C. 
albicans cell wall contains a matrix mainly composed of glycosylated proteins that 
represent 30-40% of the cell wall dry weight (399). Lipids are minor components of the 
cell wall, but still have important functions (400). In fact, phospholipidomannan (PLM), 
is an important glycolipid of C. albicans, with linear β-1,2-oligomannose chains as the 
major component. β-1,2-oligomannosides of PLM have a role in virulence and 
immunomodulation (401) and are thought to be strong immunogens (402). Curiously, 
β-1,2-oligomannosides are expressed only in C. albicans and C. tropicalis, which are the 
most pathogenic Candida species. 
 
Cell wall glucans 
β-glucans are the most abundant polysaccharides of the fungal cell wall and represent 
approximately 60% of the cell wall components (399). Contrarily to other fungal 
species, C. albicans does not contain α-glucans. β-glucans occur as β-(1-3)-linked 
glucose polymers with β-(1-6)-linked side chains of varying length, tertiary structure 
and distribution, characteristics that have been shown to influence host immunity 
modulation (403). In general, large β-glucans lead directly to leukocyte activation, 
triggering phagocytosis, the production of cytokines, chemokines and other 
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inflammatory mediators (404). Intermediate-sized β-glucans (glucan phosphate) do not 
elicit leukocyte response in vitro yet being active in vivo. Small and low molecular 
weight β-glucans, such as the algae β-glucan laminarin, are recognised by glucan 
receptors but do not stimulate downstream signals (404). The ability of β-glucans to 
modulate immune recognition, and consequently the immune response, has caught 
pharmaceutical interest (405). Glucans and mannans are released by C. albicans in 
synthetic medium, as well as in the blood of infected patients, and these molecules can 
induce anaphylactic shock and coronary arthritis in murine models (406). On the other 
hand, treatment with β-glucans reduced fungal burdens and increased survival of 
infected animals. β-glucans have been shown to inhibit tumour growth and increase 
survival times, but the success of this treatment is dependent on a number of factors 
including the type of tumour (407, 408). The use of β-glucans as immune boosters has 
been assessed in clinical trials with promising results, though the mechanism anti-
infective is not completely understood (404, 409). The anti-tumour activity is the best-
examined property of β-glucans. In general, β-glucans are considered as safe but they 
have been implicated in triggering autoimmune diseases such as arthritis and are 
thought to be involved in respiratory burst disorders. Also, intravenous injection of 
particulate β-glucan caused the formation of granulomas, though it can be overcome 
by using active soluble glucans (410). 
 
Chitin 
Chitin is a β-(1,4)-linked homopolymer of GlcNAc that forms antiparallel  hydrogen-
bonded chains called microfibrils (411). Three genes encoding chitin synthases are 
described in C. albicans. CHS2 is preferentially expressed in the hyphal state although 
its lack does not have any effect on chitin levels, the yeast to hyphal transition or 
virulence in a mouse model (412). Chs1 is involved in septum formation and essential 
for cell integrity and virulence (413). Strains defective in Chs3 are less virulent in a 
mouse model than the parental strain. Exposure of C. albicans to cell wall stresses such 
as CaCl2 or Calcofluor White can increase the chitin synthase activity (414). 
Additionally, caspofungin treatment, which targets the β-(1,3)-glucan synthesis 
increases Chs3 levels in the cell (415). A fourth Chs was identified by in silico analysis: 
Chs8, which is similar to Chs2 and is responsible for 25% of the chitin synthase activity 
 38 
 
but not essential for growth (416). The chitin synthase can be used as a target to 
control fungal infections because of the importance of chitin in the structure of the cell 
wall and its absence in the host. So far, two important inhibitors of chitin synthase 
have been described: polyoxins and nikkomycins. Nevertheless, they show high 
antifungal activity in vitro but they do not present effective activities in in vivo studies 
(417).  
 
Cell wall proteins 
Cell wall proteins can fall into two classes. Class I proteins are not covalently linked to 
the cell wall and are extractable with detergents or chaotropic agents. Class 2 proteins 
can only be solubilized after the destruction of structural polysaccharides or by 
breaking the specific bonds which link them to the polysaccharides (417). Within this 
group is the major class of cell wall proteins, the glycosylphosphatidylinositol (GPI)-
anchored cell wall proteins, attached through a GPI remnant to β-(1,3)-glucan or chitin 
by a highly branched β-(1,6)-glucan linker (418, 419). These proteins are usually highly 
glycosylated with mannose-containing polysaccharides, and carbohydrates can 
account for up to 90% of their molecular mass. Mannoproteins are bound to the β-
glucan/chitin inner layer through lateral chains of β-(1,6)-glucan or to β-(1,3)-glucan via 
alkali-sensitive linkages. The mannan structures are very important for the 
discrimination between fungal species and serotypes and are known to be present in 
C. albicans but absent in S. cerevisiae. Three different types of β-1,2-mannose have 
been found in distinct Candida species (420-422). In C. albicans, phospholipomannan 
reacts with antibodies specific to β-1,2-mannose (423). For phospholipomannan, it has 
been suggested that it may have relevance in adhesion, protection and signaling (424, 
425). Similar to β-glucans, both mannans and mannoproteins from C. albicans cell wall 
have important immunostimulatory activities (426-430) . 
The number of in silico predicted GPI proteins identified in C. albicans is almost twice 
as high as of that identified in S. cerevisiae, though the function for many of them is 
yet to be discovered (431). GPI proteins are located at the cell surface and are thus 
expected to interact with the host cells. In addition, C. albicans is highly adapted to its 
environment compared to other opportunistic fungi suggesting the evolutionary 
development of numerous mechanisms to colonize its host.  
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5. Immunity to C. albicans infections  
The host immune response to fungal infections comprises diverse mechanisms and 
involves both the innate and the adaptive immune system. A complex and continuous 
balance between pro- and anti-inflammatory signals is required to maintain a stable 
host-fungus relationship, the disruption of which can have pathological consequences. 
The relative importance of specific innate and adaptive defence mechanisms in C. 
albicans infections differs, depending on the anatomical site of infection and on 
organism characteristics, such as morphotype (yeast, pseudohyphae and hyphae).  
 
5.1. Recognition of C. albicans by the innate immune system 
Pattern recognition receptors (PRRs) expressed on host innate immune cells recognise 
pathogen-associated molecular patterns (PAMPs) in fungi (432). The receptors that are 
involved in the recognition of C. albicans by leukocytes and the respective fungal 
PAMPs are depicted in Figure 1. PRRs on phagocytes initiate downstream intracellular 
events that promote the activation of the immune system and the clearance of fungi, 
being the specific immune response generated dependent on the PRRs triggered. 
However, PRR-mediated cell activation might as well promote some infections and 
cause tissue damage. Fungi have developed several mechanisms that exploit PRRs in 
order to manipulate host immune responses and survive, or even replicate, within the 
host.  
 
5.1.1. PAMPs 
The fungal cell wall varies in composition depending on the morphotype, growth stage 
and environment of the fungal species, and is the main source of PAMPs that are 
recognised by PRRs on mammalian cells. During the course of C. albicans infection, 
multiple host PRRs are likely to be stimulated by the fungal PAMPs depending on the C. 
albicans morphotype and on the host cell types involved. Therefore, the final immune 
response will depend not only on the relative degree of stimulation of the individual 
receptors, but also on receptors synergy or antagonism and on their cellular 
localization. 
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5.1.2. Pattern recognition receptors and their targets 
 
Toll-like receptors (TLRs). The functional role of TLRs in antifungal host defence was 
first reported by Lemaitre et al. (433), who showed that drosophila flies deficient of 
toll were highly susceptible to infection with Aspergillus fumigatus. Of the 13 TLRs 
described in human and mice to date, only TLR2, TLR4, TLR6 and TLR9 have been 
reported to be involved in the defence against C. albicans. 
Fungicidal pathways appear to be dependent on signalling via MyD88, the signalling 
adaptor that is a major component of TLR signalling and an essential component of IL-
1R signalling (434). 
 
TLR2. Although inhibition or deletion of TLR2 resulted in decreased production of pro-
inflammatory cytokines and neutrophil recruitment after stimulation with C. albicans 
(435, 436), TLR2-deficient mice had increased resistance to disseminated candidiasis 
associated with increased production of IL-12 and INF-γ and decreased production of 
the anti-inflammatory cytokine IL-10 (434, 437). Furthermore, TLR2-deficient 
macrophages were able to clear C. albicans infections better than wild type 
counterparts (438). Such an anti-inflammatory role for TLR2 in host defence is 
supported by the demonstration that zymosan can induce immunological tolerance 
through a TLR2-mediated pathway (439). Even though the TLR2 ligand from C. albicans 
remains unidentified, there is evidence that phospholipomannan and β-glucans might 
be recognised by TLR2 and TLR6 (424, 440). 
 
TLR4. There are controversial studies about the role of TLR4 during C. albicans 
disseminated infection. Netea et al (435) have reported that it is important for 
chemokine production, neutrophil recruitment and kidney fungal burden control, even 
if no changes in cytokine production could be found. In contrast, Gil and Gozalbo (441) 
and Murciano (442) stated that TLR4 was not relevant for the survival of mice infected 
with C. albicans. TLR4 is the receptor for bacterial lipopolysaccharide (LPS) (443, 444), 
but the nature of fungal PAMPs recognised by TLR4 is still poorly known. C. albicans 
and S. cerevisiae mannan, especially shorter O-linked mannan (445, 446) might be 
recognised by this receptor.  
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TLR6. The role of these receptors in response to C. albicans is less well studied. 
TLR2/TLR6 heterodimers are involved in zymosan recognition, but cytokine production 
is only moderately reduced in TLR6-deficient macrophages. Also, TLR6 does not seem 
to play a role in disseminated C. albicans infections (440). 
 
TLR9. Blocking TLR9 in human monocytes reduces production of the anti-inflammatory 
cytokine IL-10 after stimulation with C. albicans. This effect is also observed in murine 
TLR9-deficient macrophages (van de Veerdonk et al, 2008). The natural ligands for 
TLR9 are unmethylated CpG sequences. A recent study indicates that TLR9 recognises 
C. albicans DNA driving to IL-12 production by myeloid DCs (447).  However, no 
increased susceptibility of TLR9-deficient mice to disseminated candidiasis has been 
observed (434, 447).  
 
C-type lectin receptors (CLRs) 
The CLRs proved to recognise fungal PAMPs are Dectin-1, Dectin-2, macrophage 
mannose receptor (MR), galectin-3, dendritic cell-specific ICAM3-grabbing nonintegrin 
(DC-SIGN) and mincle.  
 
Dectin-1 is the most extensively studied receptor implicated in fungal recognition. 
Dectin-1 recognises β-1,3 glucans via its extracellular C-type lectin-like domain (CTLD) 
(403). Dectin-1 stimulation with curdlan, a linear β-(1,3)-glucan, stimulates IL-2 and IL-
10 production by DCs. ROS production upon zymosan and C. albicans stimulation 
requires Dectin-1 (398, 448, 449). However, the role of this receptor in C. albicans ROS 
signalling is still unclear because ROS production is not altered in macrophages from 
dectin-1-deficient mice when challenged with C. albicans (450). In addition, Dectin-1 is 
required for phagocytosis (398, 451, 452). Dectin-1-deficient mice are more 
susceptible to infection with C. albicans, resulting in increased fungal burden and 
lower survival (448). However, another study using a different mouse strain of dectin-
1-deficient mice found increased susceptibility to Pneumocystis but not to C. albicans 
(450). Dectin-1 can also cooperate with TLRs to induce pro-inflammatory responses. In 
macrophages, cooperative signalling through Dectin-1 and TLR2 heterodimers is 
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required for the induction of TNF-α in response to C. albicans and zymosan (404, 449). 
Remarkably, Dectin-1 amplifies TLR4-dependent pathways (453). Furthermore, Dectin-
1 can couple with other TLRs, resulting in the synergistic induction of TNF-α and IL-10 
(454). In murine macrophages, a collaboration of Dectin-1 and DC-SIGNR1 for fungal 
binding exists (455), and in human DCs, a co-stimulation of DC-SIGN and Dectin-1 
induces arachidonic acid signalling (456).  
 
Dectin-2 has specificity for high mannose structures (457, 458). The receptor 
preferentially recognises hyphal forms of C. albicans. However, the receptor can also 
weakly recognise yeast forms (457, 459). The cytoplasmic tail of Dectin-2 appears to 
associate with the FcγR chain (459, 460), a signalling adaptor associated with several 
other transmembrane receptors. This induces TNF-α and IL-1ra in response to hyphal 
forms of C. albicans (459, 461). Blocking of Dectin-2 in a C. albicans infection model did 
not affect innate immune resistance but abrogated Th17 response (462), and when 
combined with Dectin-1 loss, the Th1 response decreased (461).  
 
The human dendritic cell-specific ICAM3-grabbing nonintegrin (DC-SIGN) is primarily 
expressed on immature DCs, but has also been found in macrophage populations (463, 
464). DC-SIGN recognises high mannose structures in a calcium dependent way (465). 
Eight orthologues of DC-SIGN exist in mice, although these molecules appear to have 
different expression profiles and several structural differences (466). The role of this 
receptor in response to fungi has not been studied extensively, but DC-SIGN has been 
proposed to mediate fungal uptake (467). Among the murine homologues, only 
SIGNR1 (also termed murine DC-SIGN) and SIGNR3 recognise fungal PAMPs (455, 468). 
DC-SIGN can induce intracellular signalling, modulating TLR-mediated responses (469).  
 
Mannose Receptor (MR) recognises oligosaccharides that terminate in mannose, 
fucose and GlcNAc through several carbohydrate-recognition domains. MR was shown 
to preferentially recognise branched N-linked mannans (445). A recent study indicated 
that IL-17 production was induced by the MR, and that Dectin-1/TLR2 amplified the IL-
17 production (470).  
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Mincle appears to be involved in the recognition of C. albicans by macrophages, 
although it is not essential for phagocytosis. Mincle-deficient mice are susceptible to C. 
albicans, and blocking of Mincle in macrophages leads to reduced TNF-α (471, 472). 
Like other CLRs, Mincle induces inflammatory cytokines and chemokines via the 
association with the Fc gamma (Fcγ) chain (473).  
 
Complement receptor 3 (CR3). The CR3 integrin mediates adhesion, chemotaxis and 
phagocytosis in complement-dependent but also complement-independent ways (474-
477) and recognises β-glucans of unopsonised yeast (477). The recognition of β-
glucans by CR3 promoted phagocytosis but did not trigger protective host responses, 
such as the respiratory burst, and could suppress pro-inflammatory signals (478). In 
agreement with these immunosuppressive effects in vitro, CR3-deficient mice are 
more resistant to disseminated candidiasis. Curiously, a recent study using human 
neutrophils suggested that CR3 but not Dectin-1, was the major receptor for β-glucan 
bearing particles (479).  
 
Galectin-3 is a receptor mainly expressed by macrophages crucial for the recognition 
of β-1,2 linked oligomannosides (480). Galectin-3 on the surface of murine 
macrophages can discriminate between pathogenic C. albicans, that bears β-1,2 linked 
oligomannosides, and non-pathogenic S. cerevisiae, which lack these residues, in 
collaboration with TLR2 (481). Binding of recombinant Galectin-3 to the specific β-1,2 
linked mannosides of C. albicans directly induces death of C. albicans cells (482).  
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Figure 1. Cell membrane pattern recognition receptors sensing C. albicans. Recognition 
is mediated by TLRs and CLRs. Both TLR4 and TLR2 can induce proinflammatory signals 
in monocytes, macrophages and DCs through the MyD88 and Mal-mediated pathways, 
as well as the TRIF pathway to initiate Th1 responses. A second downstream effect of 
TLR4 signalling involves TRIF and TRAM adapter proteins that activate TBK1 and the 
IRF3 transcription factor required for the expression of type I interferon genes. TLR2 
binding stimulates strong IL-10 and TGF-β and induces proliferation of regulatory T 
cells (Treg) and immunosuppression, but is also able to induce proinflammatory 
cytokines such as TNF-α or IL-6. However, through an Erk and c-Fos-dependent 
pathway, TLR2 is also able to inhibit IL-12 synthesis and Th1 responses. The 
proinflammatory effects of TLR2 can be amplified by dectin-1 and galectin-3. In 
addition to the amplification of TLR2 effects, the lectin-like receptor dectin-1 induces 
IL-2, IL-10 and Th17 responses through a Syk/CARD9 cascade, independent of its 
interaction with TLR2. The MR induces proinflammatory effects in monocytes and 
macrophages, whereas chitin-dependent stimulation induces mainly Th2 responses, 
although the identity of its receptor is unknown. Other less well characterized 
pathways include stimulation of inflammatory cytokine release by dectin-2, Mincle, 
and CD36/SCARF lectin receptors, and of the immunosuppressive cytokine IL-10 by DC-
SIGN in DCs. Adapted from Netea and Maródi 2011 (483) 
 
MAL, MyD88 adapter-like; IRAK, interleukin-1 receptor-associated kinase; TRAF, TNF receptor-
associated factor; TAK, tumour growth factor (TGF) β-activated kinase; TRIF, Toll–interleukin-1 receptor 
domain-containing adapter inducing interferon b; TRAM, TRIF-related adapter molecule; TBK, TRAF 
family member-associated NF-kB activator-binding kinase; IRF, interferon response factor; Syk, T cell 
lineage-specific tyrosine kinase; MR, mannose receptor; DC-SIGN, DC-specific intracellular adhesion 
molecule-grabbing non-integrin.  
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5.2. Innate Immunity 
The so-called innate immunity comprises constitutive mechanisms that are used by the 
host to respond to fungal pathogens in a rapid and conserved manner. Innate immune 
mechanisms are present at sites of continuous interaction with fungi and include the 
barrier function of the skin and mucosal epithelial cell surfaces of the respiratory, GI 
and genitourinary tracts. It is the first line of defence and is a crucial instructor of the 
subsequent adaptive immune response (484, 485). Microbial antagonism, defensins, 
collectins and the complement system also provide constitutive defence mechanisms 
(484). C. albicans activates complement by the classical and alternative pathways with 
deposition of C3 on the cell fungal surface. Complement activation facilitates the 
recruitment of phagocytes to infected tissues and enhances their anti-Candidal 
activity. Mice deficient in C5 production have an increased propensity to develop 
disseminated infection (486-488). 
One of the functions of the innate immune system during fungal infections is the 
destruction of the pathogen through phagocytosis or secretion of microbicidal 
compounds against fungal elements that cannot be ingested. Phagocytosis and direct 
pathogen killing is mainly effected by monocytes, macrophages and neutrophils (485).  
Protection against disseminated candidiasis relies mainly on components of innate 
immunity. The role of phagocytic cells such as macrophages, monocytes and, in 
particular, neutrophils is paramount, since quantitative and qualitative abnormalities 
of these cells are often associated with a lethal outcome (489). Namely, inborn errors 
of reactive oxygen radical production, leading to defective intracellular killing, as is the 
case in patients with chronic granulomatous disease make these hosts more prone to 
Candida infections (37).  
Apart from the phagocytic cells residing in target organs at the time of infection, other 
effector cells, like neutrophils and monocytes, are recruited to sites of infection guided 
by inflammatory mediators such as chemokines and complement fragments.  
Neutrophils and monocytes recognise and engulf opsonised and non-opsonized yeast 
cells via cell-surface PRRs. Binding to individual TLRs and IL-1 receptor (IL-1R) activates 
specialized antifungal effector functions on neutrophils and other phagocytes (434). 
TLR signalling on monocytes/macrophages and DCs also play an important role in the 
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orchestration of neutrophilic inflammation by the indirect regulation of neutrophil 
recruitment, activation and survival (490, 491). 
Killing occurs by oxidative mechanisms, including generation of reactive oxygen and 
nitrogen intermediates, and by non-oxidative mechanisms (485, 492) ). Phagocytosis 
and killing are augmented by opsonization and pro-inflammatory cytokines. Larger 
structures of Candida hyphae and pseudohyphae may prevent phagocytosis and in 
those cases, several phagocytes collaborate to effect extracellular killing. Although 
defective neutrophil function can result in disseminated infection, inappropriate or 
overwhelming neutrophil activation can also be a major cause of disease. 
The interaction of macrophages with fungi is complex and the exact mechanism and 
efficiency of fungal killing are likely to depend on numerous factors, including 
macrophage source and environment, activation state, and fungal pathogenicity and 
morphology (493). Human macrophages, for example, are more efficient in killing C. 
albicans, than mouse macrophages, and C. albicans is able to escape from the latter by 
growing hyphae that break out the cell, releasing fungal cells into the extracellular 
environment. 
Besides their role as professional phagocytes, innate immune cells can initiate the 
adaptive immune response via secretion of pro-inflammatory cytokines and 
chemokines and presentation of antigens. 
 
Dendritic cells (DCs) 
Fungal recognition by DCs is crucial for antigen-processing and presentation to T-cells 
(397, 494, 495) . DCs capture and process antigens, express cell-surface lymphocyte co-
stimulatory molecules, migrate to lymphoid organs and secrete cytokines to initiate 
immune responses (496-499)(. In this way, DCs play an important role in linking innate 
with adaptive immunity (497). The type of response depends in part upon the 
morphotype of Candida encountered and the antigens displayed by the fungus (500). 
DCs can phagocytose both Candida yeast and hyphae, through receptors distinct for 
each morphotype, which lead to DC maturation and activation (500, 501). DCs that 
ingest the yeast form induce differentiation of CD4+ T cells toward a T helper type-1 
(Th1) pathway, whereas CDs that ingest hyphae induce T helper type-1 (Th2) responses 
by inhibiting IL-12 production and inducing IL-4 (500, 502). The multiple, functionally 
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distinct, receptor signalling pathways in DCs, by affecting the balance between CD4+ 
effector T cells and Treg, are likely to be exploited by fungi to facilitate host 
commensalism or invasion (484). 
 
5.3. Adaptive immunity 
Adaptive immune responses comprise two major types, the so-called cell mediated 
and humoral immunity. They are mediated by different machineries of the immune 
system and have distinct roles during infection.  
T cell-mediated responses 
The Th1 and Th2 cell subsets were initially shown to participate and determine the 
outcome of C. albicans infections (503) . However, other T cell subsets such as Th17 or 
Treg cells were subsequently shown to be also involved in the host immune response 
to this pathogen (484, 504, 505). Development of a Th1-type response was initially 
shown to be determinant in the host’s ability to control fungal infections and 
correlated with protection. Development of Th1 responses is influenced by the 
concerted action of several cytokines, prominently IL-12, in the relative absence of Th2 
cytokines, such as IL-4 (505). The immunosuppressive cytokine IL-10 may also 
contribute to impair Th1 protective responses (505, 506). Progression of infection is 
associated with predominance of a Th2-type response (484) and, depending on the 
type of infection, of Treg (437).  
Activation of Th17 cells may also occur in fungal infections, and be involved in what 
was classically defined as Th1- and Th2-type responses. Indeed, a role for Th17 cells in 
supporting Th1 cell responses has been shown in murine models of mucosal 
candidiasis (507, 508). The ability of IL-17A, produced by Th17 cells, to mobilize 
neutrophils and induce the production of defensins greatly contributes to efficient 
control of an infection at different body sites. However, the role of Th17 cells in the 
course of Candida infections remains unequivocally determined, as it may depend on 
the stage and site of infection, and is probably influenced by environmental stimuli 
(484). This cell subset may also be involved in the immunopathogenesis of fungal 
diseases (509). Nevertheless, this subject, or its precise mechanisms remain a matter 
of debate.  
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Although T cells have an acknowledged role in host defence against candidiasis, the 
importance of these cells appears to be rather limited during disseminated Candida 
infections (489, 510).  
CD8+ T cells are believed to exert direct anti-Candida activity, lysing yeast cells as well 
as yeast-containing phagocytes (505). However, in a model of acute systemic 
candidiasis, CD8+ T cells were not necessary for host protection but had a role in 
limiting host’s pathology (511). In contrast, these cells were shown to be important for 
resistance to gastric and disseminated candidiasis of endogenous origin (512).  
 
Regulatory T cells (Treg)  
During a fungal infection, an optimal immune response must eliminate the fungus 
while limiting collateral damage to tissues and restoring a homeostatic environment. 
Secretion of IL-10 represents one of the mechanisms by which Treg mediate 
suppression and control inflammatory responses (513). Several clinical observations 
indicated that an inverse relationship between IFN-γ and IL-10 production might occur 
in patients with fungal infections (514, 515). High levels of IL-10, which negatively 
affect IFN-γ production, are detected in chronic Candida infections, and thus have 
been linked to increased susceptibility to fungal infections (437, 484, 516, 517). TGF-β 
production has also been associated with disease progression (518). Moreover, during 
C. albicans infection the absence of IL-10 is beneficial for the host response (506). 
However, taking into account its major role in the resolution of inflammation, IL-10 
production may be a consequence, rather than a cause of infection. To be so, in the 
case of chronic fungal infections, which are characterized by persistent inflammation, 
IL-10 may act as a homeostatic response aimed at keeping inflammation under control. 
However, as Treg activity may impair the efficacy of protective immunity, fungal persistence 
may be a host detrimental consequence. Thus, Treg may be responsible for different 
infection outcomes, ranging from protective tolerance to increased fungal burden 
(437, 519, 520). Additionally, Treg participate in the development of protective 
memory after yeast priming (520). 
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B cell-mediated responses 
The role of B cells in protection against Candida is not as extensively studied as the one 
played by T cells. Clinically, B cell deficiency is not associated with increased 
susceptibility to infection. Moreover, mice that lack functional T and B cells develop 
ongoing mucosal infection (most certainly due to the lack of T cells) without 
progression to disseminated disease (521). In contrast, susceptibility to acute systemic 
candidiasis was increased in mice deficient in B cells (522). 
 
Antibodies 
The role of antibodies during Candida infections is less clear as earlier studies 
suggested that Candida-specific antibodies do not have a protective role (5, 523). In 
fact, high titre anti-Candida antibodies are regularly found in patients that cannot clear 
Candida (524). Recently there has been renewed interest in antibody-mediated 
protection against fungal infections, with a focus on different Candida antigen targets, 
such as mannans, glucans, heat-shock proteins, Saps, and adhesins, with the aim of 
producing monoclonal or recombinant antibodies as prospective novel treatments 
(525, 526). The understanding of the role played by antibodies in the host response to 
Candida is currently growing. However, in murine models, protective and non-
protective antibodies have been described and monoclonal anti-Candida antibodies 
are currently undergoing clinical trials in humans (527). It has been observed that the 
protective potential of antibodies with enhanced phagocytosis and killing of the fungus 
is dependent upon epitope specificity, serum titre, and ability to rapidly and efficiently 
fix complement to the fungal surface (528).  
 
5.4. Mechanisms of immune evasion in C. albicans 
Candida has developed numerous sophisticated mechanisms aimed at to elude and 
overcome host defences (3, 529, 530) . C. albicans may avoid inflammation, and this 
contributes to fungal adaptation and opportunism (531). This fungus can block 
recognition by masking β-1,3-glucans under the mannose/mannoprotein layer. These 
glucans are exposed in the bud scar of C. albicans yeasts but are masked on hyphae, 
thus favouring fungal escape from recognition by dectin-1 (532, 533). 
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C. albicans may also inhibit opsonisation/complement function by binding negative 
regulators of the complement cascade (534-536). Once detected by the immune 
system, blocking phagocytosis is another potential survival strategy. Cell size is an 
effective restriction to ingestion, and hyphal forms of C. albicans are not efficiently 
internalized (537). Another mechanism employed by C. albicans to avoid phagocyte 
attack is the contact-independent inhibition of NO production (538, 539). Even after 
internalization, C. albicans may affect phagocyte function, by escaping from the 
phagocyte after elongation of the hyphae and causing disruption of the phagocyte. 
Interestingly, this only occurs in certain monocyte/macrophage populations, whereas 
neutrophils can inhibit hyphae formation (371). Alterations of the intracellular fate 
have also been described. Trafficking of phagocytosed C. albicans was aberrant in 
murine macrophages, and a significant fraction of fungal cells ended up in a 
membrane-bound compartment associated with the ER, often at near neutral pH 
(540), although the underlying mechanism is unknown. As reported above, C. albicans 
Saps are able to degrade several proteins involved in the host immune response such 
as histatin-5 and proteins of the complement system (281, 282). In addition to all these 
mechanisms, a soluble factor, yet to be characterized, released by live C. albicans shifts 
tryptophan metabolism and inhibits host Th17 responses (504).  
6. Vaccination  
Because of the rising incidence of life-threatening candidiasis, high treatment failure 
rates, and huge health care costs, more effective prophylactic and therapeutic 
strategies are needed (44, 45). Recently, a renewed interest in the development of 
vaccination strategies against both mucosal and disseminated Candida infections has 
arisen, including induction of cell-mediated immunity by active immunization and also 
passive vaccination with antibodies (541, 542).  
 
6.1. Vaccination against disseminated candidiasis 
For many years the development of fungal vaccines did not receive much attention 
from the pharmaceutical companies. One reason was the general conviction that most 
patients who develop life-threatening fungal infections have profound defects in 
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immunity. One major concern about vaccinating those patients against invasive fungal 
infections was the belief that the immune systems of such patients were unlikely to 
respond protectively to vaccination and might suffer from aggravation of the 
immunological disorder following the immunostimulation by vaccine antigens and 
adjuvants. However, only 10-20% of patients who develop Candida bloodstream 
infection are seriously immunocompromised. Vaccination of high-risk groups of 
patients is a particularly promising strategy to prevent disseminated fungal infections 
because risk factors are clearly identified and correspond to common iatrogenic and/or 
nosocomial conditions that result in a substantial increase in the colonization burden 
of Candida spp. or in the disruption of protective anatomical barriers rather than to 
severe immunosuppression (541, 543, 544). Furthermore, development of these risk 
factors precedes infection, affording a window of opportunity to vaccinate highly at-
risk patients before the establishment of infection. Such patients - including 
thosecandidate to transplants, patients that will undergo gastric or cardiac surgery and 
those affected by tumours - could benefit of advance active immunization against 
Candida, since the therapy or medical proceedings predispose to fungal infection 
(193). Since many of these risk factors are of relatively short duration, normally 4 to 6 
weeks, an immunization approach would need to protect patients just for the short 
period of time during their increased susceptibility. In theory, antibodies can be 
induced by vaccination in at-risk subjects before predisposing therapy or 
immunosuppression (541). Because of the relative longevity of IgG (from weeks to 
months, depending on the IgG isotype), its persistence at a good protective level in the 
circulation even during a relatively prolonged immunosuppression or hospitalization 
period is to be expected (544). Vaccines merely eliciting antifungal CMI will not be 
appropriate for this purpose. 
6.2. Proposed Candida vaccines 
Protection against disease may be actively or passively acquired through vaccination 
and the transfer of preformed antibodies. The nature of immunizing antigen and its 
immunodominant epitopes, interaction with APCs (usually DCs), antigen processing 
through MHC class II or MHC class I pathways, and type of adjuvant, all determine the 
nature of elicited immunity and its outcome in terms of protection. 
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Protection against disseminated candidiasis has been reported following both active 
vaccination and passive transfer of antibodies (Table 1) and it is clear that antigens 
targeted for vaccination need not be restricted to virulence factors, which markedly 
increases the antigen repertoire available for testing.  
 
Table 1.  Proposed C. albicans vaccines 
Antigen Protectiona 
Mucosal; 
Disseminated 
Nature of 
protectionb 
Reference 
Mannan, Mannoproteins +;ND Abs, B cells, CMI – Th1 (331, 379, 545-
547)  
1,3-β-glucan (Laminarin) +;+ Abs (548-552) 
Secreted aspartyl protease 2 +;+c Abs (331, 378-381) 
Agglutin-like sequences 1 and 3 +; + CMI – Th1,Th17 (547, 553-556)  
Phosphoglicerate Kinase +;ND Abs (557) 
Enolase ND;+ Abs, CMI – Th1 (558) 
Low virulent strains -; + CMI (559) 
Candida membrane antigen ND; +d Abs, CMI (560, 561)  
Heat shock proteins +;+  (562, 563)  
Heat killed cells ND;+ Unknown (564, 565)  
Hyr-1 ND;+ Abs (534, 566) 
β-1,2-Mannotriose and 
mannobiose 
ND;+ Abs (567, 568)  
C. albicans ds DNA +e;ND CMI – Th1 (569) 
DCs transfected with fungal RNA ND;+ CMI – Th1 (570, 571) 
a+: protective; -: not protective, may enhance virulence; ND: not determined;  
bAbs- Antibodies; CMI- Cell mediated immunity; c C. albicans peritonitis ; dDisseminated of endogenous 
origin in newborns; 
e 
gastrointestinal 
  
The protective mechanism for most active vaccines against disseminated or mucosal 
candidiasis studied to date, relies on the induction of cell-mediated, pro-inflammatory, 
Th1 or Th17 responses, which improve phagocytic killing of the fungus (541, 544) 
Cutler et al 2007,. However, antibody participation in antifungal protection cannot be 
ruled out when CMI responses are elicited by vaccination. In fact, a type-1 cytokine 
response could be necessary for the formation of some protective antibodies against 
C. albicans proteins and most polysaccharide antigens, which, in murine models, are of 
the IgG2a isotype (572). 
The best protective effects observed to date have been obtained by immunization with 
viable cells from virulent or avirulent C. albicans strains. DNA vaccines are now 
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believed to be the strongest immunization approach for CD8 cytotoxic effector 
generation, due to preferential antigen processing through MHC class I pathway (569). 
Whole cell or DNA vaccines maintain a persistent activation of CMI effectors. While 
positively controlling the infectious agent, they may nonetheless be also inducing 
strong inflammation with potential undesirable effects (544). Moreover, C. albicans is 
a member of the normal microbiota and vaccines against this opportunistic pathogen 
might result in unwanted inflammation, such as allergic manifestations (543, 573).  
Antibodies have long been considered irrelevant in host defense against disseminated 
candidiasis. The existence of inhibitory antibodies, rather than the absence of 
protective ones, has mostly contributed to this assumption. The clinical evidence that 
antibodies are protective against fungal infections is limited to few cases (527, 574, 
575) , but over the last two decades, a number of antibodies directed against C. 
albicans cell wall polysaccharides and glycopeptides, proteins and peptide epitopes, 
have been shown to confer protection in experimental models (Table 1). The 
demonstration of protective anti-Candida antibodies makes possible their use in 
immunoprophylaxy or immunotherapy against disseminated Candida infections 
through passive vaccination, an intervention that would have some advantages. There 
are several examples of recombinant antibodies against fungal infection (576, 577). 
Some protective antibodies can be generated in a human format devoid of Fc 
component, suggesting that they can work without the cooperation of the immune 
system, and thus could be appropriate for use in severely immunocompromised 
patients. Other monoclonal antibodies against Candida do need the Fc component and 
complement activation and deposition on cell surface for protection (572, 573). 
Great efforts have been made in the characterization of the protective immune 
mechanisms against Candida infections and in the vaccination field but still, no 
therapeutic vaccine successfully used to fight Candida infections have been so far 
provided. Nevertheless, the increasing evidence, from clinical observations and animal 
models of candidiasis, that some Candida-specific antibodies can be immunoprotective 
during infection, points to the viability of an immunotherapeutic approach for the 
treatment and management of candidiasis, particularly in severely immunosuppressed 
patients, in combination with antifungal therapy (544, 572) . 
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7. Objectives and outline of the thesis 
The work presented in this dissertation was developed at Centre of Molecular and 
Environmental Biology of Minho University (CBMA-UM) and Instituto de Ciências 
Biomédicas Abel Salazar of Porto University (ICBAS-UP).  
Secreted aspartyl proteases have long been implicated in Candida albicans 
pathogenesis, mostly taking into account the observed attenuated virulence of Δsap 
null mutant strains. However, the exclusive contribution of SAP genes for their 
attenuated phenotype remains to be unequivocally confirmed since the Ura-status of 
these mutant strains could have also contributed for the attenuation. Although Sap2 
has been successfully used in several vaccination assays against mucosal and 
peritoneal candidiasis, the efficacy of Sap2 formulations in immunoprotection against 
hematogenously disseminated candidiasis is yet to be attempted. Moreover, the usage 
of Sap4-6 as antigen targets for vaccination against this type of C. albicans infection 
might be promising. 
Thus, considering the contribution of Saps to C. albicans disseminated candidiasis, and 
the potential usage of these virulence determinants as antigen targets in vaccination 
assays to protect against this infection, the general objectives of this work were: i) to 
characterize the host immune response to systemic candidiasis elicited by different C. 
albicans strains; ii) to evaluate the role and importance of Saps in the course of murine 
disseminated candidiasis, established either by the hematogenous or the 
intraperitoneal routes; iii) to evaluate Sap1-3 contribution to host response evasion by 
degrading and inactivating host galectin-3; iv) to establish immunoprotective protocols 
against hematogenously disseminated candidiasis by using Sap2 and Sap5 as target 
antigens. 
This dissertation is organized in seven chapters: 
Chapter 1 consists of a general introduction presenting a review of the current 
knowledge on Candida infections, with a focus on systemic candidiasis, including data 
on incidence, independent risk factors and groups at risk. Candida albicans virulence 
factors are also addressed here, with a particular emphasis on Saps. Moreover, a 
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description of C. albicans cell wall components and their recognition by host Pattern 
Recognition Receptors is presented. Innate and adaptive immunity to C. albicans 
infections is also reviewed in this chapter. Finally, a review of the usefulness of 
immune-based prevention and therapy of C. albicans infections and a list of published 
proposed vaccines is included. 
Chapter 2 presents data concerning the relative virulence of three C. abicans reference 
strains in a murine model of hematogenously disseminated candidiasis and the elicited 
host immune response. Different studies published on vaccination against Candida 
infections use distinct C. albicans strains. However, this usage appears to be based on 
laboratory strain availability rather than on an appropriate selection. Moreover, 
comparative studies that addressed C. albicans virulence barely focused on the overall 
elicited immune response. The main objective of this chapter is thus to comparatively 
evaluate virulence of three reference C. albicans strains, often used in virulence and 
antifungal drug testing, and characterize several features of the innate and adaptive 
immune response to infection established through the hematogenous challenge with 
each strain. 
Chapter 3 re-addresses the importance of the SAP1-SAP6 genes in a murine model of 
hematogenously disseminated candidiasis. This work aimed at confirming the 
importance of Saps in this infection model, by using single or triple mutant strains 
deficient in these virulence-associated genes, and also at characterizing the elicited 
host immune response. 
Chaper 4 focuses on the role of SAP1-SAP6 genes in a murine model of C. albicans 
peritonitis. Here, the analysis performed in the previous chapter is extended to the 
murine model of Candida peritonitis, with the objective of re-evaluating virulence of 
Δsap null mutant strains in this model as well as the elicited host immune response. 
In Chapter 5 the ability of Sap1-3 to contribute for C. albicans evasion of host 
immunity, by degrading the host PRR galectin-3 is explored. Galectin-3 recognizes C. 
albicans and induces fungal death. Thus, impairing recognition through galectin-3 
would favour pathogen survival. This work aimed at addressing if galectin-3 is a 
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substrate for Sap1, Sap2 or Sap3 and whether degradation of this PRR occurs in vivo in 
C. albicans infected tissues. 
Chapter 6 presents data concerning the development of immunoprotective protocols 
against hematogenously disseminated candidiasis by using Sap2 and Sap5 enzymes as 
target antigens. Several approaches using commercially available adjuvants are tested 
in order to fulfil the main objective which consisted in establishing a vaccination 
strategy that could confer protection to mice against disseminated candidiasis. 
Chapter 7 presents the concluding remarks consisting of an integrated discussion of 
the results achieved in the Chapters 2, 3, 4, 5, and 6 in the context of the initially 
proposed objectives. Future perspectives are also suggested at the end of the chapter.    
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ABSTRACT 
 
The murine model of hematogenously disseminated Candida albicans infection is 
widely used to ascertain strain virulence and host-fungus interaction. Here, a 
comparative study assessed survival and kidney fungal burden in mice infected 
intravenously with three different C. albicans strains with different attributed 
virulence, SC5314, ATCC 90028 and ATCC 32354. A comprehensive analysis of the early 
immune response in the spleen of yeast-challenged mice was also done. SC5314 was 
the most virulent strain and elicited a more marked inflammatory response, with 
higher neutrophil recruitment. In contrast, ATCC 32354 presented the lowest virulence 
and stimulated less markedly the innate response than the other strains. These results 
provide additional evidence on the association between C. albicans virulence and the 
host early innate immune response.  
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INTRODUCTION 
The opportunistic human pathogen Candida albicans can cause both mucocutaneous 
and disseminated infections, particularly in debilitated or immuno-compromised hosts, 
being the most common cause of fungal invasive infections (1, 2). The murine model of 
hematogenously disseminated candidiasis closely resembles infection introduced into 
patients directly through catheters, is highly reproducible, and its clinical course is 
similar to untreated clinical disseminated candidiasis (3-5). Therefore, it has been 
widely used for investigating C. albicans virulence, host-fungus interactions, and 
efficacy of antifungal agents (6). Sepsis has been recognized as the major cause of 
death in the murine model of disseminated candidiasis (4), and the kidney is the main 
target organ for infection in this model (3, 5). However, evaluation of virulence only in 
terms of fungal kidney burdens and survival times gives little information of the 
fungus-host interactions and elicited host immune responses.  
The innate immune system is the first line of host defence upon intravenous C. 
albicans challenge (7, 8). This arm of the immune system is mainly comprised of 
phagocytic cells that must recognize and respond to fungi, opposing fungal invasion 
and eliminating fungi from infected tissues and organs (9-11). The nature of the fungus 
is determinant in fungal recognition and drives the production of chemokines and 
directive cytokines, expression of co-stimulatory molecules and presentation of fungal 
antigens to T lymphocytes, affecting polarization of the T helper type of response (8, 
12). The interplay between the host and the fungus is dynamic, and the balance 
between elimination of the fungus and tissue damage at the site of infection will 
depend not only on the host response, but also on the fungus ability to react to host 
effector molecules and cells (10, 12). It is well documented that properties of different 
yeast isolates, such as cell wall composition and morphogenesis, may modify fungal 
recognition and the ensuing immune response (12-16). 
Within C. albicans, clinical isolates were found to differ considerably in virulence for 
mice, as revealed by differences in survival times and organ fungal burden after 
systemic infection (17-20). Nevertheless, the effects on the host response of the 
virulence properties of different Candida strains have been poorly evaluated, and 
focused on C. albicans internalization and killing by phagocytes, rather than on the 
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overall immune response (11, 21-23). In this respect, the study presented here aimed 
at evaluating the virulence of three different isolates of C. albicans, SC5314, ATCC 
90028, and ATCC 32354, in a murine model of hematogenously disseminated infection, 
and comparing both innate and acquired immunity against the intravenous challenge 
with the different strains. 
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MATERIALS AND METHODS 
 
Mice 
Male BALB/c mice, 8-10 weeks old, were purchased from Charles River (Barcelona, 
Spain) and kept under specific pathogen-free conditions at the Animal Facility of 
Instituto de Ciências Biomédicas Abel Salazar, Porto, Portugal. All procedures involving 
mice were performed according to the European Convention for the Protection of 
Vertebrate Animals used for Experimental and other Scientific Purposes (ETS 123), 
86/609/EEC Directive and Portuguese rules (DL 129/92). Authorization to perform the 
experiments was issued by the competent national board authority (Direção Geral de 
Veterinária), document number 0420/000/000/2010. 
 
Candida albicans strains and culture conditions 
The C. albicans strains used in this study were the wild-type strains SC5314, ATCC 
90028 and ATCC 32354. All strains were maintained as frozen stocks in 30% glycerol at 
-80ºC. To prepare the inocula for infection, strains were grown in a shaking incubator 
for 14 to 16 hours at 30ºC in Winge medium (0,2% glucose, 0,3% yeast extract). Yeast 
cells were harvested, washed twice with sterile, nonpyrogenic phosphate-buffered 
saline, counted in a haemocytometer and resuspended at the appropriate 
concentrations. Inocula were confirmed by Colony Forming Unit (CFU) counts on 
Sabouraud dextrose agar (Difco, Detroit, MI, USA) for up to 48 h at 37ºC.  
 
Candida albicans hematogenously disseminated  infections 
Mice were injected intravenously (i.v.), in the lateral tail vein, with 1×105 C. albicans 
yeast cells in 0.2 ml PBS. To evaluate the progress of hematogenously disseminated 
candidiasis, mice were weighed and monitored twice daily, for a maximum of 70 days. 
Moribund mice were humanely terminated, and their deaths recorded as occurring the 
following day. 
Alternatively, mice were sacrificed 18 and 72 h post-infection to determine organ 
fungal burden and/or immunological parameters. Control mice were injected i.v. with 
PBS. Kidneys were aseptically removed, homogenized, and quantitatively cultured on 
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Sabouraud dextrose agar (Difco) at 37ºC. Values were expressed as log CFU per gram 
of tissue.  
 
Flow cytometric analysis  
The assessment of cell surface and cytoplasmic lineage or activation markers on 
different splenic leukocyte populations was performed by flow cytometric analysis 
(FACS). Spleens were aseptically removed and homogenized to single cell suspensions 
in Hank’s Balanced Salt Solution (HBSS) (Sigma Aldrich, St Louis, MO, USA). A number 
of 1x106 leucocytes were stained per sample.  
The following monoclonal antibodies (mAbs), along with the respective isotype control 
were used (at previously determined optimal dilutions) for immunofluorescence 
cytometric analysis in FACScan (Becton-Dickinson, San Jose, CA, USA) using CELLQUEST 
software (Becton-Dickinson): 
Phycoerythrin (PE) conjugated rat anti-mouse CD40 (1C10) (Southern Biotechnology 
Associates, Birmingham, ALA, USA); Fluorescein isothiocyanate (FITC) conjugated anti-
mouse/rat Foxp3 (FJK-16s), Phycoerythrin-Cyanin 5 (PE-Cy5) rat anti-mouse CD4 (L3T4) 
(RM4-5), and PE anti-mouse F4/80 antigen (BM8) (eBioscience, San Diego, CA, USA); 
Biotin conjugated anti-mouse PDCA-1(JF05-1C2.4.1) (Miltenyi Biotech, Inc., Auburn, 
CA, USA); FITC hamster anti-mouse CD11c (HL3), FITC anti-mouse Ly-6G and Ly-6C (Gr-
1) (RB6-8C5), PE anti-mouse CD25 (PC61), PerCP-Cy5 anti-mouse CD19 (RA3-6B2), PE 
anti-mouse CD80 (B7-1) (16-10A1), PE anti-mouse CD86 (B7-2) (GL1), PE rat anti-
mouse I-Ad/I-Ed (2G9), PE conjugated rat anti-mouse IL-4 (BVD4-1D11), FITC anti-
mouse IFN-γ (XMG1.2), PE rat anti-mouse IL-17A (TC11-18H10),  and PE rat anti-mouse 
IL-10 (JES5-2A5) (all from BD Pharmingen, San Diego, CA). Biotin conjugated mAbs 
were revealed with Streptavidin-PE-Cy5 (BD Pharmingen). Cells were pre-incubated for 
15 minutes with anti-FcγR (a kind gift of Dr Jocelyne Demengeot, Gulbenkian Institute 
of Science, Oeiras, Portugal) before CD11c and Foxp3 staining. The Foxp3 Staining 
Buffer Set (eBioscience) was used for fixation and permeabilization of splenocytes 
surface stained with CD4 and CD25 mAbs.  
The intracellular expression of the cytokines IFN-γ, IL-4, IL-17A and IL-10 was detected 
in splenic CD4+ T lymphocytes. Splenocytes were obtained as described above. Red 
blood cell lysis was performed by incubation with 0,15M ammonium chloride. Cells 
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were washed and resuspended in complete RPMI medium (Sigma) (RPMI 1640 
supplemented with 50U of penicillin/ml, 50 µg of streptomycin/ml, 1% HEPES buffer 
(Sigma), 10% FCS (Invitrogen, Carlsbad, CA, USA), and 5 µM 2-mercaptoethanol). 1x106 
cells were transferred to 96-well tissue culture plates (Nunc, Roskilde, Denmark) and 
stimulated for 4,5 hours with 20 ng/ml phorbol myristate acetate (Sigma) and 200 
ng/ml ionomycin (Sigma) in the presence of 10 µg/ml of brefeldin A (Roche, Penzberg, 
Germany).  
Staining of cell surface markers CD4 was performed as described above, after a pre-
incubation step of 15 minutes with anti-FcγR, followed by fixation with 2% 
formaldehyde. Cells were permeabilized with 0,5% saponin in flow cytometric buffer 
(PBS containing 1% BSA and 0,01M sodium azide) and, subsequently, cells were 
incubated for 15 minutes with anti-FcγR and stained for 30 minutes at room 
temperature with the appropriate antibody. Intracellular staining with the isotypic 
control was performed to confirm the specificity of antibody binding. 
The IFN-γ+/IL-4+ CD4+ T cell ratios were calculated to determine the polarization of the 
immune response towards a Th1- or Th2-type. The immune response in non-infected 
mice was defined as unpolarized. 
 
Statistical Analysis 
Unless otherwise stated, results shown are from one experiment, representative of 
two independent experiments. Statistical significance of results was determined by 
one-way ANOVA and post-hoc Bonferroni’s multiple comparison test, and survival data 
were analysed with the log-rank test, by using the GraphPad Prism 4 Software 
(GraphPad Software, Inc., La Jolla, CA, USA). Results were considered statistically 
significant with P values of less than 0.05.  
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RESULTS 
 
Virulence of C. albicans strains SC5314, ATCC 90028 and ATCC 32354 in intravenously 
infected BALB/c mice 
The widely used Candida albicans strain SC5314 and strains ATCC 90028 and ATCC 
32354 with different reported virulence abilities (17) were compared for their 
virulence in a model of hematogenously disseminated candidiasis. Striking differences 
in survival time were observed after i.v. infection of BALB/c mice with SC5314 and 
ATCC 90028 or ATCC 32354 (P= 0.0013 and P= 0.0066, respectively) (Figure1A).  
 
 
Figure 1. C. albicans virulence in the murine model of hematogenously disseminated 
candidiasis. (A) Survival curves of BALB/c mice injected i.v. with 1×105 cells yeast cells of C. 
albicans WT strains SC5314, ATCC 90028 and ATCC 32354. P=0.0013 SC5314 vs ATCC90028 and 
P=0.0066 SC5314 vs ATCC 32354, as determined by log-rank test (n=5); (B) Kidney fungal 
burden of BALB/c mice 12 and 72 hours after i.v. infection with 1×105 SC5314 (●), ATCC 90028 
(▲) or ATCC 32454 (□) C. albicans cells, as indicated.  Data are from one experiment 
representative of two independent experiments. Each symbol represents an individual mouse, 
horizontal bars are means of CFU numbers in each group (n=4), * P<0.05; *** P<0.001, as 
determined by one-way ANOVA and post-hoc Bonferroni’s multiple comparison test. 
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The median survival time of SC5314- and ATCC 90028-infected infected mice was 9 and 
57 days, respectively.  All mice injected with either SC5314 or ATCC 90028 strains 
succumbed to candidal infection. In contrast, mice infected with ATCC 32354 had an 
extended overall survival time, compared to mice infected with the other C. albicans 
strains. At the end of the experiment (70 days), 60% of the mice infected with ATCC 
32354 survived the infection (Figure 1A). 12 h after i.v. challenge, SC5314-infected 
mice presented significantly lower CFU counts than ATCC 90028-infected mice, and 
similar kidney counts to ATCC 32354-infected mice (Figure 1B), though mice infected 
with the former strain presented a greatly diminished survival time. Nevertheless, as 
depicted in Figure 1B, 72 h after challenge, kidneys from mice infected with strain 
SC5314 presented higher fungal burdens than those of ATCC 90028- and ATCC 32354-
infected mice, which had no different kidney CFU numbers, despite the differences 
observed in survival. No later time points were assessed, since mice inoculated with    
1 × 105 SC5314 cells were frequently moribund by 6 to 7 days after infection.  
 
Early host immune response in C. albicans-challenged mice 
Given the marked differences found in mice survival times, we evaluated the early host 
immune response to an i.v. challenge with the different tested strains. At the earliest 
time point analysed, mice infected with strain ATCC 90028, which presented the 
highest kidney fungal burden, showed the highest proportions and numbers of splenic 
inflammatory monocytes (F4/80+Gr-1+) and reduced frequency and numbers of 
macrophages (F4/80hiGr-1-) whereas neutrophils  (F4/80-Gr-1+) did not vary from 
controls or the other infected groups (Figure 2). This scenario changed completely by 
72 h after infection. SC5314-infected mice, which presented the highest kidney CFU 
counts at this time point, had a significant increase in the proportions and numbers of 
neutrophils, as compared with any of the other groups (Figure 2). Inflammatory 
monocytes were present in higher proportions and numbers in the spleen of mice 
infected with the most virulent strains, SC5312 and ATCC 90028. Curiously, no relevant 
changes were observed in the assessed myeloid spleen cell populations in mice 
infected with ATCC 32354.   
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Figure 2 (A) Representative examples of flow cytometric analysis of F4/80 and Gr-1 expression 
on the surface of mice splenic cells 12 and 72h after i.v. injection with PBS or 1×105 C. albicans 
SC5314, ATCC 90028 or ATCC32354 cells, as indicated. Gated populations correspond to 
macrophages (F4/80highGr-1neg), neutrophils (F4/80neg/lowGr-1high) and inflammatory monocytes 
(F4/80highGr-1high). (B) Scatter plots of the frequencies of macrophages, neutrophils and 
inflammatory monocytes ; (C) Scatter plots of the total numbers of macrophages, neutrophils 
and inflammatory monocytes, as indicated. Each symbol represents an individual mouse. (n=3 
for controls and n=4 for infected mice). *P<0.05;  **P<0.01; ***P<0.001. Statistical comparison 
with non-infected controls was omitted for simplicity. 
 
In general, expression of MHC class II and co-stimulatory molecules CD80, CD86, CD40 
on the surface of spleen conventional and plasmacytoid dendritic cells (cDCs and pDCs, 
respectively) did not markedly change upon infection. Some alterations could however  
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be observed. Mice infected with SC5314 had increased expression of the co-
stimulatory molecule CD86 on the surface of both cDCs and pDCs 72 h after infection, 
indicating a higher activation of these cells as compared to the other infected groups 
(Figure 3).  
 
Figure 3 Representative flow cytometric analysis of CD11c and PDCA-1 on splenic BALB/c mice 
cells. (A) Conventional dendritic cells (cDC) were defined as CD11chigh and plasmacytoid 
dendritic cells (pDC) as CD11clow PDCA-1+, as shown. (B) CD80, CD86, CD40 or MHC class II 
expression on the surface of splenic cDC or pDC, as indicated, 12 and 72 h after C. albicans i.v. 
Infection (n=3 for controls and n=4 for infected mice). * P<0.05; **P<0.01. 
 
An elevated expression of CD86 on the surface of B cells was also observed in SC5314-
infected mice (data not shown). In contrast, SC5314-infected mice presented a 
diminished expression of CD40 on the surface of pDCs at the earliest time point and of 
MHC class II molecules on cDCs 72 h upon challenge. Mice infected with strain ATCC 
90028 had diminished CD80 and elevated MHC class II expression on cDCs at 12 h and 
72 h after infection, respectively (Figure 3).  
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Figure 4 Representative examples of flow cytometric analysis of intracellular IL-12 expression 
in CD11c+-gated spleen cells, 72 h after i.v. injection with PBS or 1×105 C. albicans SC5314, 
ATCC 90028 or ATCC32354 cells. Numbers inside dot-plots correspond to mean percentage ± 
SD of IL-12+ cells (n=3 for controls and n=4 for infected mice). *P<0.05;  ***P<0.001 when 
comparing with either PBS or ATCC 32354 groups. No other significant differences were 
observed. 
 
Mice infected with the most virulent strains had the highest frequencies of spleen cDCs 
expressing the pro-inflammatory molecule IL-12 (Figure 4), yet the frequencies of CD4+ 
T cells expressing IFN-γ were not significantly different from the one found in ATCC 
32354-infected mice (Figure 5A).  
 
 
Figure 5 (A) Expression of intracellular IFN-γ in gated spleen CD4+ T cells, 72 h after C. albicans 
i.v. Infection. (B) IFN-γ/IL-4 ratio normalized by the control mean ratio (n=3 for controls and 
n=4 for infected mice).  
 
Interestingly, the IFN-γ+/IL-4+ cell ratio in these mice was the highest, suggesting a Th1 
bias in the immune response. No significant differences were observed in IL-10 and IL-
17A expression by CD4+ T cells. Expression of the regulatory T cell marker Foxp3 within 
CD4+CD25+ T cells was reduced in SC5314- and ATCC 90028-infected mice groups, but 
not in mice infected with the less virulent ATCC 32354 strain (data not shown).  
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Altogether, these results confirm virulence differences among the tested strains, in this 
infection model, and suggest an association between C. albicans virulence and the 
elicited inflammatory response. 
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DISCUSSION 
 
Distinct C. albicans isolates may show very distinct virulence and infection patterns in 
mice (20, 21, 24, 25) and elicit both qualitatively and quantitatively different host 
responses (18, 21). The virulence of three different C. albicans strains, SC5314, ATCC 
90028 and ATCC 32354 was compared here by determining survival and fungal burden 
in the kidneys of BALB/c mice after intravenous challenge. The evaluation of the ability 
to colonize and invade the kidneys has been usually used to measure virulence of C. 
albicans strains (3, 26). A near-linear relationship has been demonstrated between 
mouse median survival times and C. albicans kidney CFU counts, determined 12 h after 
challenge (3, 27). However, we could not find such an association between kidney CFU 
counts and mice survival time at this early time point. In the infection model used, 
SC5314 was the most virulent C. albicans strain tested, causing lethal infection in a 
relatively short time. This C. albicans strain has already been classified as highly 
virulent in the murine model of hematogenously disseminated candidiasis and causing 
severe infection in the kidney (3, 18, 19). Not surprisingly, strain ATCC 32354 
presented lower virulence than the two other strains tested, since in a previous report 
it has been shown to have intermediate virulence in murine hematogenously 
disseminated candidiasis (17). Accordingly, neutrophilic infiltration and edematous 
corneal stroma were prominent in corneas infected with SC5314, but less severe with 
strain ATCC 32354 (28). Unexpectedly, mice infected with ATCC 90028, which was 
considered a highly virulent strain in the i.v. infection model (17), presented a 
markedly higher survival time than SC5314-infected counterparts.  
Several studies support a direct relationship between colony count in the infected 
kidney and mortality (3, 27, 29). However, although renal failure was long considered 
to be the cause of mice death in the murine model of disseminated candidiasis (29-32), 
the major cause of death was later proved to be progressive sepsis (4). Here, such a 
relationship between kidney fungal burden and mortality was not obvious as mice 
infected with SC5314 or ATCC 32354, which greatly differed in survival times, 
presented similar C. albicans kidney load. This might indicate that survival may be 
instead determined by the host immune response. This hypothesis may be in 
agreement with a previous report showing that the early innate immune response, 
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assessed through cytokine and chemokine measurement in the spleen and kidneys, 
determines and predicts the progression of C. albicans infection (21).  
It is noteworthy that the highest virulent strain, SC5314, induced a more marked 
inflammatory response, as assessed by the high recruitment of neutrophils and 
inflammatory monocytes into the spleen. Also, DCs from mice infected with this strain 
produced the highest levels of the pro-inflammatory cytokine IL-12 and presented the 
highest up-regulation of co-stimulatory molecule CD86 on their surface. The generated 
inflammation may be worsening organ pathology rather than protecting the host, as 
suggested before (12, 21). That would explain the more precocious death of SC5314-
infected mice. Contrastingly, in mice infected with the other strains, a lower splenic 
neutrophil influx could reflect a milder inflammatory response, translated in extended 
survival times. It is intriguing that SC5314 strain, which display a high virulence in the 
model used here, in which immune protection mainly depends on polymorphonuclear 
neutrophils was reported to be much less efficient at infecting the mucosa (18, 33), for 
which cell mediated immunity is essential for host protection (7).  
The ATCC 32354 strain barely elicited a detectable inflammatory response, as assessed 
by leukocyte recruitment or activation in the spleen. Nevertheless, mice infected with 
this strain, were the ones presenting the highest IFN-/IL-4 ratio. This could indicate a 
bias towards a Th1-type immune response, presumably protective (7, 12), without 
aggressive inflammatory pathology. In this regard, it must be noted that mice infected 
with ATCC 32354 strain, contrasting with what was observed in the mice infected with 
the most virulent strains, did not present a decrease in splenic T regulatory cell 
proportions. It is conceivable that this may help in inflammation control as these cells 
have been implicated in limiting inflammatory pathology in the murine model of 
hematogenously disseminated candidiasis (34).  
The vast majority of gene disruption studies have been carried out in a single strain, 
SC5314, background. It is already known that different strains may present distinct 
virulence phenotypes and elicit dissimilar immune responses. In consequence, results 
obtained with one strain cannot be taken as representative of the whole species. This 
must be taken into account when delineating vaccination or immunotherapeutic 
strategies to prevent or manage systemic C. albicans infections.  
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ABSTRACT 
 
Candida albicans secreted aspartyl proteinases (Sap) are considered virulence-
associated factors. Several members of the Sap family have been claimed to play a 
significant role in the progression of candidiasis established by the hematogenous 
route. This assumption was based on the observed attenuated virulence of sap null 
mutant strains. However, the exclusive contribution of SAP genes for their attenuated 
phenotype was not unequivocally confirmed as the Ura-status of these mutant strains 
could also have contributed to the attenuation. In this study, we have re-assessed the 
importance of SAP1-SAP6 in a murine model of hematogenously disseminated 
candidiasis, using sap null mutant strains not affected in their URA3 gene expression 
and compared their virulence phenotype with Ura-blaster sap mutants. The median 
survival time of BALB/c mice intravenously infected with a mutant strain lacking SAP1-
3 was equivalent to that of the wild-type SC5314, while those infected with mutant 
strains lacking SAP5 showed slightly extended survival. Nevertheless, no differences 
could be observed between the wild-type and a Δsap456 mutant in their ability to 
invade and colonize mice kidneys. Likewise, deficiency in SAP4-6 had no noticeable 
impact on the immune response elicited in the spleens and kidneys of C. albicans 
infected mice. These results contrast with the behaviour of equivalent Ura-blaster 
mutants, which presented a significant reduction in virulence. Our results suggest that 
Sap1-6 do not play a significant role in C. albicans virulence in a murine model of 
hematogenously disseminated candidiasis and that, in this model, Sap1-3 are not 
necessary for successful C. albicans infection. 
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INTRODUCTION 
 
The polymorphic yeast Candida albicans is an important opportunistic human 
pathogen, causing infections that range from superficial mucosal lesions to life-
threatening systemic disease. It is by far the most common cause of fungal invasive 
infections, which could be attributed to the little immunosuppression required to 
predispose to invasive Candida infections (39). Host physical barriers and immune 
system integrity are crucial factors in controlling the establishment of infection. 
However, the high adaptability of C. albicans to different host niches, by the 
expression of appropriate sets of virulence-related genes, is also determinant (18, 51). 
Several of these virulence attributes may participate in and influence the infective 
process, depending on the site and stage of invasion and on the nature of the host 
response (36). The secretion of hydrolytic enzymes during infection is required as a 
virulence attribute to aid adhesion, invasion, and destruction of host immune factors, 
in addition to nutrient acquisition (20). Within these, secreted aspartyl proteases (Sap), 
encoded by a ten-member gene family (SAP1-SAP10) have been the most extensively 
studied (34). The 10 SAP genes that compose this family can be divided into 
subfamilies based on amino acid sequence homology alignments (SAP1-3, SAP4-6, 
SAP9-10). These genes exhibit differential expression profiles at different stages and 
sites of infection (34, 32, 46, 49) and have been linked with the virulence of the fungus 
since their discovery (10, 26, 48).  
The contribution to virulence of SAP1-3, SAP4-6, SAP7 and SAP9-10 genes in different 
models of infection has been studied by using sap null mutant strains (1; 13; 15; 19; 22; 
24, 25, 28, 33, 43, 54). The subfamily of genes SAP4-6, in particular, were shown to 
contribute significantly to C. albicans virulence in models of acute systemic candidiasis, 
murine peritonitis and Candida gastrointestinal infection (15, 24, 43). These genes are 
mainly expressed during hypha formation (21, 33) and SAP5, in particular, was found 
to be up-regulated at all time-points after either intravenous or intraperitoneal mice 
infection (44, 50, 57). 
Hube et al. (19) reported that Δsap1, Δsap2 and Δsap3 null mutants displayed 
attenuated virulence in models of acute systemic candidiasis. The triple deletion of 
SAP4-6 resulted in a more marked impact on C. albicans virulence, in similar 
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experimental settings, suggesting an important role for these hypha-related genes in 
the establishment of disseminated candidiasis (43). These mutant strains were 
generated from the auxotrophic laboratory strain CAI4 with the most common method 
used for disrupting genes in C. albicans, the Ura-blaster technique (16). The use of the 
URA3 marker for mutant construction in C. albicans can lead to misinterpretation of 
the results in mutant virulence studies (5, 8, 11, 27). Though this can now be overcome 
by integration of URA3 at the ENO1 (52) or RPS10 loci (8), the mutant strains used in 
the referred studies did not share a common site of URA3 integration. Therefore, it is 
conceivable that the Ura-status could have influenced the results and thus, the 
attenuated nature of these mutants during acute systemic candidiasis remains to be 
confirmed unequivocally (37). Therefore, in this study, we have used a set of Δsap null 
mutants constructed by Lermann and Morschhäuser (28) from the prototrophic wild-
type strain SC5314 using the SAT1-flipping stategy (41) to re-address the importance of 
the SAP1-SAP6 genes in a murine model of hematogenously disseminated candidiasis. 
In addition, we analyzed the histopathology of several organs and aspects of the 
immune response elicited in the spleens and kidneys of BALB/c mice infected with the 
wild-type strain and a sap null mutant lacking SAP4 to SAP6. 
 
 122 
 
MATERIALS AND METHODS 
 
Mice 
Male BALB/c mice, 8-10 weeks old, were purchased from Charles River (Barcelona, 
Spain) and kept under specific pathogen-free conditions at the Animal Facility of 
Instituto de Ciências Biomédicas Abel Salazar, Porto, Portugal. All procedures involving 
mice were performed according to the European Convention for the Protection of 
Vertebrate Animals used for Experimental and other Scientific Purposes (ETS 123), 
86/609/EEC Directive and Portuguese rules (DL 129/92). 
 
Candida albicans and culture conditions 
The C. albicans strains used in this study are listed in TABLE 1.  
 
TABLE 1. Candida albicans strains used in this study 
Strain Genotype Reference 
SC5314 
 
SAP123MS4C and -D 
 
 
 
SAP456MS4A and -B 
 
 
 
SAP4MS4A 
 
SAP5MS4A 
 
SAP6MS4A 
 
CAF2-1  
 
M119  
 
 
 
DSY459 
Prototrophic wild-type strain 
 
sap1Δ::FRT/sap1Δ::FRT 
sap2Δ::FRT/sap2Δ::FRT 
sap3Δ::FRT/sap3Δ::FRT 
 
sap4Δ::FRT/sap4Δ::FRT 
sap5Δ::FRT/sap5Δ::FRT 
sap6Δ::FRT/sap6Δ::FRT 
 
sap4Δ::FRT/sap4Δ::FRT 
 
sap5Δ::FRT/sap5Δ::FRT 
 
sap6Δ::FRT/sap6Δ::FRT 
 
URA3/ura3Δ::imm434 
 
sap1Δ::hisG/sap1Δ::hisG 
sap2Δ::hisG/sap2Δ::hisG  
sap3Δ::hisG/sap3Δ::hisG::URA3::hisG 
 
sap6Δ::hisG/sap6Δ::hisG 
sap4Δ::hisG/sap4Δ::hisG  
sap5Δ::hisG/sap5Δ::hisG::URA3::hisG 
16 
 
27 
 
 
 
27 
 
 
 
27 
 
27 
 
27 
 
15 
 
23 
 
 
 
42 
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All strains were maintained as frozen stocks in 30% glycerol at -80ºC. Yeast growth was 
tested in synthetic glucose minimal (2% glucose, 0.67% Bacto-yeast nitrogen base 
without amino acids) and complex YPD (2% glucose, 1% yeast extract, 2% Bacto-
peptone) liquid media at 30 and 37ºC, in a shaking incubator for 24 h. Growth was 
measured at 60 minute-intervals and the generation times were calculated. Hyphae 
formation was induced by the addition of calf serum (Invitrogen, Carlsbad, CA, USA) 
(10%) or N-acetyl-glucosamine (2.5 mM) (Sigma, St Louis, USA) at 37ºC. To prepare the 
inocula for infection, C. albicans strains were grown in a shaking incubator for 14 h at 
30ºC in Winge medium (0.2% glucose, 0.3% yeast extract). Yeast cells were harvested, 
washed twice with sterile, nonpyrogenic phosphate-buffered saline (PBS), counted in a 
haemocytometer and resuspended at the appropriate concentrations. Inocula were 
confirmed by Colony Forming Unit (CFU) counts on Sabouraud dextrose agar (Difco, 
Detroit, MI, USA) for up to 48 h at 37ºC. 
 
C. albicans hematogenously disseminated infections 
Mice were injected intravenously (i.v.), in the lateral tail vein, with 1x105 or 5x105 C. 
albicans yeast cells in 0.2 ml PBS. To evaluate the progress of hematogenously-
disseminated candidiasis, mice were weighed and monitored twice daily. Moribund 
mice were humanely terminated, and their deaths recorded as occurring the following 
day. 
Other groups of mice were infected with 5x104 yeast cells and sacrificed 3 and 7 days 
post-infection to determine organ fungal burden and/or immunological parameters. 
Control mice were injected i.v. with PBS. Kidneys were aseptically removed, weighted, 
homogenized, and quantitatively cultured on Sabouraud dextrose agar (Difco) at 37ºC. 
Values were expressed as log CFU per gram of tissue. Alternatively, kidneys, liver, lungs 
and brain were fixed in 10% phosphate-buffered formaldehyde, followed by periodic 
acid-Schiff reagent staining and counterstaining with haematoxylin of the paraffin-
embedded tissues, in order to evaluate both fungal morphology and composition and 
distribution of inflammatory infiltrates. 
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Quantitative real-time PCR (qRT-PCR) 
BALB/c mice were i.v. infected with 1x105 C. albicans SC5314, SAP123MS4C and 
SAP456MS4A yeast cells. Total RNA was isolated from the kidneys of three mice per 
group, 3 and 7 days after infection. Briefly, the kidneys were removed, homogenized in 
PBS and centrifuged at 1500 g, 4ºC for 10 min. Pellets were washed twice with ice cold 
RNAse-free water and frozen in liquid nitrogen until RNA extraction which was 
performed by using the hot acidic phenol method (4) Total RNA was incubated with 
Deoxyribonuclease I (DNAse I), Amplification Grade (Invitrogen) for 15 min at room 
temperature to eliminate genomic DNA contamination. DNAse I was inactivated 
according to the manufacturer’s instructions. 
The SuperscriptTM III Platinum® Two-Step qRT-PCR Kit with SYBR® Green was used to 
generate first-strand cDNA from each DNAse I-treated RNA sample. The RT conditions 
were 10 min at 65°C, 60 min at 37°C, and 10 min at 65°C. Quantitative PCR was 
performed with Platinum® SYBR® Green qPCR SuperMix-UDG (Invitrogen). Primers were 
added to the reaction mix at a final concentration of 200 nM. Three microliters of each 
cDNA sample were added to a 25 µl PCR mixture containing 12.5 µl of Platinum® SYBR® 
Green qPCR SuperMix-UDG, 0.5 µl of 10µM specific forward and reverse primers 
(TABLE 2) and 8.5 µl of RNase free water (Invitrogen). Each reaction was performed in 
a Corbett Rotor-Gene 6000 (Quiagen). Thermocycling conditions for SAP and ACT1 
quantification were 2 min at 50ºC (UDG incubation), 5 min at 95°C, followed by 40 
cycles of 95°C for 15 sec, 60°C for 30 sec and 72°C for 30 sec. The specificity of each 
primer pair was verified by the presence of a single melting temperature peak. 
Calibration and efficiency of SAP and ACT1 primers were assessed in titration 
experiments using C. albicans SC5314 genomic DNA (500 ng to 5 pg) in serial dilutions. 
Negative (water) control and a four point curve of SC5314 genomic DNA were included 
in each run. DNAse I-treated RNA was used to exclude genomic DNA contamination. 
SAP1-10 gene expression was normalized to the housekeeping gene ACT1 and 
analysed by using both the standard curve and the comparative Ct (∆∆Ct) methods. 
Data are presented as fold difference in expression relative to the WT gene expression 
from infected mice. Each experimental condition was performed in triplicate and 
reactions were done in duplicate in different days for reproducibility purposes.  
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TABLE 2. SAP and ACT1 primers used in this study and expected fragment length 
Gene Primer 5’-3’ Amplicon (bp) 
Forward Reverse 
ACT1 
SAP1 
SAP2 
SAP3 
SAP4 
SAP5 
SAP6 
SAP7 
SAP8 
SAP9 
SAP10 
TGCTGAACGTATGCAAAAGG 
TGAGGCTGCTGGTGATTATG 
ATCAGCTGGTTTCGTTGCTT 
TGTTACTGGTCCCCAAGGTGAA 
AATGATGTGGGCAAAAGAGG 
ATTTCCCGTCGATGAGACTG 
GTCAACGCTGGTGTCCTCTT 
TTCTCGTGATGCTGTCCAAG 
TTTGGTGGGGTTGATAATGC 
 ACCGGGTCTTCAGATTTGTG 
AACGGAAATGTTGCTTCTGG 
TGAACAATGGATGGACCAGA 
TGCCAACAGCTTTGAGAGAA 
GGGACAGCTTGTCTTTTGGA 
CTTGTCCTTGACCAGCTTGACAT 
ACGGCATTTGAATCTGGAAC 
ACCACGCCATTTTGGAATAC 
GCAGGAACGGAGATCTTGAG 
CCAGCAGGAAGACCATAAGC 
GGCAGCAGCCAATTTATCAG 
TTCCTCGTCGGTTTCTATGG 
TGAATCGCCTATCGAAAACC 
186 
224 
105 
209 
155 
205 
197 
183 
198 
180 
192 
 
Flow cytometric analysis  
The assessment of cell surface and cytoplasmic lineage or activation markers on 
different splenic leukocyte populations was performed by flow cytometric analysis 
(FACS). Spleens were aseptically removed and homogenized to single cell suspensions 
in Hank’s Balanced Salt Solution (HBSS) (Sigma). A number of 1x106 leucocytes were 
stained per sample.  
The following monoclonal antibodies (mAbs), along with the respective isotype 
controls were used (at previously determined optimal dilutions) for 
immunofluorescence cytometric analysis in FACScan (Becton-Dickinson, San Jose, CA, 
USA) using CELLQUEST software (Becton-Dickinson): 
Phycoerythrin (PE) rat anti-mouse CD40 (1C10), biotin rat anti-mouse Major 
Histocompatibility Complex (MHC) class II (NIMR-4) (Southern Biotechnology 
Associates, Birmingham, ALA, USA); fluorescein isothiocyanate (FITC) anti-mouse/rat 
Foxp3 (FJK-16s), PE-Cy5 rat anti-mouse CD4 (L3T4) (RM4-5), and PE anti-mouse F4/80 
antigen (BM8) (eBioscience, San Diego, CA, USA); FITC hamster anti-mouse CD11c 
(HL3), FITC anti-mouse Ly-6G and Ly-6C (Gr-1) (RB6-8C5), PE anti-mouse CD25 (PC61), 
FITC anti-mouse CD45R/B220 (RA3-6B2), PE anti-mouse CD80 (B7-1) (16-10A1), PE 
anti-mouse CD86 (B7-2) (GL1), PE rat anti-mouse IL-4 (BVD4-1D11), FITC anti-mouse 
IFN-  (XMG1.2), and PE rat anti-mouse IL-10 (JES5-2A5) (all from BD Pharmingen, San 
Diego, CA). Biotin conjugated mAbs were revealed with Streptavidin-PE-Cy5 (BD 
Pharmingen). Cells were preincubated for 15 min with anti-
Jocelyne Demengeot, Gulbenkian Institute of Science, Oeiras, Portugal) before CD11c 
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and Foxp3 staining. The Foxp3 Staining Buffer Set (eBioscience) was used for fixation 
and permeabilization of splenocytes previously surface stained with CD4 and CD25 
mAbs.  
The intracellular expression of the cytokines IFN-γ, IL-4 and IL-10 was detected in 
splenic CD4+ T lymphocytes. Intracellular expression of the cytokines IFN-  and IL-4 
was also detected in renal CD4+ T lymphocytes. Splenocytes were obtained as 
described above. Red blood cell lysis was performed by incubation with 0.15M 
ammonium chloride. Cells were washed and resuspended in complete RPMI medium 
(Sigma) (RPMI 1640 supplemented with 50U of penicillin/ml, 50 µg of streptomycin/ml, 
1% HEPES buffer (Sigma), 10% FCS (Invitrogen), and 5 µM 2-mercaptoethanol). The 
kidneys were minced with a razor blade and incubated for 30 min at 37ºC in RPMI 
1640 complete medium containing collagenase (Sigma-Aldrich) at 2 µg/ml. Cells were 
homogenized to single cell suspensions, washed and resuspended in RPMI 1640 
complete medium. Mononuclear cells were separated from the above suspensions by 
layering 5 ml onto 2.5 ml of a polysucrose-sodium ditrizoate solution (Histopaque 
1083®, Sigma) and centrifuged at 800 g for 20 min at room temperature. Mononuclear 
cells collected from the medium-Histopaque interface were washed and resuspended 
in RPMI 1640 complete medium. Spleen and renal 1x106 cells were transferred to 96-
well tissue culture plates (Nunc, Roskilde, Denmark) and stimulated for 4.5 h with 20 
ng/ml phorbol myristate acetate (Sigma) and 200 ng/ml ionomycin (Sigma) in the 
presence of 10 µg/ml of brefeldin A (Roche, Penzberg, Germany).  
Staining of cell surface marker CD4 was performed as described above, after a 
preincubation step of 15 min with anti-FcγR, followed by fixation with 2% 
formaldehyde. Cells were permeabilized with 0.5% saponin in flow cytometric buffer 
(PBS containing 1% BSA and 10mM sodium azide) and, subsequently, cells were 
incubated for 15 min with anti-FcγR and stained for 30 min at room temperature with 
the appropriate antibody. Intracellular staining with the isotypic controls was 
performed to confirm the specificity of antibody binding. 
Th1 cells were defined as CD4+IFN-γ+Il-4- and Th2 cells were defined as CD4+IFN-γ-Il-4+. 
Ratios of Th1/Th2 were generated to determine the presence of a polarized immune 
response. The immune response in non-infected mice was defined as unpolarized. 
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Serum IFN-γ, IL-4 and IL-10 measurements 
The concentration of IL-4 in the sera of C. albicans infected mice and non-infected 
controls was quantified with the Quantikine® M Murine IL-4 ELISA kit and serum IFN-γ 
and IL-10 were quantified with the Duo-Set ELISA kits (all from R&D Systems, 
Minneapolis, MN, USA) according to manufacturer’s instructions.   
 
Statistical Analysis 
Unless otherwise stated, results shown are from one experiment, representative of 
three independent experiments. Statistical significance of results was determined by 
unpaired Student t-test and survival data were analyzed with the log-rank test, using 
the GraphPad Prism 4 Software (GraphPad Software, Inc., La Jolla, CA, USA). Results 
were considered statistically significant with P values of less than 0.05.  
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RESULTS 
 
Virulence of C. albicans in a murine model of hematogenously disseminated infection 
Prior to the virulence studies, we have determined the generation time for each strain 
in synthetic defined and complex media at 30º and 37ºC, and the ability to form 
hyphae in serum- or N-acetylglucosamine-containing media. No yeast growth defects 
were observed under the conditions tested (similar generation times) and filamentous 
growth was similar to that of the wild-type (WT) strain SC5314 under the hypha-
inducing conditions analyzed (data not shown).  
To explore the role of aspartyl proteases Sap1-6 as virulence factors in the course of 
hematogenously disseminated candidiasis, BALB/c mice were initially infected i.v. with 
5x105 and 1x105 cells of C. albicans WT strain SC5314 and two independent series of 
homozygous deletion triple mutant strains lacking SAP1-3 (SAP123MS4C and 
SAP123MS4D) or lacking SAP4-6 genes (SAP456MS4A and SAP456MS4B) (28). The 
independent mutant strains behaved indistinctively (data not shown) and therefore 
results presented below correspond to those obtained with strains SAP123MS4C and 
SAP456MS4A.   
Mice infected with the highest inoculum showed 100% mortality for every group by 
day 6 after infection and no differences could be observed (data not shown). 
No differences in survival time were observed after i.v. infection of BALB/c mice with 
1x105 CFU of the WT or Δsap123 mutant SAP123MS4C strains (P= 0.5698 by log rank 
test) (Figure 1A). Mice infected with the Δsap456 mutant strain SAP456MS4A had an 
extended overall survival time, compared to the WT infected counterparts (Fig. 1). The 
median survival time of SAP456MS4A-infected mice were 13 and 16 versus 10 and 12 
days of WT-infected mice, as determined on the independent experiments shown in 
Figure 1 A, and B, respectively.  All mice injected with either the WT or the triple 
mutant strain SAP123MS4C succumbed to candidal infection within 17 days. In 
contrast, at the end of the experimental period (30 days), 15 to 20% of the mice 
infected with the Δsap456 mutant survived infection. Nevertheless, the kidneys of the 
surviving mice had Candida microabscesses and granulomas as revealed by 
histopathological analysis (data not shown). Despite these differences, statistical 
comparisons of the survival curves revealed that survival of mice infected with the WT 
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strain did not differ significantly from those of mice infected with the Δsap456 mutant 
(P=0.1405 and P=0.1331, Figure 1 A and B, respectively).  
 
Figure 1 Influence of SAP1-6 on C. albicans virulence in a murine model of hematogenously 
disseminated candidiasis. Male BALB/c mice were i.v. injected with 1x105 cells of (A) C. 
albicans WT strain SC5314 and the mutant strains SAP123MS4C and SAP456MS4A; (B) C. 
albicans WT strain SC5314 and the mutant strains SAP4MS4A, SAP5MS4A, SAP6MS4A and 
SAP456MS4A; (C) C. albicans WT strain SC5314 and CAF2-1, and the mutant strains 
SAP123MS4C, M119, SAP456MS4A, and DSY459.  Each strain was injected into 7 mice per 
group, per experiment, and survival was monitored twice daily for 30 days (A and B) or for 60 
days (C). Results are representative of two to three independent experiments. 
 
To ascertain the contribution of each of the deleted genes of the triple Δsap456 
mutant to the slightly extended survival observed, Δsap4, Δsap5 and Δsap6 single 
mutant strains were used. As shown in Figure 1B, survival time of mice infected with 
SAP4MS4A, SAP5MS4A and SAP6MS4A strains was statistically equivalent to that of 
WT-infected counterparts (P= 0.6265, P= 0.2121 and P= 0.9465, respectively). The 
observed median survival time was, however, consistently longer in mice infected with 
mutants lacking SAP5, such as with strains SAP5MS4A and SAP456MS4A. The survival 
curves of mice injected with these two strains were similar (P= 0.8621). 
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These results are in apparent contrast with previous studies, in a similar model of 
murine hematogenously disseminated candidiasis, using single mutant strains deficient 
in SAP1, SAP2 or SAP3 (19) and a triple mutant lacking the SAP4 to SAP6 genes (43), 
constructed with the Ura-blaster technique (16). In those studies, mutant strains 
deficient in each of the SAP1 to SAP3 genes and the Δsap456 triple mutant strain 
DSY459, were reported to survive longer than WT-infected mice, and the latter, to 
have significantly decreased mean CFU in the kidneys (43). Therefore, parallel 
experiments with the SAT1-flipping mutants and Ura-blaster triple mutants Δsap123 
M119 (23) and Δsap456 DSY459 (43) were performed using the same batch of BALB/c 
mice and the same experimental conditions. Strain CAF2-1 (16) was also included. As 
shown in Figure 1C, significant differences in survival time were observed between 
mice infected with strains Δsap123 M119 and Δsap456 DSY459, and the respective 
control strain CAF2-1 (P=0.0089 and P=0.0065, respectively). Mice infected with the 
Ura-blaster mutants survived significantly longer than mice infected with the 
equivalent SAT1-flipping mutants. The medium survival time of mice infected with 
mutants lacking SAP1-3 was 21 days for the Ura-blaster constructed Δsap123 M119, 
and 10 days for Δsap123 mutant SAP123MS4C (P=0.0127). Similar results were found 
when comparing the triple mutants lacking SAP4-6 genes. Medium survival time was 
51 days for mice infected with the Ura-blaster mutant and 13 days with the SAT1-
flipping mutant (P=0.0096). Survival of mice infected with the WT strain SC5314 and 
with the URA3 heterozygous strain CAF2-1 was similar (P=0.7005) 
The evaluation of fungal ability to invade the kidneys has been frequently used to 
measure virulence of C. albicans strains (29, 37). The number of C. albicans CFU in the 
kidneys of mice infected, either with the SAT1-flipping or the Ura-blaster mutants, as 
well as with the respective control strains was similar, except for mice infected with 
the Δsap456 DSY459 strain (Figure 2). Seven days after infection, CFU numbers were 
significantly reduced in mice infected with the latter mutant (P=0.0149, CAF2-1 vs 
Δsap456 DSY459). 
The two sets of mutants tested behaved distinctly in the same experimental model, 
suggesting that the observed differences could be due to the effect of ectopic URA3 
insertion, and not caused by disruption of SAP genes. However, the limited impact of 
SAP gene deletion in C. albicans virulence could be due to a compensatory expression 
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of the non-deleted SAP genes, as reported for the Ura-blaster mutants (33; 45). 
Expression of SAP1-10 in SC5314 and in SAT1-flipping triple mutants was evaluated by 
qRT-PCR in kidney samples, 3 and 7 days after infection. Only the results of the latter 
time-point analyzed are presented, since after 3 days the fungal burden was often 
insufficient to obtain reproducible results. The expression levels were always inferior 
or similar to ACT1 expression In the WT strain, except for SAP7. 
 
 
Figure 2 Kidney fungal burden of BALB/c mice 3 and 7 days after i.v. infection with 5x104 CAF2-
1 (), M119 (), DSY459 () SC5314 (),  SAP123MS4C (), and SAP456MS4A () C. 
albicans cells.  Data are representative of two independent experiments. Each symbol 
represent an individual mouse, horizontal bars are means of CFU numbers in each group. 
 
No significant differences in SAP1 to SAP10 expression were observed in either mutant 
compared with SC5314. However, mRNA levels of SAP4 were higher in the Δsap123 
mutant and the expression of SAP1, SAP2 and SAP3 trended higher in the Δsap456 
mutant (Figure 3). Thus, the virulence phenotypes observed do not seem to be due to 
significant compensatory upregulation.  
Although not significant, a reduction in virulence was consistently seen in the mutant 
Δsap456. Therefore, the impact of SAP4 to SAP6 deficiency on C. albicans virulence 
was further evaluated.  
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Figure 3 Compensatory upregulation of SAP1-10 in sap triple mutants SAP123MS4C, and 
SAP456MS4A from kidney homogenates, 7 days after .i.v. infection with 1x105 cells. Results are 
presented as fold difference in expression relative to the WT SC5314 from infected mice. 
 
The ability of WT and Δsap456 triple mutant strains to infect and injure several organs 
was assessed by histopathological analysis of the kidneys, liver, lungs and brain, 3 and 
7 days after infection. As shown in Figure 4, similar C. albicans cell morphology and 
invasive abilities by the WT and mutant strains were observed. The kidneys of both 
mice groups showed moderate multifocal renal medullary interstitial neutrophylic 
infiltration, with small areas of ductular necrosis. Intralesional PAS-positive organisms 
both in yeast and septated, branched hyphal morphology, were detected 3 days after 
C. albicans i.v. infection with strains SC5314 (Figure 4A) and SAP456MS4A (Figure 4B). 
At the later time-point tested, 7 days after infection, analysis of the kidneys of WT (Fig. 
4C) and mutant-infected (Figure 4D) mice showed moderate to severe, focally 
extensive to coalescing, renal medullary interstitial neutrophylic infiltration 
surrounding numerous PAS-positive organisms. These were present mainly as 
septated, branched hyphal structures, which largely effaced the medulla and invaded 
the urothelium. Invasion of liver, lungs and brain was not consistently seen (data not 
shown). Altogether, these results suggest that SAP4 to SAP6 genes are not essential for 
invasion of the kidneys during hematogenously disseminated candidiasis.  
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Figure 4. Representative photomicrographs of histological sections of kidneys from BALB/c 
mice infected with 5x104 SC5314 (A and C) and SAP456MS4A (B and D) C. albicans cells. Three 
days post i.v. infection, PAS-positive hyphae and yeast-like organisms were present in the renal 
medulla, partially effacing the renal tubuli and eliciting moderate neutrophylic infiltration both 
in WT- (A) and mutant-infected mice (B). 7 days post i.v. infection, numerous PAS-positive 
hyphae and yeast-like organisms were present in the renal medulla, extensively effacing the 
renal tubuli, eliciting intense neutrophylic infiltration and invading the urothelium (arrows) 
with no clear differences between WT (C) and mutant (D) strains. P-renal pelvis. Bar=100 μm.  
 
Host immune response to hematogenously disseminated candidiasis  
To determine the effect of SAP4 to SAP6 disruption on the immune response elicited 
by C. albicans systemic infection, BALB/c mice were infected i.v. with 5 × 104 C. 
albicans yeast cells of WT and Δsap456 mutant strains. At days 3 and 7 upon infection, 
absolute numbers and phenotype of different splenic leukocyte populations were 
quantitated by flow cytometric analysis. Macrophages and neutrophils, represent the 
first line of host immune defence when C. albicans cells infect the bloodstream or the 
endothelia (47, 58). Macrophages typically express the F4/80 cell surface marker, 
whereas neutrophils have a Gr-1high surface phenotype. Murine splenic cells expressing 
both antigens with either inflammatory or immunosuppressive function have also 
been described in the context of C. albicans infections (30, 56). According to the 
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expression of these two surface markers, three cell populations were analyzed in this 
study: F4/80highGr-1neg, F4/80highGr-1high and F4/80neg/lowGr-1high.  
 
 
 
Figure 5 (A) Scatter plots of the total numbers of neutrophils (F4/80neg/lowGr-1high), 
inflammatory monocytes (F4/80highGr-1high), macrophages (F4/80highGr-1neg), cDC (CD11chigh), B 
cells (B220+), Treg (CD4+CD25+Foxp3+), and Teffector (CD4+CD25+Foxp3-) as indicated, observed 
3 and 7 days after infection in the spleens of non-infected control mice (open triangles) and 
mice challenged i.v. with 5x104 WT (open squares) and SAP456MS4A (filled circles) C. albicans 
cells. Data are representative of three independent experiments. Each symbol represents an 
individual mouse, horizontal bars are means of cell numbers in each group (n=3 for control and 
n=4 to 5 for infected mice groups). Statistically significant differences between controls and C. 
albicans infected mice are indicated *P<0.05; ** P<0.01; *** P<0.001. (B) Relative proportions 
of splenic Teffector (black bars) and Treg (white bars) in the spleens of non-infected controls 
(PBS) and SC5314 or SAP456MS4A i.v. infected mice, 3 and 7 days after challenge.  
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These were respectively designated as macrophages, inflammatory monocytes and 
neutrophils (55). An extensive recruitment of neutrophils and inflammatory monocytes 
into the spleen could be observed in infected mice compared to non-infected controls, 
3 and, more markedly, 7 days after infection. Higher numbers of spleen macrophages 
were also detected in the infected mice 7 days upon infection. The total numbers of 
these myeloid cell populations in WT-infected mice were equivalent to the ones in 
mice infected with the Δsap456 triple mutant (Figure 5A). 
Dendritic cells were previously shown to play a major role in the induction of the cell-
mediated immune response to C. albicans infection (9, 38) and to directly influence the 
infection outcome (6). Therefore, the numbers and surface maturation markers of 
splenic conventional dendritic cells (cDC), defined as CD11chigh cells, were assessed 
upon C. albicans infection. Higher numbers of splenic cDC, comparatively to non-
infected controls, were observed at the earlier time-point analyzed. The cDC surface 
expression of the co-stimulatory molecules CD40 and CD80, remained practically 
unchanged after C. albicans i.v. infection, as evaluated by flow cytometry and recorded 
as Mean Fluorescence Intensities (MFI). In contrast, the co-stimulatory molecule CD86 
was upregulated on the surface of splenic cDC from C. albicans-infected mice, 3 and 7 
days after infection. The cDC surface expression of MHC class II molecules was slightly 
down-regulated in infected mice 3 days after infection, and upregulated at day 7 post-
infection, as compared to that of non-infected controls. No significant differences on 
cDC numbers (Figure5A) and surface expression of any of the assessed co-stimulatory 
and antigen-presenting molecules was detected between WT and SAP456MS4A-
infected mice at the two tested time-points (Figure 6). 
B cells have been shown to mediate host resistance to i.v. established C. albicans 
systemic infection (60). B cell numbers were significantly increased 7 days after 
infection in either WT or SAP456MS4A challenged mice (Figure 5A). As observed on 
splenic cDC, an up-regulation of the co-stimulatory molecule CD86 was observed 3 and 
7 days post-infection on the surface of B-cells of the infected mice, compared to non-
infected controls. The expression of CD80 and MHC class II molecules on the surface of 
B cells was observed up-regulated only at day 7 after challenge.  
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Figure 6 Expression of CD40, CD80, CD86, and MHC II molecules on the surface of spleen 
conventional dendritic cells (cDC) and B cells of BALB/c mice 3 and 7 days after i.v. injection 
with PBS (controls, grey histograms) or i.v. infection with 5×104 SC5314 (solid line) and 
SAP456MS4A (dashed line) C. albicans yeast cells. Staining with respective isotypic controls 
was omitted for simplicity. Numbers below histograms represent means ± one standard 
deviation of the mean fluorescence intensities of antibody stainings for non-infected controls 
(up) and SC5314 (middle) or SAP456MS4A (down) infected mice. (n=3 for control and n=5 for 
infected mice groups). Statistically significant differences between controls and C. albicans 
infected mice are indicated (* P<0.05; ** P<0.01). Results shown are from one experiment, 
representative of three independent experiments. 
 
Challenge with the SAP4 to SAP6 deficient mutant did not result in any differences to 
the WT strain, regarding either B cell numbers or co-stimulatory molecules expression 
(Figures 5A and 6). 
Although CD4+ T cells have been reported to have little influence on survival and on 
fungal burden during acute systemic candidiasis (3, 23), the CD4+ T cell subset of 
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naturally occurring regulatory T cells (Treg) has been shown to promote host 
susceptibility to C. albicans (35, 53), to limit tissue damage and/or enhance healing, 
but not to directly augment clearance of the organism from infected tissues (31). To 
ascertain the impact of SAP4 to SAP6 deficiency on the immune response mediated by 
CD4+ T lymphocyte cell populations, the numbers of CD4+, CD4+CD25+, 
CD4+CD25+Foxp3+ (Treg) cells and also of CD4+CD25+Foxp3- (Teffector) cells were 
assessed in the spleens of the infected BALB/c mice. The numbers of splenic CD4+ and 
CD4+CD25+ T cells of infected mice were not significantly different from the ones of 
non-infected controls (data not shown). However, as assessed by Foxp3 expression 
within the CD4+CD25+ T cell population, reduced percentages and numbers of Treg 
were observed 7 days after C. albicans infection. This correlated with higher splenic 
percentage and numbers of Teffector cells in these mice (Figure 5A), resulting in higher 
Teffector/Treg ratios compared to non-infected controls (Figure 5B). The percentage 
and numbers of both Teffector and Treg cells were not significantly different between 
the two C. albicans-infected groups.  
To better elucidate the effector function of the CD4+ T cells from WT and 
SAP456MS4A-infected mice, the proportion of splenic CD4+ T cells producing IFN-γ, IL-4 
and IL-10 was determined by intracytoplasmatic cytokine staining analysis. An 
increased frequency of CD4+ T cells expressing IFN-γ or IL-4 was observed in C. 
albicans-infected mice, comparatively to the non-infected controls. Although the 
frequency of cells producing either cytokine increased upon infection in the spleens of 
C. albicans-challenged mice, a bias towards a Th1 type response was observed (high 
IFN-γ/IL-4 ratio). The frequency of CD4+ T cells expressing IL-10 was also increased in 
the spleens of infected mice (Figure 7). The intracellular expression of IFN-γ and IL-4 
was also evaluated in kidneys CD4+ T cells as it associates with the outcome of 
infection (48). As observed in the spleen, the frequency of CD4+ T cells expressing IFN-γ 
and IL-4 cytokines increased in infected mice. Although a trend for extended survival 
was observed in mice infected with the mutant strain SAP456MS4A, the percentage of 
CD4+ T cells producing the cytokines IFN-γ or IL-4 in the kidneys of either group of 
infected mice were similar, resulting in equivalent Th1/Th2 cell ratios (Figure 7). No 
serum IFN-γ, IL-4 and IL-10 were detected by ELISA, 3 and 7 days after infection, either 
in infected or uninfected mice (data not shown).  
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Figure 7 Cytokine production in the spleen and kidneys of BALB/c mice infected i.v. with 5×104 
SC5314 and SAP456MS4A C. albicans cells. (A) Representative examples of flow cytometric 
analysis of intracellular IFN-γ and IL-4 expression on gated splenic and renal CD4+ T cells, as 
indicated. Numbers inside dot plot regions represent means ± one standard deviation of the 
frequency of IFN-γ+ or IL-4+ CD4+ T cells. (B) IFN-γ+/IL-4+ CD4+ T cell ratio, normalized 
considering the ratio of non-infected controls as basal (zero value). (C) Dot plots showing the 
percentage of splenic CD4+ T cells producing IL-10. Numbers inside dot plots represent means 
± one standard deviation of the frequency of IL-10+ CD4+ T cells. Data are representative of two 
independent experiments (n=4 for non-infected control and n=7 for infected mice groups). 
Statistically significant differences between controls and C. albicans infected mice are 
indicated *P<0.05; ** P<0.01.  
 
Overall, these results indicate that SAP4 to SAP6 deficiency do not have a significant 
impact on the immune response elicited in the spleen and kidneys of BALB/c mice 
hematogenously challenged with C. albicans. 
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DISCUSSION 
 
The secretion of aspartyl proteases has long been recognized as a virulence-associated 
trait of Candida albicans (10, 26, 49). The importance of specific Sap isoenzymes for 
the pathogenicity of this fungus has been investigated in different infection models by 
comparing the virulence of mutants deficient in individual or multiple SAP genes with 
that of a WT control strain. In this study, the importance of SAP1 to SAP6 gene 
expression for C. albicans virulence was evaluated by using sap null mutants derived 
from the WT strain SC5314. Virulence of mutant strains lacking SAP1 to SAP3 was 
indistinguishable from that of the WT SC5314 strain, while SAP4 to SAP6 deletion 
caused a slight attenuation in virulence. Previous reports have shown that deficiency in 
SAP4 to SAP6 attenuated virulence to a higher extent than deficiency in SAP1, SAP2 or 
SAP3 (19, 43). Here, an increased median survival time was consistently observed in 
mice infected with mutants lacking the SAP5 gene, such as the single SAP5MS4A or the 
triple SAP456MS4A deletion mutant strains, comparatively to that of animals infected 
with the WT SC5314 strain. However, the differences found were narrow and not 
always significant. Moreover, histopathology analysis did not indicate a reduced ability 
of the SAP456MS4A mutant to invade the kidneys, though sap null mutant strains, 
lacking SAP6 gene, were previously shown to have reduced invasiveness in a model of 
experimental peritonitis (15). Deletion of SAP4 to SAP6 did not result in clear 
differences in hypha formation and similar morphotypes were observed, both in vitro 
and in vivo, for WT and mutant strains. This is not unexpected, as SAP4 to SAP6 
expression is associated with, but not required for hyphal morphology (15). 
Additionally, expression levels of SAP4 to SAP6 may not be directly linked to organ 
invasion, since a C. albicans strain expressing high levels of SAP4 to SAP6 was non-
invasive (57).  
The results obtained with SAT1-flipping mutants contrast with the ones obtained when 
using the Ura-blaster sap null mutants, which survived much longer. When analyzing 
another parameter associated with C. albicans virulence, such as kidneys CFU, no 
differences were observed among mice groups, except for the ones infected with 
strain DSY459, which presented a lower fungal burden. Discrepancy between different 
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methods of evaluating virulence has already been reported in mice intravenously 
infected with C. albicans mutant strains, including sap null mutants, where differences 
in mice survival were not associated with differences in organ fungal burden (19, 54, 
62). The differences found between the two sets of mutants are most likely due to the 
ectopic insertion of URA3, which must have contributed to the reduced virulence of 
the Ura-blaster constructed mutant strains. It is widely known that the Ura-status of C. 
albicans strains influences adherence (5) and virulence (27, 52). Although this can be 
overcome by integration of URA3 at the ENO1 (52) or RPS10 loci (8), the strains used in 
this study and in previous reported studies (19, 43) did not share a common site of 
URA3 integration.  
The disruption of SAP1-3 and SAP4-6 led to an increased expression of SAP4 and SAP1-
3, respectively, suggesting that C. albicans attempts to compensate the functional loss 
of these subfamilies by upregulating alternative SAP genes during hematogenously 
disseminated candidiasis. Therefore, the compensatory upregulation observed could 
be, in some extent, contributing to the lack of phenotype seen in these mutants. 
However, the equivalent Ura-blaster mutants, despite the compensatory upregulation 
reported (33, 45) showed a markedly reduced virulence in this model 
Recently, Lermann and Morschhäuser (28) and Naglik et al. (33) have reevaluated the 
role of SAP1-6 in a model of reconstituted human epithelia (RHE) and reported that 
SAP1-6 were not essential for successful C. albicans RHE infection, in contrast to earlier 
reports (45, 46). The present study thus reports an additional model in which the SAP 
gene subfamilies SAP1-3 and SAP4-6 seem to have little influence on the outcome of 
infection. 
As mice infected with the Δsap456 triple mutant displayed a slightly extended survival 
time, it could be expected that it might result from a more effective host immune 
response. This would be in agreement with a previous report suggesting an 
immunomodulatory role of Sap4-6 upon macrophage phagocytosis (7). However, the 
analysis of diverse features of the innate and acquired immune response elicited in 
BALB/c mice upon infection with either the WT or the Δsap456 triple mutant did not 
show any significant differences between these two yeast strains. The similar ability of 
both strains to recruit inflammatory cells is in accordance with their similar observed 
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virulence, taking into account the prominent role of innate immunity and of 
neutrophils in particular, in host protection against disseminated candidiasis (2, 60).  
The proportion of splenic Teffector and Treg cells was highly similar in the spleens of 
mice infected with either the WT or the Δsap456 mutant. Likewise, the frequencies of 
CD4+ T cells expressing IFN-γ, IL-4 and IL-10, cytokines previously shown to be relevant 
for resistance or susceptibility to systemic candididasis (48), were similar in the two 
infected mice groups. In vivo models indicate that regulatory T cells attenuate Th1-
type antifungal responses and induce tolerance to the fungus (31, 35). As higher IFN-
γ/IL-4 ratios were observed in splenic and renal CD4+ T cells of infected mice than in 
non-infected controls, it can be assumed that even though the kidneys of infected 
mice presented high fungal burden 7 days after challenge, a protective Th1-type 
response of equivalent magnitude might be occurring both in WT and Δsap456 mutant 
infected mice. 
Although our results suggest that B cells may have a role in the activation of T cells 
during experimental disseminated candidiasis, in accordance with the increased 
susceptibility observed in B cell-deficient mice (61), they also indicate that SAP4 to 
SAP6 deficiency does not affect such a role of B cells.  
Differences in C. albicans morphology have been frequently shown to influence both 
type and magnitude of the host immune response in the course of candidiasis. 
Dendritic cells, and also neutrophils, modulate adaptative responses to the fungus 
depending on the Candida morphotype encountered (38, 42, 47). As indistinguishable 
morphotypes were found for WT and Δsap456 mutant both in vitro and in vivo, this is 
also in agreement with the lack of significant differences observed in the immune 
response elicited by these strains. 
A relative independence on aspartyl protease activity for the establishment of 
hematogenously disseminated candidiasis was previously reported (14), as treatment 
with pepstatin A, a potent protease inhibitor, did not protect mice against intravenous 
infection with C. albicans. As previously suggested, an explanation for these 
observations may be the requirement for Sap only where anatomical barriers had to 
be crossed prior to dissemination (14, 25).  When C. albicans cells are delivered directly 
into the bloodstream, low molecular weight peptides are available and yeast growth 
may be protease independent.  
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The relative importance of specific SAP genes for C. albicans pathogenicity is highly 
determined by the type of infection and its dependence on protease activity for 
successful invasion and colonization of various host niches. Treatment with pepstatin A 
resulted in reduced virulence in intranasal (14) and intraperitoneal (25) models, but 
had no protective effect in the intravenous model. The subfamily of SAP genes SAP1 to 
SAP3, SAP2 in particular, was proved important in a model of rat vaginal infection, 
while SAP4 to SAP6 had little impact on this infection model (12). On the opposite, only 
Δsap456 mutants, Δsap6 in particular, showed reduced virulence in a murine model of 
Candida peritonitis and keratitis, while deletion of SAP1, SAP2 or SAP3 genes had no 
significant effect on these infection models (15, 22). Moreover, immunological 
neutralization of Sap2 was shown to have a protective effect in C. albicans infected 
hosts during vaginal and oral infection (12, 40), and also in experimental peritonitis 
(59). 
Though individual processes resulting from the action of a single or small group of 
genes may be important in specific stages of infection, cooperative gene functions are 
essential for the multiple processes of C. albicans infection (37). Thus, although the 
protease family as a whole may contribute to C. albicans virulence in the course of 
acute systemic candidiasis, other factors must be the major contributors to invasion 
and cell damage in this model.  
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ABSTRACT 
 
Candida albicans secreted aspartyl proteases (Saps) have been considered virulence-
associated factors. Here, we assessed the importance of SAP1 to SAP6 expression in 
the immune response induced in mice intraperitoneally infected with the wild-type 
(WT) strain SC5314 and SAT1-flipping mutants ∆sap123 and ∆sap456. WT-infected 
mice presented higher proportions of T regulatory cells (Foxp3+) in the spleen and 
mesenteric lymph nodes than control and sap-null mutant-infected counterparts. In 
addition, CD4+CD25+ T cells of WT-infected mice were the most effective in 
suppressing the proliferative response of CD4+CD25- T cells whereas those of ∆sap456-
infected mice were the least suppressive. Moreover, CD4+ T cells of WT-infected mice 
were the ones producing the highest levels of IL-10. Interestingly, ∆sap456-infected 
mice presented less Foxp3+ cells in kidney lesions and lower kidney C. albicans CFU 
than the other infected mice. Altogether, these results implicate Sap expression in the 
modulation of the host immune response to C. albicans.   
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INTRODUCTION 
 
The opportunistic yeast Candida albicans is an important human pathogen causative of 
superficial to deep-seated infections. It represents the most frequently isolated species 
in Candida peritonitis, an infection with current increasing incidence and high 
associated mortality rates (1, 2).  
Different T helper (Th) cell subsets, which include Th1, Th2, Th17, and T regulatory cells 
(Treg) have been shown to influence the outcome of C. albicans infections (3-7). Treg 
play an important role in controlling local and systemic immune responses during 
fungal infections (4, 8, 9). These cells, classically defined as CD4+CD25+Foxp3+ T cells 
(10), can respond to self-antigens and control autoimmunity (11). Yet, they may also 
recognize antigens expressed by different pathogens (12-16), playing either a host 
protective or detrimental role in the immune response to infectious agents (16). This 
differential role depends on the pathogen and on the nature of the infection (16). A 
host protective role of Treg was shown in murine gastrointestinal (4) and oral (7) 
models of candidiasis. Conversely, a host deleterious role of Treg was shown in murine 
hematogenously disseminated candidiasis, in which depletion of this T cell subset 
resulted in extended survival and lower fungal burden (5).  
C. albicans displays a number of virulence factors, among which the ten-member 
family of secreted aspartyl proteases (Saps) has been included (17, 18). Sap 
isoenzymes are differentially expressed during infection (19, 20) and may affect its 
outcome (21-24). The hypha-associated Sap4-6 were considered important for 
effective organ invasion and damage in experimental Candida peritonitis, while Sap1-3 
did not seem to have such a determinant role (21, 23). Several functions have been 
attributed to Saps, from adhesion to nutrient acquisition, tissue degradation and 
immune evasion (25). Although not yet demonstrated, an immunomodulatory role has 
also been suggested for some of these proteases (26-29). In this study, the effect of 
SAP1 to SAP6 expression on the host immune response to experimental C. albicans 
peritonitis, was examined after intraperitoneal infection with wild-type (WT) strain 
SC5314 or with SAT-1 flipping constructed mutant strains lacking SAP1 to SAP3 or SAP4 
to SAP6 (30).  
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MATERIALS AND METHODS 
 
Mice 
Male BALB/c mice, 8-10 weeks old (Charles River, Barcelona, Spain) were kept under 
specific pathogen-free conditions at the animal facilities of Instituto de Ciências 
Biomédicas Abel Salazar, Porto, Portugal. Procedures were performed according to the 
European Convention for the Protection of Vertebrate Animals used for Experimental 
and other Scientific Purposes (ETS 123), 86/609/EEC Directive and Portuguese law (DL 
129/92). Authorization to perform the experiments was issued by the competent 
national board authority, Direcção Geral de Veterinária (0420/000/000/2010). 
 
Candida albicans and culture conditions 
The C. albicans strains used in this study were the WT strain SC5314 (31) and its SAT1-
flipping-derived triple mutants lacking SAP1-3 genes, SAP123MS4C and SAP123MS4D 
(sap1 Δ : : FRT/sap1 Δ : : FRT; sap2-1 Δ : : FRT/sap2-2 Δ : : FRT;sap3 Δ : : FRT/sap3 Δ : : 
FRT) or lacking SAP4-6 genes, SAP456MS4A and SAP456MS4B (sap4-1Δ : : FRT/sap4-2 Δ 
: : FRT; sap5-1 Δ : : FRT/sap5-2 Δ : : FRT; sap6-1 Δ : : FRT/sap6-2 Δ : : FRT) (30). Inocula 
were prepared at the appropriate concentrations as previously described (32).  
 
C. albicans infections 
Mice were injected intraperitoneally (i.p.) with 1×107 C. albicans yeast cells and 
sacrificed 2, 6, 12 and 72 h or 7 days after infection. Peritoneal exudates were 
collected upon injection of 2 or 5 mL of PBS for chemokine or inflammatory cell counts, 
respectively. Control mice were injected with PBS alone. Kidneys and liver were 
aseptically removed, weighted, homogenized, and quantitatively cultured on 
Sabouraud dextrose agar at 37ºC. Values were expressed as log colony-forming units 
(cfu) per gram of tissue. Alternatively, histopathology of kidneys, liver, lungs, heart and 
brain was evaluated as described (32). 
 
Immunohistochemistry 
Immunohistochemistry was used to assess the number and frequency of Foxp3+ cells in 
kidneys and liver formalin-fixed, paraffin-embedded 4 µm sections mounted on amino-
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propyl-tri-ethoxy-silane (Sigma-Aldrich) coated slides. Immunostaining was performed 
as previously described (33) with modifications. Namely, antigen retrieval was done by 
incubating the slides in 10mM citrate buffer (pH 6) for 3 min in a pressure cooker 
before endogenous peroxidase blocking. Normal rabbit serum (Dako) (1:5), unlabeled 
rat anti mouse/rat Foxp3 mAb (FJK-16s, eBioscience) (1:100), and biotin-labelled rabbit 
anti-rat antibody (Dako) (1:200) were used. Slides were evaluated under light 
microscopy. Numbers of Foxp3+ T cells were registered and the frequency was 
calculated relatively to the respective lesion area. 
 
Flow cytometric analysis  
Spleens and mesenteric lymph nodes (MLN) were aseptically removed and 
homogenized in Hank’s Balanced Salt Solution (Sigma). Anti-mouse mAb of the 
indicated specificities and fluorophore conjugates and clones (within brackets), or 
respective isotype controls were used for immunofluorescence cytometric  analysis in 
a FACScan (Becton-Dickinson) using CELLQUEST software (Becton-Dickinson): CD40 
(PE; 1C10), Major Histocompatibility Complex (MHC) class II (Biotin; NIMR-4) (Southern 
Biotechnology Associates); Foxp3 (FITC; FJK-16s), CD4 (PE-Cy5; RM4-5), and F4/80 (PE; 
BM8) (eBioscience); CD11c (FITC; HL3), Ly-6G and Ly-6C (Gr-1) (FITC; RB6-8C5), CD25 
(PE; PC61), CD45R/B220 (FITC; RA3-6B2), CD80 (PE; 16-10A1), CD86 (PE; GL1), IL-4 (PE; 
BVD4-1D11), IFN-γ (FITC; XMG1.2), IL-17A (PE; TC11-18H10) and IL-10 (PE; JES5-2A5). 
Biotin conjugated mAb were revealed with Streptavidin-PE-Cy5 (all from BD 
Pharmingen). Staining for CD11c, Foxp3 or cytokines IFN-γ, IL-4, IL-17A and IL-10 was 
performed as described elsewhere (32). 
  
Cell cultures and suppression assays 
Mononuclear spleen cells to be used as antigen presenting cells (APC) were prepared 
from naïve mice as previously described (32). Collected cells were irradiated at 3000 
rad in a Gammacell 1000 Elite irradiator (Nordion International). CD4+, CD4+CD25- and 
CD4+CD25+ cells from control and 3-day-infected mice were isolated from pooled 
spleen cells of four mice per group, by using a magnetic cell sorting CD4+CD25+ T-cell 
isolation kit (Miltenyi Biotech) following manufacturer’s instructions. Sorted cells were 
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plated at 2.5 × 104/well in U-shape 96-well plates together with 105 APC without 
stimulus or stimulated with 1 µg/mL anti-CD3 mAb (145.2C11, BD Pharmingen). 
Cultures were set in sextuplicates and maintained for 72 h at 37ºC and 5% CO2. The 
CellTraceTM CFSE Cell Proliferation Kit (Molecular Probes, Invitrogen) was used for 
naive CD4+CD25- T cell (responder cells) labelling, at a final concentration of 5 µM CFSE 
(5-(and-6)-carboxyfluorescein diacetate succinimidyl ester), according to 
manufacturer’s instructions. Responder cells were plated at 2.5 × 104/well in U-shape 
96-well plates together with 105 APC and 1µg/mL anti-CD3 mAb. To evaluate Treg 
suppressive function, CD4+CD25+ T cells from the different groups were added at 
different CD4+CD25+:responder T cell ratios (1:1, 0.5:1, 0.25:1 and 0.1:1). Responder 
cells without anti-CD3 stimulus were used as negative controls. Stimulated responder 
cells with no suppressor populations added were used as positive controls. Unlabelled 
stimulated responder cells were used to define cell auto-fluorescence. Stimulated 
responder cells co-cultured with variable ratios of CD4+CD25- T cells were used to 
exclude suppression due to cell number/well. Cultures were set in 
sextuplicates/condition and maintained for 72h at 37ºC and 5% CO2. 
Proliferation/suppression was determined based on CFSE fluorescence by flow 
cytometric analysis.  
 
Cytokine measurements 
The concentration of IL-4 in culture supernatants of CD4+, CD4+CD25- and CD4+CD25+ T 
lymphocytes from infected mice and controls was quantified with the Quantikine® M 
Murine IL-4 ELISA kit (R&D Systems) and IFN-γ, IL-10 and IL-17A were quantified with 
the Mouse IFN-γ, IL-10 and IL-17A (homodimer) ELISA Ready-Set-Go!® kits (all from 
eBioscience), according to manufacturer’s instructions. The concentration of IL-10 in 
liver and kidney homogenates was similarly determined. Liver and kidneys were 
homogenized in 4 mL and 2 mL of PBS, respectively, and the homogenates were 
centrifuged and 0.45 mm pore-size filtered before use. The concentration of KC, MIP-2 
and MCP-1 chemokines in peritoneal cavity lavage fluids was evaluated by using the 
respective ELISA Duo-Set® kits (R&D Systems), according to manufacturer’s 
instructions. 
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Statistical Analysis 
Statistical significance of results was determined by one-way ANOVA and post-hoc 
Bonferroni’s multiple comparison test, by using the GraphPad Prism 4 Software 
(GraphPad Software). Results were considered statistically significant with  P values of 
less than 0.05.  
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RESULTS 
 
Limited effect of SAP expression on the inflammatory response to C. albicans i.p. 
infection  
Expression of SAP4-6, has been implicated in the success of C. albicans experimental 
peritonitis (21, 23). However, how these genes affect the host immune response in this 
model is not known. Recruitment of the different leukocyte populations into the 
peritoneal cavity was assessed in BALB/c mice challenged i.p. with C. albicans WT or 
mutant strains lacking SAP1 to SAP3, or SAP4 to SAP6. Two independently generated 
mutant strains for each SAP subset were used to exclude unspecific effects resultant 
from gene disruption. The independent mutant strains behaved indistinctively (data 
not shown) and therefore, results presented below correspond to those obtained with 
Δsap123, and Δsap456 strains SAP123MS4C and SAP456MS4A, respectively. Among all 
infected mice groups, similar frequencies and numbers of neutrophils, eosinophils, 
macrophages and inflammatory monocytes, respectively defined by the Gr-1hi, 
F4/80+Gr-1intSSChi, F4/80hi and Gr-1+F4/80+ phenotypic characteristics (34), as well as 
of dendritic cells (CD11chi), were observed 6 h after fungal challenge (Supplementary 
Table 1). In agreement, among infected mice groups, no significant differences were 
observed in KC, MIP-2 and MCP-1 chemokine levels in the peritoneal lavage fluids 
collected 2 h upon infection that remained not different 12 h upon challenge 
(Supplementary Table 2). In contrast, 72 h upon infection, strains lacking SAP4 to SAP6 
induced a significantly higher recruitment of inflammatory monocytes (Figure 1). No 
other significant differences were observed among the other analysed cell populations 
at this time point (Supplementary Table 1). These results, by showing that lack of SAP4 
to SAP6 expression allows a higher recruitment of inflammatory monocytes, suggest 
that Sap4-6 impair the early inflammatory response to C. albicans.  
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Figure 1 (A) Flow cytometry analysis of F4/80 and GR-1 expression on the surface of BALB/c 
mice peritoneal exsudate cells 72h upon i.p. challenge with PBS or WT, Δsap123 or Δsap456 C. 
albicans strains, as indicated. Numbers within dot plots correspond to the mean ± one 
standard deviation of the frequency of the gated population, corresponding to inflammatory 
monocytes. Statistically significant difference between WT and Δsap456 infected mice is 
indicated (* P<0.05) (B) Number of inflammatory monocytes recruited into the peritoneal 
cavity 72 h post infection with WT, Δsap123 or Δsap456 or treatment with PBS alone, as 
indicated (n=4). Statistically significant differences among C. albicans infected mice are 
indicated (* P<0.05; *** P<0.001). Results shown are from one experiment representative of 
three independent experiments. 
 
Higher frequency and numbers of effector T cells in sap456-infected mice  
Given the reported importance of CD4+ T cells in host defense against candidiasis, 
splenic and MLN CD4+ T cells were analysed in mice infected i.p. with the WT or 
mutant strains. Interestingly, Treg (Foxp3+) frequency, in both CD4+CD25+ and 
CD4+CD25- T cell subsets, was found reduced in the spleen and MLN of sap456-
infected mice, as compared with the WT-infected counterparts, 3 days after infection 
(Figure 2). Moreover, the mean fluorescence intensity (MFI) of Foxp3 staining in both 
cell subsets was also lower in sap456- than in WT-infected mice (Figure 2). Similar 
frequencies of CD25-expressing CD4+ T cells were found among the infected groups.  
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Figure 2 (A) Flow cytometry analysis of intracellular Foxp3 expression in splenic and MLN 
CD4+CD25+ and CD4+CD25- T cells from BALB/c mice, 3 days after i.p. challenge with PBS or 1 × 
107 C. albicans WT, Δsap123 and Δ sap456 yeast cells, as indicated. Dot plots are a 
representative example of each group. (B) Number of T effector (CD4+CD25+Foxp3-) cells 
observed in the spleens and MLN of i.p. injected mice, 3 days after challenge. (C) Mean 
fluorescence intensity of Foxp3 staining within splenic and MLN CD4+CD25+ T cells. Results are 
of a representative experiment out of five independent experiments  (n=4 in each group). 
Statistically significant difference between WT and Δ sap456 infected mice is indicated 
(*P<0.05; **P<0.01). 
 
The lower proportion of Treg within the CD4+CD25+ subset implied an increased 
frequency of T effector (CD4+CD25+Foxp3-) cells (Teff) in the sap456-infected mice, 
which was accompanied by an increase in total splenic and MLN Teff numbers. 
Conversely, no significant differences in Treg numbers were observed in these organs 
among infected groups (data not shown). No noticeable differences were detected 7 
days after infection in the assessed CD4+ T cell subsets frequency and numbers among 
the infected groups. Frequencies and numbers of B lymphocytes, myeloid cells and 
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DCs, as well as co-stimulatory and MHC class II molecules expression on B cells and 
DCs, also did not vary significantly among the different infected groups (data not 
shown). The above results indicate that SAP4 to SAP6 expression influences Treg/Teff 
ratio in the course of murine C. albicans peritonitis.      
 
CD4+CD25+ T cells from WT-infected mice suppress more efficiently the proliferation 
of responder cells 
Although Foxp3 is the best available marker to identify Treg, it does not allow their 
isolation for functional tests. Therefore, as CD25 is a good marker for murine Treg (35), 
the immunosuppressive ability of splenic CD4+CD25+ T cells isolated from non-infected 
or infected mice groups, was comparatively evaluated by measuring their ability to 
inhibit the in vitro proliferation of CFSE- labelled responder cells upon anti-CD3 mAb 
stimulation. CD4+CD25+ T cells sorted from WT- or Δsap456-infected mice presented 
the highest and lowest suppressive abilities, respectively, whereas CD4+CD25+ T cells 
from Δsap123-infected mice presented intermediate suppressive activity (Figure 3).  
 
 
 
Figure 3 Flow cytometric evaluation of anti-CD3 mAb (1 µg/ml) induced proliferative response 
of 2,5 x 104 CFSE-labelled naive CD4+CD25- T cells cultured for 3 days with 105 irradiated 
APC/well, in the absence (A- negative control, no mAb added; B-positive control) or presence 
of CD4+CD25+ T cells obtained from: C- control mice or mice infected with D- WT, E- Δsap123, 
F- Δsap456 strains. Histograms correspond to the optimal determined ratio 0.5 CD4+CD25+:1 
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responder cells. Indicated percentages correspond to cells that divided at least once. The 
proliferation indexes for each condition were: A: 1.01; B: 9.06; C: 3.64; D: 2.05; E: 2,91; F: 5,16. 
CD4+CD25+ cells added in each condition were sorted from pooled splenic cells of 4 mice per 
group. Results are a representative example out of five independent experiments.  
 
The proliferative response was not inhibited following co-culture with CD4+CD25- T 
cells from the different groups, confirming that suppression was due to CD4+CD25+ T 
cell activity and not to cell density per se  (proliferation index of 17.6, 17.1, 16.4, and 
16.8 in co-cultures using cells from non-infected, WT-, Δsap123-, and Δsap456-
infected mice, respectively). These results show that C. albicans SAP expression affects 
the suppressive activity of host Treg. 
 
CD4+ T cells from WT-infected mice produce higher levels of IL-10 
Previous studies associated IFN-g and IL-17 with resistance to C. albicans infection, 
whereas IL-4 and IL-10 were associated with host susceptibility to this fungus (36). 
Therefore, cytokine expression was evaluated in splenic CD4+ T cells through 
intracellular cytokine staining for IFN-γ, IL-4, IL-10 and IL-17A. No significant 
differences were detected in the frequencies of CD4+ T cells expressing any of the 
analysed cytokines, among the different mice groups, 3 and 7 days upon infection 
(data not shown). Nevertheless, increased levels of IL-10 were detected in culture 
supernatants of splenic CD4+, CD4+CD25- and CD4+CD25+ T cells sorted from WT-
infected mice, as compared with the ones from Δsap456-infected counterparts (Figure 
4). Conversely, the different sorted subsets of CD4+ T cells from infected mice groups 
produced similar levels of IFN-γ, IL-4 and IL-17A (data not shown). Cytokine levels in 
control cultures were always the lowest (Figure 4 and data not shown) and those in 
unstimulated cultures were below or near detection threshold. IL-10 levels were also 
evaluated in parenchymal organs presenting C. albicans induced lesions, the liver and 
kidneys. Interestingly, liver homogenates from WT-infected mice had the highest IL-10 
levels (Figure 4D). No such difference could be observed in the kidneys (data not 
shown). These results show that lack of SAP expression reduced the production of IL-
10 elicited in the host upon C. albicans i.p. infection.  
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Figure 4 IL-10 cytokine concentration in the supernatants of anti-CD3 mAb-stimulated (1 
µg/ml) 72 h cultures of 2,5 x 104 (A) CD4+ , (B) CD4+CD25- and (C) CD4+CD25+ T cells from 
control or i.p.-infected mice, as indicated. Bars represent the mean + one SD of six wells per 
group. Results are a representative example out of five independent experiments (D) IL-10 
concentration in liver homogenates of mice infected 72 h before with the indicated strains or 
sham –infected controls (PBS). Data represent means + one SD (n=4) and are representative 
examples of three independent experiments.   
 
Treg cells accumulate in liver and kidneys lesions in C. albicans infected mice 
The extent to which Foxp3+ T cells were recruited into C. albicans induced lesions and 
their distribution therein was evaluated in infected mice. Foxp3+ cells accumulated at 
low frequency at the periphery of liver and kidney microabscesses and no differences 
in their frequency or distribution were observed among the infected groups. In 
contrast, Foxp3+ cells were more abundant and found within the infiltrate area in 
kidney lesions with smaller inflammatory infiltrates, like interstitial nephritis. 
Interestingly, Foxp3+ cells were 2 to 3-fold less frequent within these lesions in 
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Δsap456-infected mice, though no differences could be observed in cell distribution 
(Figure 5). No accumulation of these cells was observed in non-infected mice organs or 
in non-lesioned areas of infected organs.  
 
 
 
Figure 5 Detection of Foxp3+ cells in C. albicans induced kidney lesions, 3 days after i.p. 
infection with WT, Δsap123 and Δsap456 strains, as indicated. Foxp3+ cells (brown, denoted by 
arrows) accumulated in small number at the periphery of C. albicans microabscesses (A). In 
contrast, a larger number of Foxp3+ cells were found within the infiltrates of interstitial 
nephritis (B). Recruitment of Foxp3+ cells to interstitial nephritis lesions of mice infected with 
Δsap456 was smaller than the observed in WT and Δsap123 infected mice. Microscopic images 
of the slides viewed at 200× magnification. These results are representative of data from three 
independent experiments (n=4 per group, per experiment).  
 
 
Lower fungal burden in the kidneys of Δsap456-infected mice 
As shown in Figure 6, higher cfu numbers were found in the kidneys of WT-infected 
mice, as compared with Δsap456-infected mice, whereas in Dsap123-infected mice 
renal cfu numbers were not different from the ones of the other infected groups. 
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Moreover, 58% and 51% of Δsap456- and Δsap123-infected mice, respectively, 
completely eliminated the fungus from the kidneys and liver by day 7 after infection,  
while this was observed in only 35% of WT-infected mice. Liver fungal burden was not 
different among the infected mice groups (Figure 6).  
 
Figure 6 Kidney and liver fungal burden of BALB/c mice 3 days after i.p. infection with 1×107 
WT (□), sap123 (▼) or Δsap456 (○) C. albicans cells, as indicated.  Data are representative 
examples of six independent experiments, (n=8 per group). Each symbol represents an 
individual mouse; horizontal bars correspond to medians of CFU numbers in each group.  
 
The above data shows that, in this peritonitis model used here, lack of SAP4 to SAP6 
expression impairs the ability of C. albicans to infect the kidneys, though no clear 
differences could be observed in C. albicans-induced lesions either in the kidneys or in 
the liver (Supplementary Figure 1). 
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DISCUSSION 
 
Impaired organ colonization and tissue damage was reported for the sap4-6 mutant 
DSY459 in murine models of peritonitis (21, 37). Additionally, it was shown that SAP5 
was immediately induced after C. albicans i.p. inoculation (19) and SAP4-6 were found 
upregulated during liver invasion (38). All these data implicate SAP4-6 as virulence 
determinants in C. albicans-induced peritonitis. One explanation for the lower 
virulence of those mutants would be an impaired capacity to invade the host from the 
peritoneal cavity and ultimately infect parenchymal organs. Here, however, no clear 
differences were observed concerning organ invasion, among the used C. albicans 
strains, either in the morphology of the fungi or in the depth and extension of the 
lesions. Nevertheless, a higher fungal load was found in the kidneys of WT-infected 
mice comparatively to that of Δsap456-infected mice. The observed variability in size 
and number of fungal-induced lesions, particularly in the kidneys, could result from 
SC5314 strain intrinsic characteristics. Indeed, a C. albicans clinical isolate previously 
used to induce peritonitis (27) infected more evenly the liver and kidneys of BALB/c 
mice and yielded higher cfu numbers than did SC5314 (our unpublished results). A 
reduced ability in colonizing mucosal surfaces has also been reported for this strain 
(39). By using the SAT-1 flipping constructed Δsap456 mutants we did not observe an 
attenuated invasiveness, as reported for the DSY459 strain (37, 40). Nevertheless, the 
experimental conditions used here differ from those used in the referred studies and 
the disparity of results may not be directly attributable to the strains themselves. 
An alternative explanation for the lower fungal burden found in Δsap456-infected 
mice could be that, as already suggested (21, 26), Sap4-6 have an immunomodulatory 
role, either direct or indirect, which would be deleterious to the host. We hypothesize 
that lack of SAP4-6 expression may allow the host to mount a more effective immune 
response against an i.p. challenge with C. albicans. The higher recruitment of 
inflammatory monocytes to the peritoneal cavity of Δsap456-infected mice could 
represent a first step in this response, as these cells are considered important effectors 
in protective immunity to several pathogens (41-44). Interestingly, in a model of 
respiratory aspergillosis, inflammatory monocytes facilitated the adaptive CD4+ T cell 
response (41). Assessing their role in C. albicans-infected mice would be worth to 
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investigate since Δsap456-infected mice, which presented higher numbers of these 
cells in the peritoneal cavity, had a higher Teff/Treg ratio than WT-infected 
counterparts. 
 In the WT-infected mice, the higher recruitment of Treg into the kidneys early after 
challenge might delay the arrival or activation of effector cells, therefore hindering 
fungal clearance. A similar early local recruitment of Treg was reported in invasive 
aspergillosis, having a detrimental effect in recruited neutrophils (45).  
The effect of SAP4-6 expression seems to occur mainly at the regulatory level of the 
immune response. Our results, by showing a much lower in vitro suppression of T cell 
proliferation by CD4+CD25+ T cells sorted from Δsap456- than WT-infected mice, 
support this hypothesis. Moreover, the detection of lower levels of the 
immunosuppressive cytokine IL-10 in Δsap456-infected mice liver homogenates and 
splenic CD4+ T cell culture supernatants, than in WT counterparts, further agrees with 
a role for Sap4-6 in the impairment of the host immune response to Candida 
peritonitis. Several studies recognized the role of fungal secreted proteases on T cell 
stimulation and overall immune response (46-49). Different fungal proteases, including 
aspartyl proteases, were shown to impact on T cell function either directly or indirectly 
via DC modulation. However, as surface expression of maturation markers on splenic 
and MLN DCs, assessed 12 h upon infection, was not affected by SAP deficiency (our 
unpublished results), a DC-dependent mechanism seems unlikely.  
Fungal aspartyl proteases have been successfully used in experimental vaccination 
assays that often resulted in the production of host protective cytokines, longer 
median survival rates, reduction of fungal burden, and amelioration of inflammatory 
pathology (27, 46, 47). Moreover, T cells from mice immunized with an aspartyl 
protease of Coccidioides posadasii produced IL-10 upon in vitro antigen restimulation 
(49). Interestingly, treatment of live C. albicans with the aspartyl protease inhibitor 
pepstatin significantly reduced IL-10 levels detected in peritoneal exudates of i.p.-
infected mice (50).  
Mice infected with strains lacking SAP1 to SAP3 frequently presented an intermediate 
effect between WT and Δsap456 mutants. Although we cannot exclude a 
compensatory effect by other SAP genes, which could have diluted the impact of the 
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missing genes in virulence, evidence from this and other studies referred herein 
support a relatively less important role of Sap1-3 in this infection model. The 
importance of Saps for the course of candidiasis is known to highly depend on the 
infection model. In fact, a role for Saps in a murine model of hematogenously 
disseminated candidiasis was not evident, since the outcome of infection and ensuing 
host immune response were not different in mice infected with the WT or the ∆sap 
null mutant strains used in the present study (32).  
Globally, results presented herein implicate Sap4-6 in the modulation of the host 
immune response to C. albicans peritonitis, providing additional evidence for the role 
of these enzymes as virulence determinants in this infection model. 
These enzymes may constitute one of the mechanisms used by the fungus to dampen 
host immune response and therefore, their usage as target antigens in C. albicans 
vaccination could be worth to investigate.  
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Supplementary Table 1. Frequencies and counts of inflamammatory cells recruited into the peritoneal cavity of BALB/c mice 6 and 
72h upon i.p. infection. 
Cell Type Marker 
                                                                                     6h 
PBS SC5314 Δsap123 Δsap456 
Freq. (%) Cells (× 10
-5
) Freq. (%) Cells (× 10
-5
) Freq. (%) Cells (× 10
-5
) Freq. (%) Cells (× 10
-5
) 
Resident macrophage F4/80
hi 39,66 ± 9,14 16,52 ± 4,44 13,8 ± 1,66
a
 9,58 ± 1,44 13,16 ± 0,31
a
 11,54 ± 0,75 15,8 ± 1,09
a
 11,11 ± 6,77 
Neutrophils Gr-1
hi 0,4 ± 0,09 0,17 ± 0,07 71,5 ± 2,32
a
 49,72 ± 6,12
a
 70,29 ± 3,74
a
 61,51 ± 1,2
a
 68,07 ± 0,51
a
 48,50 ± 11,62
a
 
Inflammatory monocytes F4/80
+
Gr-1
+ 0,01 ± 0,00 0,01 ± 0,00 0,12 ± 0,01
b
 0,83 ± 0,19
c
 0,15 ± 0,02
a
 0,11 ± 0,02
a
 0,13 ± 0,03
b
 0,87 ± 0,01
a
 
Eosinophils F4/80
+
Gr-1
int
SSC
hi
 2,03 ± 0,20 0,87 ± 0,25 1,88 ± 0,41 1,28 ± 0,17 1,44 ± 0,22 1,26 ± 0,20 2,34 ± 0,48 1,62 ± 0,47 
Dendritic cells CD11c
hi
 1,08 ± 0,11 0,46 ± 0,1 3,75 ± 1,79 2,52 ± 1,09
c
 2,86 ± 0,36
b
 2,51 ± 0,41
c
 4,48 ± 1,3
a
 2,95 ± 0,62
c
 
                                                                     72h 
Resident macrophages F4/80
hi 36,49 ± 3,48 15,40 ± 3,4 41,31 ± 5,59 27,83 ± 10,66 39,99 ± 4,79 25,50 ± 4,73 39,74 ± 2,49 35,92 ± 10,07
c
 
Neutrophils Gr1
hi 0,28 ± 0,08 0,11 ± 0,08 21,82 ± 7,44
b
 14,67 ± 7,21
c
 18,79 ± 3,55
b
 11,89 ± 1,97
b
 21,94 ± 6,77
b
 19,48 ± 7,14
b
 
Inflammatory monocytes F4/80
+
Gr-1
+
 0,01 ± 0,00 0,02 ± 0,00   4,45 ±1,68
c
* 2,70 ± 0,56
c
*** 7,24 ± 2,38
b
 4,71 ±1,86
b
* 8,73 ± 1,87
a
 7,58 ± 0,83
a
 
Eosinophils F4/80
+
Gr-1
int
SSC
hi
 1,91 ± 0,46 0,83 ± 0,34 6,89 ± 1,21 3,80 ± 0,97 6,54 ± 3,71 3,02 ± 1,63 6,89 ± 0,52 5,52 ± 1,27 
Dendritic cells CD11c
hi
 1,03 ± 0,18 0,44 ± 0,14  1,88 ± 0,22
c
 1,24 ± 0,36
c
 1,70 ± 0,28 1,10 ± 0,30 1,63 ± 0,35 1,44 ± 0,29
b
 
 
Different cell types were identified with markers and flow cytometry. Data represent means ± SD; n=4. Data are from one experiment representative of three 
independent experiments. 
a
 P<0,001; 
b
 P<0,01; 
c
 P<0,05, when compared with PBS. * P<0,05; ***P<0,001, when compared with Δsap456;  
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Supplementary Table 2. Chemokine levels in the peritoneal cavity lavage 
fluids of BALB/c mice 2 and 12h upon i.p. infection (pg/peritoneal cavity)  
 
ND – not detectable; 
a
 P<0,001; 
b
 P<0,01; 
c
 P<0,05, when compared with PBS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chemokine 
                                                                  2h 
 
PBS 
 
SC5314 
 
Δsap123 
 
Δsap456 
KC 79,31 ± 70,76 3727,30 ± 322,32
a
 3221,44 ± 88,44
a
 3719,39 ± 783,94
a
 
MIP-2 ND   894,41 ± 351,81
c
 1196,63 ± 94,78
b
 1307,11 ± 351,88
a
 
MCP-1  63,47 ± 67,21
a
   691,80 ± 202,05
a
    689,14 ± 146,87
a
   933,30 ± 386,03
a
 
                                                                                        12h 
 
KC 11,01 ± 11,46 631,55 ± 427,71 392,98 ± 453,64 180,85 ± 74,92 
MIP-2 ND ND ND ND 
MCP-1 3,30 ± 1,46  810,33 ± 152,97b 499,43 ± 214,67  364,41 ± 245,64 
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Supplementary Figure 1 Lack of SAP expression did not significantly affect C. albicans-
induced organ pathology. Representative photomicrographs of PAS-stained 
histological sections of liver and kidneys from BALB/c mice infected with C. albicans 
WT, Dsap123 and Dsap456, at the indicated time points upon i.p. infection. Structures 
containing filamentous C. albicans and inflammatory cells whithin fibrin deposits could 
be observed in close contact with the liver serosa, without detectable organ invasion 
(12 h). Lesions in the liver comprised superficial microabscesses, often detached, 
showing healing by fibrosis (72 h). Microabscesses with moderate to intense 
neutrophylic infiltration, as well as interstitial nephritis, were observed mostly in the 
kidneys cortical area in addition to the organ surface, and interstitial nephritis was 
often observed (72 h). Most of the times, multiple lesions of variable size and type 
were present in each organ. Hyphal fungal elements were visible inside the larger 
lesions (arrows on magnified insets). Localization and size of the C. albicans induced 
lesions as well as composition of the inflammatory infiltrates was mostly similar in all 
infected groups. PAS-positive hyphae organisms within lesions are denoted by arrows. 
Seven days after infection. 
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ABSTRACT 
 
The mammalian pattern recognition receptor galectin-3 was shown to specifically bind 
beta-1,2 mannosides on the cell wall of the pathogenic yeast Candida albicans. This 
interaction directly induces fungal cell death and also promotes pro-inflammatory 
cytokine TNF-alpha production by the host cells. To circumvent host immune defenses, 
C. albicans developed multiple evasion mechanisms. Among these, production of 
secreted aspartyl proteases (Saps) has been particularly highlighted due to their ability 
to degrade and/or inactivate diverse host immune effector molecules. Although C. 
albicans possesses a 10 member Sap family, Sap2, belonging to the Sap1-3 subfamily, 
is the most extensively characterized. In this study, we assessed the pattern of 
galectin-3 expression in the kidneys of mice i.v.-infected with C. albicans and 
investigated whether this lectin could be degraded by Sap1 to Sap3 isoenzymes. 
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INTRODUCTION 
 
Galectins are a family of β-galactoside-binding animal lectins that are involved in 
several biological processes and are expressed in a wide variety of cell types, including 
macrophages, dendritic cells and epithelial cells (1, 2). Initially thought to bind only 
endogenous glycans and mediate development processes and regulation of immune 
homeostasis (1-3), it has now become clear that galectins can also bind glycans on the 
surface of several microorganisms and parasitic worms, and mediate recognition and 
effector functions in innate immunity (4). Within this family, galectin-3 (Gal-3) is the 
best characterized and has been linked to modulation of immune and inflammatory 
responses (5, 6). Gal-3 recognizes and binds β-1,2-linked oligomannosides on the cell 
wall of Candida albicans and, in consequence, has been considered to function as a 
macrophage receptor for this fungal pathogen (7). Gal-3 can differently sense C. 
albicans and the non-pathogenic yeast Saccharomyces cerevisiae through a mechanism 
involving TLR2 and Gal-3, leading to increased production of the inflammatory cytokine 
TNF-α upon C. albicans recognition (8). In a mouse model of experimental colitis, C. 
albicans colonization is promoted by pre-existing inflammatory conditions, which in 
turn augmented the inflammatory process through Gal-3 with up-regulation of TLR2 
expression and TNF-α (9). Accordingly, synthetic analogues of β-1,2 oligomannosides 
administered orally prevented yeast colonization in the gut (10). This supports the 
roles of Gal-3 in both inflammation and the regulation of host immune responses to C. 
albicans. Interestingly, the selective binding of Gal-3 to the C. albicans cell wall glycans 
is fungicidal (11), an observation that gives emphasis to the direct effector functions of 
galectins in innate immunity. 
C. albicans has developed efficient strategies to evade the host recognition and 
immune attack (12, 13). C. albicans secreted aspartyl protease (Sap) family comprises 
10 different members (14, 15) which are differentially expressed (16-20) and that have 
been implicated in C. albicans pathogenesis (14, 21). Saps are able to degrade many 
human proteins, like the ones that protect mucosal surfaces and cell-surface proteins, 
such as keratin, collagen, vimentin, fibronectin, laminin, secretory immunoglobulin A 
(IgA), histatin-5 and mucins (22-30). Degradation of complement proteins and histatin-
5 by Saps is included in the multiple immune evasion mechanisms explored by this 
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opportunistic pathogen (23, 24). Furthermore, these proteases damage host epithelial 
and endothelial barriers and thus facilitate tissue penetration by hyphae and infection 
of host cells (22, 27).  
Given the central role of Saps for infection and pathogenicity of C. albicans and as Gal-
3 specifically recognizes and directly kills bound yeast, besides augmenting pro-
inflammatory response by the innate immune system, the ability of three secreted 
aspartyl proteases - Sap1, Sap2 and Sap3- to degrade Gal-3 is explored here.  
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MATERIAL AND METHODS 
 
Secreted aspartyl proteases 
Recombinant Sap1 (rSap1), rSap2 and rSap3 were produced in Pichia pastoris and were 
kindly provided by Dr Bernhard Hube (Jena University, Germany). All purified 
recombinant proteins exhibited protease activity in vitro, as assessed by using a 
standard fluorescence-based casein assay (Molecular Probes). Reactions were also 
performed in the presence of the general aspartic protease inhibitor pepstatin A 
(Sigma Aldrich). C. albicans SC5314 cells were grown in inducing medium (yeast carbon 
base (Difco) supplemented with 0.5% BSA (Sigma) ph 4.0) for 72 h at 30ºC. Culture 
supernatants containing native Sap2 (nSap2) were filtered and concentrated in Amicon 
Ultra-15 devices (Millipore Corporation, Billerica, USA). 
 
Galectin-3 
Recombinant human Gal-3 was obtained as previously described (Stowell et al 2008). 
Recombinant Gal-3 was purified by affinity chromatography on lactosyl-Sepharose, and 
bound lectin was eluted with 100 mm lactose in PBS, 14 mm βME. Prior to 
derivatisation, βME was removed from galectin samples by using a PD-10 gel filtration 
column (GE Healthcare), followed by the addition of lactose (100 mm final 
concentration) to help maintain the stability of each galectin and reduce the likelihood 
of adduct formation at or near the carbohydrate recognition domain. 
 
Cleavage activity 
The proteolytic activity of recombinant Sap1, Sap2, Sap3 (0.5 µg each) or of 
supernatants derived from wild type C. albicans, containing nSap2 was assayed by 
incubation for 24 h with purified Gal-3 protein in 0.1M citrate buffer at 37 ◦C (pH 5.2 
and 6.8). Aliquots were taken at different time points, the reaction was stopped, and 
samples were frozen at -80º C until use. Reactions were also performed in presence of 
15 µM pepstatin A (Sigma), the general aspartyl protease inhibitor. 
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Immunoblotting 
The reactivity of anti-Gal-3 immunoglobulins was visualized by Western blot analysis. 
For that purpose, 1 µg of Gal-3 incubated with rSap1, rSap2 and rSap3, as well as with 
native Sap2, in the presence and absence of pepstatin A, were separated by sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) on 15% 
polyacrylamide gels and then blotted overnight onto nitrocellulose membranes 
(Sigma). Nonspecific binding was prevented by blocking with 2% BSA in Tris buffered 
saline (TBS) for 1 h at room temperature. After washing, membranes were incubated 
for 2 h with polyclonal IgY anti-Gal-3 (1 µg/ml) diluted in TBST 0.1% BSA. Alternatively, 
membranes were incubated with supernatant from the rat hybridoma producing 
monoclonal anti-mouse/human Gal-3 (M3/38) (diluted 1:20 in TBST 0.1% BSA). Bound 
antibodies were detected with alkaline phosphatise (AP)-conjugate anti-chicken IgY 
(diluted at 1:10000 in TBST 0.1% BSA) or AP-conjugated goat anti-rat IgG (Southern 
Biotechnology Associates, Birmingham), and revealed by using NBT/BCIP solution 
(Roche, Penzberg, Germany) as substrate. The reaction was stopped in distilled water.  
 
Mice 
Male BALB/c mice, 8-10 weeks old, were purchased from Charles River (Barcelona, 
Spain) and kept under specific pathogen-free conditions at the Animal Facility of 
Instituto de Ciências Biomédicas Abel Salazar, Porto, Portugal. All procedures involving 
mice were performed according to the European Convention for the Protection of 
Vertebrate Animals used for Experimental and other Scientific Purposes (ETS 123), 
86/609/EEC Directive and Portuguese rules (DL 129/92). Authorization to perform the 
experiments was issued by the competent national board authority (Direcção Geral de 
Veterinária), document number 0420/000/000/2010. 
 
Candida albicans and culture conditions 
C. albicans wild-type strain SC5314 (31) was used in this study. To prepare the inocula 
for infection, C. albicans was grown in a shaking incubator for 14 hours at 30ºC in 
Winge medium (0,2% glucose, 0,3% yeast extract). Yeast cells were harvested, washed 
twice with sterile, nonpyrogenic phosphate-buffered saline (PBS) (Gibco®, Grand Island, 
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NY, USA), counted in a haemocytometer and resuspended at the appropriate 
concentrations. The inoculum was confirmed by Colony Forming Unit (CFU) counts on 
Sabouraud dextrose agar (Difco, Detroit, MI, USA) for up to 48 h at 37ºC. 
 
C. albicans hematogenously disseminated infections 
Mice were injected intravenously (i.v.), in the lateral tail vein, with 5x10 4 C. albicans 
yeast cells in 0.2 ml PBS. Control mice were injected with PBS. Mice were sacrificed 7 
days after infection and the kidneys were removed and fixed in 10% Phosphate-
buffered formaldehyde, followed by dehydration and paraffin wax embedment.  
Sections of 4 µm were cut from each representative paraffin blocks for staining with 
haematoxilin-eosin and with periodic acid-Schiff reagent followed by counterstaining 
with haematoxylin, in order to evaluate both fungal morphology and composition and 
distribution of inflammatory infiltrates.   
 
Immunohistochemistry 
The presence of Gal-3 in kidney C. albicans induced lesions were assessed by 
immunohistochemistry in formalin-fixed, paraffin-embedded 4 µm sections of C. 
albicans i.v. infected mice mounted on amino-propyl-tri-ethoxy-silane (Sigma-Aldrich, 
St Louis, MO, USA) coated slides. 
Immuno-staining was performed by using the modified avidin-biotin-peroxidase 
complex (ABC) method (32). Unlabeled monoclonal antibodies rat anti mouse/human 
Gal-3 (clone M3/38) (eBioscience, San Diego, CA, USA) was used. 
Tissue sections were deparaffinised in xylene, rehydrated by graded washes of ethanol 
in water, ending in a final rinse in deionized water. Antigen retrieval was performed by 
incubating the slides in 10 mM citrate buffer (pH = 6) for 3 min in a pressure cooker. 
The slides were cooled and rinsed three times in Tris-buffered saline (TBS; 50 mM Tris, 
150mM NaCl, pH=7,6) for 5 min. Endogenous peroxidase activity was blocked by 
immersing slides in methanol containing 3% hydrogen peroxide for 10 min, followed by 
TBS washing. To reduce non-specific antibody binding, slides were incubated with 
normal rabbit serum (Dako, Glostrup, Denmark) diluted at 1:5 in TBS containing 10% 
bovine serum albumin (BSA), in a humidified chamber for 20 min at room 
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temperature. Excess normal serum was removed and replaced by the hybridoma 
supernatant containing anti-Gal-3 mAb (diluted at 1:10). After overnight incubation at 
4ºC, slides were washed with TBS and incubated for 30 min with a 1:200 dilution of 
biotin-labelled rabbit anti-rat secondary antibody (Dako). Slides were then washed 
with TBS and incubated for 30 min with the avidin-biotin complex (Dako) diluted at 
1:100. Detection was performed for 3 to 5 min with 0.05% 3,3 
diaminobenzidinetetrahydrochloride (DAB) freshly prepared in 0.05 M 
Tris/hydroxymethylaminomethane buffer, pH 7.6, containing 0.1% hydrogen peroxide 
(Dako). Finally, sections were lightly counterstained with Mayer’s haematoxylin and 
mounted in Entellan® mounting medium (Merck, Darmstadt, Germany). Dilution of 
primary antibody, biotin-labelled secondary antibody, and avidin-biotin complex were 
made with TBS containing 5% BSA. Negative controls were performed by substitution 
of the primary antibody with irrelevant immunoglobulins of the same subclass and 
concentration as the monoclonal antibodies. Slides were evaluated under light 
microscopy. 
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RESULTS 
 
C. albicans secreted aspartyl proteases cleave murine galectin-3 
The ability of C. albicans secreted proteases to cleave galectin-3 was assessed by 
incubating different Sap proteins with this lectin. The proteolytic activity of C. albicans 
wild-type SC5314 culture supernatant grown in Sap inducing medium (containing 
mostly native Sap2) and the recombinant Sap proteins rSap1, rSap2 and rSap3 were 
incubated with galectin at 37ºC, pH 5.2 or 6.8, and aliquots were collected after 1, 3, 6, 
12 and 24 h incubation. The reaction mixtures were separated by SDS-Page and Gal-3 
cleavage was evaluated by Western blotting. Gal-3 cleavage could be detected already 
at the first assessed time point at pH 5.2, and was more evident along the other time 
points. The results, obtained with protein mixtures collected after 3 h incubation, are 
shown as representative examples (Figure 1A). Assessment of Gal-3 degradation was 
based on the disappearance of the protein bands of higher molecular weight as well as 
by the appearance of novel fragments of lower molecular weights. Native Sap2 and 
recombinant Sap2 and Sap3 were the most effective in cleaving Gal-3. This lectin was 
also cleaved, to a lesser extent, by rSap1.  
 
 
 
Figure 1 Culture supernatants derived from wild-type C. albicans containing nSap2 and rSap1, 
rSap2 and rSap3 have proteolytic activity and cleave Gal-3. Saps were added to Gal-3 and 
incubated for 3 h at 37ºC, pH5.2. The mixtures were then separated by SDS-Page, transferred 
to a nylon membrane. (A) Gal-3 and the resulting degradation fragments were identified by 
using a polyclonal anti-Gal-3 Ig-Y; cleavage products are indicated by the arrows; (B) Gal-3 
integrity was evaluated by using a monoclonal anti-Gal-3 antibody (M3/38) that reacts with 
the N-terminal nonlectin domain of the protein. Arrow indicate full-length Gal-3. Gal-3 (lane 1); 
Gal-3 incubated with: nSap2 (lane 2), rSap1 (lane 3), rSap2 (lane 4), and rSap3 (lane 5). A 
representative example out of three independent assays is shown.  
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Gal-3 integrity was evaluated by using a monoclonal anti-Gal-3 antibody (M3/38) that 
reacts with the N-terminal nonlectin domain of the protein. The N-terminal non-lectin 
tandem repeated domain of Gal-3, necessary for its oligomerization and 
immunomodulatory activity, was removed during Sap-mediated cleavage (Figure 1B). 
Protein mixtures incubated at pH 6.8 did not exhibit detectable Gal-3 degradation 
(data not shown). Pepstatin A, an inhibitor of aspartyl proteases, largely blocked Gal-3 
degradation (Figure 2), confirming that the proteolytic activity observed was 
specifically due to this class of proteases.  
 
 
Figure 2 Inhibition of aspartyl protease activity. Gal-3 was incubated with nSap2 and rSap2 for 
3 h in citrate buffer at pH 5.2 alone or in the presence of pepstatin-A. Degradation of Gal-3 was 
largely blocked by pepstatin A, an inhibitor of aspartyl proteases. The mixtures were separated 
by SDS-Page, transferred to a nylon membrane and Gal-3 and the resulting degradation 
fragments were identified by using a polyclonal anti-Gal-3 Ig-Y. A representative example out 
of three independent assays is shown.  
 
Gal-3 accumulates in inflammatory infiltrates observed in the kidneys of C. albicans 
i.v.-infected mice  
Gal-3, with intact N-terminal non-lectin tandem repeated domain, accumulated in the 
inflammatory infiltrates recruited into the kidneys of BALB/c mice upon i.v. infection 
with C. albicans. The presence of this lectin was however detected in lower amounts in 
lesions where C. albicans, mainly in the hyphal form, was present in higher numbers, 
suggesting that C. albicans was able to regulate and/or degrade Gal-3.  
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Figure 3 Representative photomicrographs of PAS-stained histological sections of kidneys from 
BALB/c control mice (A) or mice i.v.-infected with 5x104 C. albicans SC5314 cells (B and C). At 7 
days after i.v. infection, moderate to intense neutrophilic infiltration was observed, without 
visible fungal cells (B) or with numerous PAS-positive organisms with hyphal morphology 
(arrowheads), extensively effacing the renal tubuli and invading the urothelium (C); 
Immunohistochemistry of kidney sections from control (D) and infected mice (E and F), using a 
monoclonal antibody anti-N-terminal domain of Gal-3 (M3/38) and revealed with DAB, 
showing higher expression of Gal-3 in the inflammatory infiltrates with low fungal burden (E). 
Gal-3 is expressed at high levels in the collecting ducts of both control and infected mice. 
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DISCUSSION 
 
Here we show that C. albicans secreted aspartyl proteases Sap1, Sap2 and Sap3 can 
degrade and inactivate the host receptor Gal-3. This activity might generate a 
microenvironment of impaired host innate immune function. Taking into account the 
concomitant decrease of intact Gal-3 and increase of Gal-3 cleavage products, the 
proteolytic activity of Sap2 and Sap3 seems stronger than that of Sap1. This result 
emphasizes that, even presenting high homology, different Saps may have a different 
enzymatic activity on specific substrates, (22, 33). In this regard, Sap1 and Sap2 have 
been reported to cleave proteins of the complement system more effectively than 
Sap3 (23). Here, Sap3 was as efficient as Sap2 in cleaving Gal-3, whereas Sap1 cleaved 
Gal-3 to a lesser extent. Each recombinant Saps and C. albicans culture supernatants 
showed comparable cleavage patterns suggesting that all Saps tested, native or 
recombinant, cleave Gal-3 at the same sites. Though Sap2 is the mainly secreted Sap 
when C. albicans is grown in media containing proteins as sole nitrogen sources, all 
three Saps tested here may be present in C. albicans supernatants (20). Sap proteins 
may participate in innate immune evasion by affecting diverse effectors with 
antifungal activity. These fungal proteins cleave the central host complement 
components and degrade other host innate immune components such as lactoferrin 
and histatin-5 of the saliva, the protease inhibitor α-macroglobulin, enzymes which 
mediate the respiratory burst of macrophages and several immunoglobulins, including 
secretory IgA, which normally is rather resistant to bacterial proteases (14, 34). 
Secretion of host Gal-3-degrading proteases, which could impair Gal-3-mediated C. 
albicans recognition and/or affect immune regulatory effects dependent on this lectin, 
may represent an alternative immune evasion mechanism. The cleavage of Gal-3 upon 
binding Leishmania major promastigotes, presumably by a membrane-bound zinc 
metalloprotease was previously shown (35).  
Sap expression is induced in C. albicans cells upon infection (14) suggesting that these 
proteases may also contribute to in vivo Gal-3 inactivation and immune evasion. Here, 
an accumulation of Gal-3 was observed in C. albicans-induced kidney lesions. However, 
Gal-3 was detected in significantly lower amounts inside lesions containing numerous 
fungal cells. It would be interesting to evaluate whether this may result from Gal-3 
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cleavage by Saps. Interestingly, Gal-3 was previously shown to promote neutrophil 
recruitment into bacterial infection sites (36, 37). As neutrophils play a major role in 
controlling C. albicans infections, C. albicans-mediated Gal-3 inactivation could 
additionally result in reduced neutrophil recruitment into the kidneys, the preferential 
infected organ during invasive Candida infections (38).  
In summary, C. albicans may use Gal-3 degradation as a strategy to control and evade 
host immune Gal-3-mediated recognition, and the ensuing inflammatory response, or 
even avoid Gal-3-mediated C. albicans killing. Here we show that the three Sap 
proteins Sap1, Sap2 and Sap3 degrade and inactivate the pattern recognition receptor 
Gal-3. This may compromise Gal-3 function, for which an intact N-terminal non-lectin 
domain was shown to be essential (39-41). Degradation of host Gal-3 might thus 
generate a protective microenvironment of reduced Gal-3 activity which may facilitate 
C. albicans survival in the host. 
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ABSTRACT 
 
The usefulness of Candida albicans recombinant secreted aspartyl protease (rSap2) as 
an immunogen for vaccination against invasive candidiasis was evaluated in a murine 
model of hematogenously disseminated candidiasis. Four different active 
immunization protocols were assayed, with four different adjuvants tested: (i) Alum; 
(ii) topical Imiquimod; (iii) Freund’s; (iv) CpG plus Alum. Moreover, as the hypha-
associated isoenzyme Sap5 is preferentially expressed during systemic candidiasis, it 
was also evaluated as target antigen for Candida vaccination, together with Alum or 
Imiquimod. Results showed that all these approaches failed to have a relevant and 
statistically significant effect on the infection course, determined by survival curves 
and kidney fungal burden. This suggests that the C. albicans Sap2 and Sap5 
isoenzymes, despite their potential role in virulence, do not appear to be suitable 
target proteins for the development of immunopreventive strategies against acute 
disseminated candidiasis.  
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INTRODUCTION 
 
Invasive candidiasis ranks among the third or fourth most frequent nosocomial 
bloodstream infections both in the United States and in many European countries,  and 
Candida albicans accounts for approximately 50% of the cases of candidemia (1-3). 
Disseminated candidiasis typically occurs after multiple weeks of hospitalization and is 
associated with a mortality of 40 to 50% and a high morbidity in those who survive, 
even after treatment with modern antifungal agents (4-6). Furthermore, development 
of Candida spp resistance to conventional antifungal therapies is of serious concern. 
Given the high morbidity and mortality rates, associated with high health care costs 
(7), the development of more effective prophylactic and therapeutic strategies is 
needed. The predominant risk factors for disseminated candidiasis are the disruption 
of protective anatomical barriers or situations leading to substantial increase in the 
colonization burden of Candida spp., such as indwelling catheters and parenteral 
nutrition, abdominal or cardiac surgery, prolonged hospital stay or stay in an intensive 
care unit, and receipt of broad-spectrum antibiotics (2). Because the risk factors for 
disseminated candidiasis precede the development of infection and are often easily 
identifiable, vaccination of at-risk patients to prevent the onset of disseminated 
candidiasis is promising. Furthermore, these patients are usually not profoundly 
immunosuppressed and would be expected to respond favorably to vaccination (8). 
Moreover, an immunization approach would need to protect patients just for the short 
period of time of increased susceptibility (9).  
The protective role of antibodies against invasive candidiasis has been controversial. 
For some effective vaccines against invasive fungal infections, the key to protection 
has been reported to be the induction of cell-mediated, pro-inflammatory, Th1 or Th17 
responses, which improve phagocytic killing of the fungus (10, 11). Nevertheless, over 
the last two decades, strong evidence has accumulated that some Candida-specific 
antibodies or their engineered derivatives can be immunoprotective against C. albicans 
infections, following both active vaccination and passive transfer of immune serum or 
antibodies (12-19).  
In addition to the host status, the pathogenicity of C. albicans also depends on a 
complex set of fungal attributes that are considered as putative virulence factors for 
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their involvement in the infectious process. Often, these consist of secreted or 
membrane bound proteins, which are among the first targets encountered by host 
defense mechanisms (20), making them attractive vaccine candidates. The secreted 
aspartyl proteases (Sap) have long been considered putative virulence factors (21, 22).  
The isoenzyme preferentially expressed following induction in vitro, Sap2 (23), has 
already been used in vaccination strategies against oral, vaginal, and intraperitoneal C. 
albicans infections (15, 24-26). Intra-dermical (i.d.) immunization with native Sap2 plus 
Alum adjuvant conferred protection to BALB/c mice, against C. albicans peritonitis. The 
mechanism of protection was not completely elucidated, but antibodies by themselves 
were at least partially responsible for the protective effect (15). For the achievement 
of a candidate vaccine against acute systemic candidiasis, the availability of 
recombinant antigen would greatly overcome the well-known difficulties in producing, 
purifying and standardizing a native antigen.  
The present studies were performed to evaluate the efficacy of alternative vaccine 
presentation strategies, using recombinant Sap2 (rSap2) in protecting 
immunocompetent BALB/c mice against hematogenously disseminated candidiasis. 
Moreover, as the hypha-associated isoenzyme Sap5 was preferentially expressed 
during systemic candidiasis (27), it was also evaluated as target antigen for Candida 
vaccination.     
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MATERIAL AND METHODS 
 
Mice 
Male BALB/c mice, 8-10 weeks old, were purchased from Charles River (Barcelona, 
Spain) and kept under specific pathogen-free conditions at the Animal Facility of 
Instituto de Ciências Biomédicas Abel Salazar, Porto, Portugal. All procedures involving 
mice were performed according to the European Convention for the Protection of 
Vertebrate Animals used for Experimental and other Scientific Purposes (ETS 123), 
86/609/EEC Directive and Portuguese rules (DL 129/92). Authorization to perform the 
experiments was issued by the competent national board authority (Direção Geral de 
Veterinária), document number 0420/000/000/2010. 
 
Secreted aspartyl proteases 
Recombinant Sap1 (rSap1), rSap2, rSap3 and rSap5 were produced in Pichia pastoris 
and were kindly provided by Dr Bernhard Hube (Jena University, Germany). All purified 
recombinant proteins exhibited protease activity in vitro, as assessed by using a 
standard fluorescence-based casein assay (Molecular Probes, Invitrogen, Eugene, OR, 
USA). Reactions were also performed in the presence of the general aspartyl protease 
inhibitor pepstatin A (Sigma Aldrich, St Louis, MO, USA). Native Sap2 (nSap2) was 
purified as previously described (15). Contaminant endotoxin was removed from all 
Sap samples by passage through a polymixin B column (Pierce, Thermo Fisher 
Scientific, Rockford, IL, USA). Samples used were confirmed to be endotoxin-free, as 
assessed by the limulus test (E-toxate, Sigma).  
 
In vitro splenocyte cell cultures and flow cytometric analysis 
Spleen cells from BALB/c naive mice were obtained by gently teasing the organ in 
RPMI-1640 supplemented with penicillin (100 IU/mL), streptomycin (50 µg/mL), 
polymixin B (50 µg/mL), 2-mercaptoethanol (0.05 M) and 10% fetal bovine serum (all 
from Sigma). Cell suspensions were washed with RPMI, distributed in 96-well plates 
(1 × 106 cells/well) and cultured for 6 and 12 h at 37ºC in a humidified atmosphere 
containing 5% CO2 in air. Plated cells were stimulated with medium alone or with 
different concentrations (6 to 100 µg per mL of culture medium) of recombinant or 
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native Sap2. rSap2 and nSap2 denatured by heat treatment for 2 min at 100ºC at the 
highest concentration were used to determine if Sap2-mediated biological effects 
were dependent on protein structure and function. Medium containing 2.5 µg/mL LPS 
or 2.5 µg/mL Concanavalin A were used as a positive controls. Polymixin B was added 
to each condition at a final concentration of 50 µg/mL to exclude contribution of 
endotoxin contamination to the measured Sap2-mediated biological effects. Each 
condition was set in triplicate. The cultured cells were washed and resuspended in PBS 
supplemented with 1% BSA and 10 mM sodium azide. The following monoclonal 
antibodies (mAbs) were used for immunofluorescence cytometric analysis in a 
FACScan (Becton-Dickinson, San Jose, CA, USA) using CELLQUEST software (Becton-
Dickinson): FITC-conjugated rat anti-mouse B220 (clone), PE-conjugated hamster anti-
mouse CD69 (clone), and FITC-conjugated rat anti-mouse CD4 (clone) (all from BD 
PharMingen, San Diego, CA, USA). Dead cells were excluded by propidium iodide (PI) 
incorporation.  
 
In vivo treatments with Sap2  
Mice were i.p. injected with 250 µg of Sap2 in 0.5 mL of PBS. Control animals were 
injected with 0.5 mL of PBS alone. 
 
ELISPOT assays  
The numbers of splenic Ig-secreting cells were assessed by an ELISA-spot assay as 
described (28). Briefly, polystyrene microtitre plates (Nunc, Roskilde, Denmark) were 
coated overnight at 4ºC with 5 µg/mL goat anti-mouse Ig (Southern Biotechnology 
Associates, Birmingham, AL, USA) or with 10 µg/mL rSap2. The wells were then 
saturated for 90 min with 2% BSA in PBS at 37ºC. Appropriate serial suspensions of 
spleen cells in RPMI 1640 supplemented with 2% fetal calf serum (Invitrogen Life 
Technologies, Carlsbad, CA, USA) and 0.05% Tween 20 were incubated in the plates for 
6 h at 37°C in a humidified atmosphere of 5% CO2 in air. The plates were then rinsed 
with 0.075% Tween 20 in water (Sigma) and washed four times with PBS containing 
0.075% Tween 20. Ag-specific or total Ab-secreting cells were revealed by the addition 
of alkaline phosphatase-coupled monoclonal goat anti-mouse-Ig (Southern 
Biotechnology Associates) overnight at 4ºC. After washing, 5-bromo 4-chloro 3-indolyl 
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phosphate (Sigma) in 2-amino 2-methyl 1-propanol (Sigma) buffer was used as 
substrate for 2 h at 37ºC. After washing four times with distilled water, the number of 
spots was quantified in triplicate wells with a dissecting microscope. 
 
Immunization protocols 
Alum adjuvant. Mice were injected intra-dermically (i.d.) three times, with a 3-week 
intervening period, with 10 µg of rSap2 in 100µL of a 1:1 PBS/Alum suspension 
(Aluminium hydroxide gel; Brenntag, Frederikssund, Denmark, a kind gift of Dr Erik 
Lindblad, Biosector, Frederikssund, Denmark). The respective control animals received 
100 µL of 1:1 PBS/Alum. Mice were also immunized by using 5 µg of rSap5 plus Alum 
adjuvant, twice at a 3-week interval.  
Imiquimod adjuvant. Mice were injected subcutaneously (s.c.) four times, with a 1-
week intervening period, with 20 µg of rSap2 in 100µL PBS, followed by topical 
application of Imiquimod (AldaraTM cream, 5% Imiquimod, Laboratoires 3M Santé, 
Cergy Pontoise, France). The respective control animals received 100µL of PBS, 
followed by topical application of Imiquimod. The equivalent to 1.25 mg of Imiquimod 
was applied to each mouse in the site of injection. A similar immunogenic procedure 
was performed by using 5 µg of rSap5 as target antigen. 
Freund’s adjuvant. Mice were injected intra-dermically (i.d.) with 10 µg of rSap2 in a 
1:1 PBS/Complete Freund suspension (Sigma). After a 3-week intervening period, mice 
were boosted with 10 µg of rSap2 in a 1:1 PBS/Incomplete Freund suspension (Sigma). 
The respective control animals received 100 µL of 1:1 PBS/Complete Freund followed 
by PBS/Incomplete Freund. 
CpG adjuvant. Mice were immunized by an intramuscular administration of a single 
dose of a mixture containing 10 µg of rSap2, 10 µg of oligodeoxynucleotide (ODN) CpG 
(Invivogen, San Diego, CA, USA) and 0,3% Alum in a 30 µL final volume. Control mice 
were similarly immunized with PBS, CpG ODN and Alum. Mice immunized with 10 µg 
of rSap2,10 µg of non-CpG ODN (Invivogen) and Alum or PBS, non-CpG ODN and Alum 
were included as another control group. 
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Antibody detection 
Specific anti-Sap2 immunoglobulin in mice sera, collected by submandibular bleeding, 
was quantified by enzyme-linked immunosorbent assay (ELISA). Briefly, polystyrene 
microtitre plates (Nunc) were coated with 5 µg/mL of rSap2, nSap2, rSap1, rSap3 or 
rSap5, and incubated overnight at 4ºC. Wells were then saturated for 1 h at room 
temperature with 2% BSA in 0.05% Tween 20-Tris buffered saline (TBST). Serial 
dilutions of the serum samples were then plated and incubated for 2 h at room 
temperature.  After washing, alkaline phosphatase-conjugate goat anti-mouse IgG, 
IgG1 or IgG2a (all from Southern Biotechnology Associates) antibodies were added and 
incubation was kept for an additional 30 min at room temperature. After washing, the 
bound antibodies were detected by development with substrate solution containing p-
nitrophenyl phosphate (Sigma) and the reaction was stopped by the addition of 0.1M 
EDTA, pH 8.0. The absorbance was measured at 405 nm. The ELISA antibody titres 
were expressed as the reciprocal of the highest dilution giving an absorvance of 0.1 
above that of the control (no serum added).     
 
Purification of serum IgG antibodies 
Sera from mice inoculated i.d. with a 3-week intervening interval, with a 1:1 PBS/Alum 
suspension or 1:1 PBS/Alum suspensions containing 10 µg of rSap2, as described above 
in immunization protocol section, were collected and pooled 21 days after the second 
inoculation. Purification of IgG from these pooled sera was then performed as follows: 
pooled serum samples were equilibrated in binding buffer (20mM sodium phosphate, 
pH 7.0) by using Amicon Ultra-15 centrifugal devices (Millipore, Billerica, MA, USA). 3 
ml of these preparations were applied to a Protein G HP affinity column (HiTrap; 
Amersham Biosciences, Bucks, UK) for each separation, according to manufacturer’s 
instructions. 
 
Immunoblotting 
The reactivities of anti-Sap2 and anti-Sap5 immunoglobulins were visualized by 
Western blot analysis. For that purpose, 1 µg of rSap1, rSap2, rSap3, and rSap5, as well 
as native Sap2 were separated by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) on 10% polyacrylamide gels and then blotted overnight 
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onto nitrocellulose membranes (Sigma). Nonspecific binding was prevented by 
blocking with 3% BSA in Tris buffered saline (TBS) for 2 h at room temperature. After 
washing, membranes were incubated for 4 h with mouse polyclonal antibodies anti-
rSap2 (5 µg/mL) or with nSap2 antiserum (1:200) diluted in TBST. Alternatively, 
membranes were incubated with rSap5 antiserum (1:200). Bound antibodies were 
detected with alkaline phosphatase-conjugate goat anti-mouse IgG (Southern 
Biotechnology Associates), using NBT/BCIP solution (Roche, Penzberg, Germany) as 
substrate. The reaction was stopped in distilled water.  
Reactivity of the purified anti-rSap2 IgG were also tested by ELISA, as described above, 
in polystyrene microplates (Nunc) coated with 5 µg/mL of rSap1, rSap2, rSap3, rSap5, 
rSap6, and nSap2.  
 
Candida albicans and culture conditions 
The C. albicans wild-type strain SC5314 was used in this study (29) and maintained as 
frozen stocks in 30% glycerol at -80ºC. To prepare the inoculum for infection, C. 
albicans was grown in a shaking incubator for 14 hours at 30ºC in Winge medium (0,2% 
glucose, 0,3% yeast extract). Yeast cells were harvested, washed twice with sterile, 
nonpyrogenic phosphate-buffered saline (PBS) (Gibco®, Grand Island, NY, USA), 
counted in a haemocytometer and resuspended at the appropriate concentrations. 
Inocula were confirmed by Colony Forming Unit (CFU) counts on Sabouraud dextrose 
agar (Difco, Detroit, MI, USA) for up to 48 h at 37ºC. 
 
C. albicans hematogenously disseminated infections 
Mice were injected intravenously (i.v.), in the lateral tail vein with 2 × 105 C. albicans 
yeast cells in 0.2 mL PBS. To evaluate the progress of hematogenously disseminated 
candidiasis, mice were weighed and monitored twice daily, for a maximum of 30 days. 
Moribund mice were humanely terminated, and their deaths recorded as occurring the 
following day. 
In some immunization protocols, a second group of similarly injected mice were 
infected with 1 × 105 and sacrificed 7 days post-infection to determine organ fungal 
burden. Kidneys were aseptically removed, homogenized, and quantitatively cultured 
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on Sabouraud dextrose agar (Difco) at 37ºC. Values were expressed as log CFU per 
gram of tissue.  
 
Statistical Analysis 
Unless otherwise stated, results shown are from one experiment, representative of at 
least three independent experiments. Statistical significance of results was determined 
by unpaired Student t-test, using the GraphPad Prism 4 Software (GraphPad Software, 
Inc., La Jolla, CA, USA). Results were considered statistically significant with P values of 
less than 0.05.  
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RESULTS 
 
Sap2 has been shown to be an effective target antigen in immunoprotective protocols 
against systemic C. albicans infection established i.p. in BALB/c mice (15). Here, the 
same immunization protocol was extended to the murine model of hematogenously 
disseminated candidiasis by using rSap2 and rSap5, to evaluate their host protective 
effect in mice infected with C. albicans strain SC5314. 
 
Immunomodulatory effects of rSap2 
The ability of rSap2 to induce B- and T-lymphocyte activation was tested in vitro. 
Moreover, rSap2-mediated B-lymphocyte activation was also tested in vivo. rSap2 
added to splenocyte cultures failed to induce the expression of the early activation  
marker CD69 on B and T lymphocytes (Figure 1).  
 
Figure 1 In vitro lymphocyte stimulatory effect of recombinant secreted aspartyl protease 2 
(rSap2). Flow cytometric analysis of CD69 expression on the surface of BALB/c mice B (B220+) 
and CD4+ T cells in spleen mononuclear cell cultures after 12 hours of incubation with rSap2 or 
medium alone. LPS and ConA were used as positive controls for B and T cells, respectively. 
Numbers represent the mean values ± standard deviation (SD) of three samples per group. 
This is a representative result of four independent experiments.  
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Similarly, BALB/c mice that received 250 µg of rSap2 i.p. showed no significant increase 
in the number of splenic immunoglobulin-secreting cells when compared with control 
animals (Figure 2A). Moreover, rSap2 injection did not induce DC maturation, as no 
altered expression of the activation markers CD80, CD86 and MHC class II was 
observed on the surface of CD11chi cells (Figure 2B). In summary, an 
immunomodulatory role of rSap2 could not be observed either in vitro or in vivo. 
 
 
Figure 2 In vivo stimulatory effect of rSap2 in BALB/c mice, 5 days after i.p. treatment with 
phosphate-buffered saline (PBS) (black bars) or with 250 µg of rSap2 (white bars). (A) Numbers 
of spleen immunoglobulin-secreting cells. (B) Expression of CD80, CD86, and MHC class II 
molecules on the surface of spleen conventional dendritic cells, as assessed by the mean 
fluorescence intensities of antibody staining. The values represent the mean + 1 SD of four 
mice per group and are a representative result of two independent experiments.  
 
Elevated anti-Sap2 and anti-Sap5 immmunoglobulins in the serum of immunized 
mice 
To determine the immunogenic efficiency of the different rSap2 and rSap5 
preparations, sera from mice immunized with different adjuvants were tested for the 
presence of antibodies specific for this protein. ELISAs were performed for the 
quantitative measurement of anti-Sap immunoglobulins in the sera collected before 
infection. The titres of anti-Sap2 and anti-Sap5 IgG were significantly higher in mice 
immunized with rSap2 and rSap5, respectively, than in the controls, regardless of the 
adjuvant or immunization protocol used. In mice immunized with rSap2 alone or rSap2 
plus Alum, IgG1 was the main IgG isotype found in serum antibodies whereas IgG2a 
antibodies were mostly absent. In rSap5 plus Alum or imiquimod-immunized mice, 
only production of antigen-specific IgG1 was observed. Conversely, in mice immunized 
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with rSap2 using Imiquimod, Freund or CpG plus Alum as adjuvants, mixed IgG1 and 
IgG2a production was detected, although with IgG1 predominance (Figure 3).  
 
 
Figure 3 Serum IgG1- and IgG2a rSap2- or rSap5-specific antibody titres in mice sera, as 
indicated. Sera were collected 15 days after the last immunization for all groups except for the 
CpG group in which sera were collected 21 days after the single immunization. Bars represent 
mean antibody titres ± SD. n=4 to 8 mice per group.  *P < 0.05; ** P < 0.01; ***P < 0.001.   
 
Western blot analysis was used to reveal purified IgG reactivity against blotted Sap 
isoenzymes. Specific reactivity was readily detectable in mice immunized with rSap2 
against rSap2 and nSap2. Anti-rSap2 IgG also reacted with rSap1 and rSap3. In 
contrast, these immunoglobulins did not react with rSap5. The reaction was always 
stronger with sera from rSap2-immunized mice against rSap1, rSap2, rSap3 and nSap2 
than the background anti-Sap2 reactivity detected in sera from control mice (Figure 
4A). Sera from rSap5-immunized mice reacted only with rSap5 (Figure 4B). These 
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results were confirmed by ELISA. Unexpectedly, rSap2-specific antibodies recognized 
nSap2 with lower intensity than rSap2 (IgG titers of 77500 ± 26299 and 12750 ± 12473, 
specific for rSap2 and nSap2, respectively).   
 
 
 
Figure 4 Western blot analysis of (A) anti-rSap2 IgG or (B) anti-rSap5 sera reactivities against 
the indicated antigens. Purified IgG antibodies and sera were obtained,15 days after the last 
immunization, from rSap2-immunized or rSap5-immunized mice, using Alum adjuvant.  
 
 
Immunization with rSap2 did not confer protection against acute systemic 
candidiasis 
Having ascertained that all immunization procedures assessed raised Sap-specific 
serum antibody levels, confirming the immunogenicity of the immunizing preparations, 
the protective effect of rSap2 immunization against hematogenously disseminated 
candidiasis was evaluated in the different groups of immunized mice.  
 
Immunization with rSap2 in the absence of adjuvant 
Mice immunized with rSap2 alone and sham-immunized controls had no detectable 
differences in the number of C. albicans CFU in the kidneys, on day 7 after inoculation 
i.v. with C. albicans (Figure 5A).  
 
Immunization with Alum adjuvant 
As observed by using rSap2 alone, no significantly different CFU counts were found in 
the kidneys of mice immunized with rSap2 plus Alum and controls, 7 days upon C. 
albicans infection (Figure 5B). In accordance, this immunization procedure did not 
protect mice against infection with a lethal C. albicans inoculum (Figure 5C). Both 
 208 
 
sham-immunized and rSap2-immunized mice showed similar median survival times 
and all mice in these groups were dead by day 8 and day 10, respectively.  
 
 
Figure 5 (A) CFU recovered from the kidneys of BALB/c mice immunized i.d. with rSap2 in PBS, 
rSap2 in alum adjuvant, or respective sham-immunized controls, and infected i.v. with 1 × 105 
C. albicans SC5314 cells three weeks after the last i.d. immunization. Data are representative 
of two independent experiments. Each symbol represents an individual mouse, and horizontal 
bars are means of CFU numbers for each group; n=5. (B) Survival rates in mice immunized i.d. 
with rSap2 in alum adjuvant or sham-immunized controls and infected i.v. with 2×105 C. 
albicans cells, three weeks after the last i.d. immunization. The median survival rates of mice 
immunized with rSap2 plus alum and adjuvant inoculated mice, as determined using the Log 
rank test, were not different (P= 0.60); n=8; results are one representative experiment out of 
two independent experiments. (C) CFU recovered from the kidneys of BALB/c mice immunized 
s.c. with rSap2 plus topical Imiquimod application or sham-immunized controls and infected 
i.v. with 1 × 105 C. albicans cells 20 days after the last immunization. Each symbol represents an 
individual mouse, and horizontal bars are means of CFU numbers for each group; n=8;  (D) 
Survival rates in mice immunized i.d. with rSap2 in Freund’s adjuvant or sham-immunized 
controls and infected i.v. with 2×105 C. albicans cells, three weeks after the last i.d. 
immunization. The median survival rates of mice immunized with rSap2 plus Freund’s and 
adjuvant inoculated mice, as determined using the Log rank test, were not different (P= 0.77); 
n=5; (E) CFU recovered from the kidneys of BALB/c mice immunized i.m. with rSap2 in CpG plus 
Alum adjuvant or sham-immunized controls and infected i.v. with1 × 105 C. albicans cells 30 
days after the last immunization. Bars represent means  ± SD; n=4. 
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Immunization with imiquimod adjuvant 
Mice were immunized by subcutaneous (s.c.) injection with rSap2 followed by topical 
application of imiquimod. Sham-immunized animals were s.c. injected with PBS 
followed by similar imiquimod application. As shown in Figure 5D, no significant 
reduction in fungal kidney burden was observed in the immunized mice, comparatively 
to controls. Two out of eight immunized mice died before the experiment was 
terminated. Moreover, two other immunized mice were moribund by the time kidney 
CFU counts were assessed. Interestingly, these mice were the ones presenting the 
highest IgG levels (data not shown).   
 
Immunization with Freund’s adjuvant 
As shown in Figure 5E, C. albicans infected mice immunized with rSap2 plus Freund’s 
adjuvant showed survival rates equivalent to those of sham-immunized controls 
injected with PBS and adjuvant alone. Sham-immunized mice showed a median 
survival time of 12 days, while the median survival time of rSap2-immunized mice was 
9 days, and all mice in these groups were dead by day 16 and day 17, respectively.  
 
Immunization with CpG plus Alum adjuvant 
Similarly to the other immunization approaches tested, immunization with rSap2 plus 
CpG/Alum adjuvant also failed to protect mice from an i.v. C. albicans challenge, as the 
number of kidney CFU was not significantly different between the immunized mice and 
controls (Figure 5F). A mouse of the rSap2 plus CpG/Alum-immunized group died prior 
to the termination of the experiment. 
 
Altogether, these results showed that no protection against systemic C. albicans 
infection established by the hematogenous route was obtained by immunizing mice 
with rSap2, independently of the used adjuvant.  
 
Immunization with rSap5 failed to protect mice against acute systemic candidiasis  
As observed by using rSap2 as target antigen, immunization with rSap5 with Alum or 
imiquimod adjuvants did not protect mice from a hematogenous challenge with C. 
albicans cells. No significantly different CFU counts were found in the kidneys of mice 
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immunized with rSap5 plus either adjuvant and controls, 7 days upon C. albicans 
infection (Figure 6A). Also no extended survival was observed in rSap5 plus Alum-
immunized mice, as compared to sham-immunized controls (Figure 6B). 
Immunization with rSap5 using imiquimod as adjuvant, also failed to reduce kidney 
fungal burden, comparative to that of controls (Figure 6C). 
 
 
Figure 6 (A) Numbers of C. albicans CFU recovered from the kidneys of BALB/c mice 
immunized twice i.d. with rSap5 in Alum adjuvant, or respective sham-immunized controls, 
and infected i.v. with 1 × 105 C. albicans cells 3 weeks after the last i.d. immunization. Bars 
represent means ± SD; n=6. (B) Survival rates in mice immunized i.d. with rSap5 in Alum 
adjuvant or sham-immunized controls and infected i.v. with 2×105 C. albicans cells, three 
weeks after the last i.d. immunization. The median survival rates of mice immunized with 
rSap5 plus Alum and adjuvant inoculated mice, as determined using the Log rank test, were 
not different (P=0.91); n=8 for rSap5 plus Alum group and n=6 for sham-immunized group.  
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DISCUSSION 
 
Previous reports have shown that mice immunized with Sap2 were protected against 
mucosal or peritoneal C. albicans infection (15, 24, 25, 30). Here immunization with 
Sap antigens was done, using different adjuvants and immunization schedules, to 
attempt protect mice against acute systemic candidiasis. 
Alum is a licensed adjuvant used in human vaccine formulations (31). It was previously 
employed to successfully immunize mice against C. albicans peritonitis (Vilanova et al., 
2004). Therefore, it was used here as a first choice adjuvant in order to assess the 
protective effect of rSap2 and rSap5 as target antigens in a murine model of 
hematogenously disseminated candidiasis. Nevertheless, as this adjuvant usually 
favors an antibody-mediated immune response, other adjuvants that promote a 
cellular-mediated Th1-type immune response, such as imiquimod, CpG or Freund’s 
(32), were alternatively used for immunization with Sap proteins. Imiquimod was 
approved to be used for topical skin treatment in humans. It binds to TLR7 in mice and 
TLR7 and 8 in humans and stimulates the production of a characteristic cytokine 
profile, promoting a Th1 bias (33). The adjuvant effects of imidazoquinolines, including 
imiquimod, specifically increase IgG2a responses (34, 35). Although not yet licensed for 
human usage, the TLR 9 agonist CpG (oligodeoxynucleotides (ODNs) containing 
unmethylated CpG motifs) has been safely used in human clinical trials (36, 37). It 
directly stimulates human B lymphocytes and plasmacytoid dendritic cells to produce 
pro-inflammatory cytokines, leading to the induction of Th1 responses and triggering 
the activation of APCs (38-40). Moreover, it was shown to be more effective than Alum 
and imidazoquinolines in augmenting both humoral and cell mediated immune 
responses (40, 41). Furthermore, when used in combination with Alum, it had greater 
potential to augment immune responses and provided higher antibody titres than 
Freund’s complete adjuvant, with only minimal tissue damage (40).  
Despite the powerful properties of the used adjuvants, the lack of observed immune 
protection in mice infected i.v. with C. albicans may nevertheless indicate that those 
adjuvants were inadequate for the generation of a protective immune response. Anti-
sap2 IgG antibodies were previously shown to be host protective against Candida 
peritonitis (15), oral (24) and vaginal Candida infection (24, 25, 30). Thus, it could be 
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hypothesized that the magnitude of the immune response elicited by the 
immunization procedures assayed here was below effective levels. However, the anti-
rSap2 titres were similar or even higher than the ones reported for mice immunized 
with native Sap2 and Alum (15). Nevertheless, mice presenting higher rSap2-specific 
antibody titres, upon immunization with rSap2 plus Imiquimod, became more 
susceptible to the i.v. infection. The immune response elicited by immunization could 
actually be deleterious to the host. Although with IgG1 preponderance, a mixed 
IgG1/IgG2a isotypic profile was observed in these mice, which presented antibody 
titres below those detected by using the other adjuvants. Other immune mechanisms 
than antibody production could have been elicited by the Imiquimod adjuvanted 
immunization, resulting in uncontrolled inflammation. Alternatively, the lack of 
protection in the immunized mice may indicate that rSap2 was an inadequate target 
antigen. We actually observed that sera collected from rSap2-immunized mice reacted 
more intensely with the recombinant protein than with nSap2. This differential 
reactivity was only observed in ELISA assays, in which no denaturation of the antigen 
was expected. This might indicate that structural differences may exist between 
recombinant and native Sap2 that might affect the protein epitopes recognized by the 
antibodies. The usage of rSap5 as target antigen was also ineffective in inducing 
protection. However, it must be noted that rSap5-specific antibody titres raised by 
immunization were lower than the ones reached by using rSap2. It could have been 
expected that rSap5 was more promising as a target antigen in systemic candidiasis 
than rSap2, as Sap5 expression has been associated with invasive candidiasis (27, 42). 
Nevertheless, C. albicans could be less dependent on Sap2 activity to successfully 
infect the host in the acute model of systemic candidiasis than in other infection 
models, in which vaccination with Sap2 was found to be protective. The reported 
observation that Sap inhibitor pepstatin A was ineffective in protecting mice against 
hematogenously disseminated candidiasis supports this hypothesis (43). Moreover, in 
this infection model, Sap1 to Sap3 proved to be unnecessary for C. albicans infection 
establishment, as mutant stains deficient in SAP1 to SAP3 were equivalent in virulence 
to the wild-type strain. Furthermore, mutant strains lacking SAP4 to SAP6 presented 
only a marginal virulence attenuation (44). It is widely recognized that the relative 
importance of specific SAP genes for C. albicans pathogenicity is greatly determined by 
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the type of infection and its dependence on protease activity for the successful 
invasion and colonization of various host niches (44-47). Thus, immunization strategies 
targeting Sap2 would be more effective in controlling C. albicans infections dependent 
on protease activity than in the murine model of acute systemic candidiasis which is 
relatively protease independent. In addition, in the present work we have used C. 
albicans SC5314 strain to infect mice. This strain was not used in any of the previous 
reports where immunization with Sap2 was assessed (15, 24, 25, 30). Thus, we cannot 
exclude that protection conferred by this immunization strategy might be strain 
dependent and that the C. albicans strain used here to infect the immunized mice 
could not strictly depend on Sap2 and Sap5 activities to successfully colonize the host.  
Overall the results presented herein indicate that immunization with C. albicans Sap 
proteins may have no effect in protecting the host against candidiasis established by 
the hematogenous route. Nevertheless, they do not completely rule out the possibility 
that using Sap antigens combined with other adjuvants might result in host protection 
in this infectious condition. 
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CONCLUDING REMARKS 
 
The increasing incidence of invasive candidiasis, associated to a high treatment failure 
rate, fully justify the search for more effective prophylactic and therapeutic strategies. 
To fulfil this goal, a more comprehensive understanding is needed of C. albicans 
virulence mechanisms and of the host immune response to this fungus, in the different 
types of candidiasis. Moreover, several studies have underlined that distinct C. 
albicans isolates may show very distinct virulence phenotypes and elicit dissimilar 
immune responses, compromising the generalization of results obtained with a single 
isolate to the whole species. In addition, the majority of those studies gave little 
information of the fungus-host interactions and elicited host immune responses, since 
they focused on phagocytosis and intracellular killing assays. The studies presented 
here comparatively evaluating the virulence of three reference C. albicans strains in 
the murine model of hematogenously disseminated candidiasis show remarkable 
differences among them. Interestingly, the highest virulent strain studied here, 
SC5314, induced a more marked inflammatory response with a high recruitment of 
neutrophils and inflammatory monocytes into the spleen and kidney tissues. In 
general, the most virulent strains tested here generated higher inflammation, which 
may be worsening organ pathology rather than protecting the host. These results 
might explain why SC5314 strain, well known to be highly virulent in this infection 
model, in which immune protection mainly depends on neutrophils, is much less 
efficient at infecting the mucosa, where cell mediated immunity is essential for host 
protection. In future studies concerning C. albicans virulence, it would be advisable to 
assess pathology together with an analysis of local immune response in affected 
organs. Also, it would be interesting to compare the cell wall composition and cell 
surface associated proteins, such as Sap9 that modulates the interaction of C. albicans 
with human neutrophils. 
The vast majority of gene disruption studies have been carried out in the SC5314 
background. As this strain elicits an uncontrolled host inflammatory response that 
results in sepsis and host death soon after intravenous challenge, this may negatively 
affect mutant virulence assessment. Other factors affecting C. albicans mutants 
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virulence assessment are undesired effects that may result from their construction. 
The majority of C. albicans mutant strains were constructed by using the Ura-blaster 
technique, which has been shown to generate mutant strains with altered URA3 
expression, influencing C. albicans virulence. Although this can now be overcome by 
the directed integration of URA3, mutant strains used in earlier studies did not share a 
site of URA3 integration and virulence phenotypes of all these mutants should thus be 
confirmed. Therefore, the importance of SAP1 to SAP6 was re-evaluated in a model of 
acute systemic candidiasis by using mutant strains constructed with the SAT1-fliping 
strategy. The obtained results show that Δsap123 and Δsap456 are as virulent as the 
WT strain contrasting the reduced virulence of equivalent Ura-blaster generated 
mutants, for which the Ura-status must have thus contributed to their attenuated 
virulence. Altogether, these results suggest that Sap1 to Sap6 do not play a significant 
role in C. albicans virulence in hematogenously disseminated candidiasis. Nevertheless, 
as shown in this thesis, Sap4 to Sap6 play a role in the infectious process of C. albicans 
peritonitis. In Δsap456-infected mice, the lower recruitment of Treg into the kidneys 
early after challenge might facilitate the arrival or activation of effector cells, therefore 
enhancing fungal clearance. Also, CD4+CD25+ T cells sorted from these mice presented 
a much lower ability for in vitro suppression of T cell proliferation and production of 
the immunosuppressive cytokine IL-10 than WT-infected mice. These observations are 
in agreement with, and support, the hypothesis that Sap4 to Sap6 play a role in the 
impairment of the host immune response to Candida peritonitis. Further studies are 
needed to determine the mechanism by which Sap4-6 interfere with the host immune 
response. As no differences were observed between the used WT and sap-null strains 
in their ability to activate DCs, other cell targets, such as monocytes or macrophages 
should be studied in more detail. Indeed, inflammatory monocytes were differentially 
recruited into the peritoneal cavity of mice infected with the WT or Δsap456 strains. 
Another mechanism needing to be clarified concerns Treg function in WT or sap-null 
infected mice. It would be important to ascertain the role of IL-10 in the suppressive 
activity of these cells. Antibody-mediated neutralization of this cytokine or cell transfer 
experiments using IL-10-deficient mice as recipients may be useful in that regard. 
Altogether, the results obtained with the sap-null mutant strains, in two different 
infection models, further highlight that the importance of specific SAP genes for C. 
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albicans pathogenicity is greatly determined by the type of infection and its 
dependence on protease activity for the successful invasion and colonization of various 
host niches. These Saps may be necessary to degrade human proteins, enabling 
nutrient acquisition, host tissue invasion, and immune evasion. The pattern 
recognition receptor Gal-3 selectively binds to C. albicans β-1,2-oligomannosides 
leading to fungal death and increased production of the inflammatory cytokine TNF-α 
upon C. albicans recognition. In this study, C. albicans Sap1, Sap2 and Sap3 isoenzymes 
were shown to degrade and inactivate Gal-3 in vitro. These results suggest that host 
Gal-3 might be also cleaved in vivo by Saps. Hence, C. albicans may degradate Gal-3 to 
control and evade host immune Gal-3-mediated recognition, and the ensuing 
inflammatory response, or even avoid Gal-3-mediated C. albicans killing. In future 
studies, co-localization of Sap1-3 or Sap4-6 and Gal-3 in the infected tissues would 
provide a more compelling evidence of the Gal-3 degradation in vivo. It would be also 
important to use other infection models, such as experimental vaginal or oral 
candidiasis, where a prominent role of Sap2 in infection was already demonstrated, to 
determine the importance of Sap-mediated Gal-3 degradation in the establishment of 
candidiasis.  
The above-mentioned results suggest that C. albicans Sap isoenzymes may be one of 
the mechanisms used by this fungus to dampen host immune response, making these 
proteins natural target antigen candidates in C. albicans vaccination. Previous reports 
have shown that mice immunized with Sap2 were protected against mucosal or 
peritoneal C. albicans infection. Here, a similar approach was attempted to protect 
mice against hematogenously disseminated candidiasis. Mice were immunized with 
rSap2 and rSap5 as target antigens, using different adjuvants and immunization 
schedules. All the tested approaches failed to protect against this type of candidiasis. 
In some occasions, the immune response elicited by immunization could actually have 
been deleterious to the host, resulting in uncontrolled inflammation. Although in this 
infection model Sap1 to Sap3 proved unnecessary for C. albicans infection 
establishment, as mutant stains deficient in SAP1 to SAP3 were equivalent in virulence 
to the WT strain, immunization with Sap2 could nevertheless result in host protection. 
It would be expected that rSap5 was more promising as a target antigen in systemic 
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candidiasis than rSap2, since Sap5 expression has been associated with invasive 
candidiasis. Nevertheless mutant strains lacking SAP4 to SAP6 presented only marginal 
virulence attenuation in this infection model. The results described here indicate that 
C. albicans is less dependent on Sap activity to successfully infect the host in 
hematogenously disseminated candidiasis than in C. albicans peritonitis, for which 
vaccination with Sap2 was protective. The observation reported by others that Sap 
inhibitor pepstatin A was ineffective in protecting mice against hematogenously 
disseminated candidiasis supports this hypothesis. Thus, immunization strategies 
targeting Sap2 would be more effective in controlling C. albicans infections more 
dependent on protease activity than in the murine model of hematogenously 
disseminated candidiasis, which is relatively protease independent. Nevertheless, it 
cannot be excluded that protection conferred by this immunization strategy might be 
strain dependent. In fact, it is shown here that strain SC5314 elicits a host immune 
response with a high inflammatory character, which might have contributed to the lack 
of protection. It would be interesting to determine whether vaccination with Saps may 
nevertheless be protective in this infection model, when using strains causing a less 
marked inflammatory response to establish infection. As the cell surface associated 
Sap9 was shown by others to have a major impact on recognition of C. albicans by 
neutrophils, promoting the activation and chemotaxis of these leukocytes, it would be 
interesting to use this antigen to attempt vaccination against yeast strains inducing an 
exacerbated neutrophilic inflammation, such as SC5314.      
Overall, the results presented herein provide additional evidence for the differential 
involvement of Saps in distinct C. albicans infection models and, by showing that host 
immune response to C. albicans is affected by lack of SAP expression, support a 
previously hypothesized immunomodulatory role for Saps. They also indicate that 
immunization with C. albicans Sap proteins may have no effect in protecting the host 
against candidiasis established by the hematogenous route, reinforcing the limited role 
of these proteins in this type of infection. Nevertheless, they do not completely rule 
out the possibility that Sap antigens, the ones used here or other, with different 
adjuvant combinations, might result in host protection in this type of disseminated 
infection.  
